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ABSTRACT 
DEVELOPMENT OF THE 2,2,6,6-TETRAMETHYLPIPERIDIN-1-YLOXYCARBONYL 
(TEMPOC) PROTECTING GROUP AND EFFORTS TOWARDS THE TOTAL 
SYNTHESIS OF Α-CYCLOPIAZONIC ACID 
 
Joseph R. Lizza, MS 
 
University of Pittsburgh, 2020 
 
 
 
 
The 2,2,6,6-Tetramethylpiperidin-1-yloxycarbonyl (Tempoc) protecting group is a new 
carbamate protecting group for various types of amines. Installation can be accomplished using 
the new reagent 4-nitrophenyl (2,2,6,6-tetramethylpiperidin-1-yl) carbonate (NPTC) under mild 
conditions. Tempoc is stable under strongly acidic and basic conditions, and displays orthogonal 
deprotection properties when used in tandem with the tert-butyloxycarbonyl (Boc) and 
benzyloxycarbony (Cbz) protective groups. Deprotection can be accomplished under thermolytic 
conditions at 135 °C, or under reductive conditions with in situ generated catalytic Cu(I). 
Furthermore, Tempoc has also been shown to be a useful protecting group in peptide synthesis. 
Protecting a broad range of biologically relevant amino esters has been accomplished in the 
presence of 1-hydroxybenzotriazole (HOBt) as an NPTC activator. Demonstration of Tempoc 
utility has been realized through the synthesis of a tripeptide fragment of Gramicidin S, a cyclic 
decapeptide that possesses antimicrobial activity. Unrelated, efforts toward the total synthesis of 
α-Cyclopiazonic acid are also discussed. The ambitious 1,3-dipolar cycloaddition of a highly 
substituted aziridine with relatively unactivated dipolarophiles led to interesting results that may 
be useful for the synthesis of other complex biologicals and natural products.  
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1.0 2,2,6,6-TETRAMETHYLPIPERIDIN-1-YLOXYCARBONYL (TEMPOC): A 
PROTECTING GROUP FOR PRIMARY, SECONDARY AND HETEROCYCLIC 
AMINES1 
1.1 INTRODUCTION 
1.1.1  Protection of amines in organic synthesis 
The increasing complexity of synthetic approaches to functionally dense molecular 
scaffolds demands the use of protecting groups (PGs).2 The use of PGs enables targeted 
transformations on a desired part of a molecule in the presence of other sensitive and reactive 
centers. As such, PGs play a critical role in carbohydrate,3 peptide,4 and small molecule synthesis.5 
Synthetic chemists are continually designing functionally dense, more reactive molecules and 
embarking on expeditious total syntheses, requiring an adaptive and expansive library of 
orthogonal protecting groups.6,7 Orthogonality is defined as the ability to remove a PG selectively 
in the presence of sensitive functionalities, such as other PGs.8 Amines are among the most 
common functionalities found in pharmaceuticals, natural products, and their synthetic 
intermediates.9–11 Amine nucleophilicity, basicity, and tendency to coordinate to transition metals, 
demand the use of protecting groups in order for chemical transformations to achieve proper 
chemoselectivity, minimal side-products, or even proceed at all. An example of amine protection 
is in Sheerer’s synthesis of (±)-acetylnorloline in 2011 (Scheme 1).12  
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Scheme 1 An example of amine protection using the tert-butyloxycarbony (Boc) group from Sheerer’s 2011 
synthesis of racemic acetylnorloline 
The authors started with N-protected lactam 1-1 and the protecting group (red) was 
maintained until 2-steps before the final transformation. The amine protection was crucial, as the 
18-step sequence contains numerous basic-amine-incompatible reagents and functional groups 
(blue) such as strong bases, electrophiles, transition metals, and undesired self-condensations. 
While trifluoroacetyl,13 tosyl,14 nosyl,15,16 phthaloyl,17 and trityl18 are frequently used for amine 
protection, carbamates with tert-butyloxycarbonyl (Boc),19 benzyloxycarbonyl (Cbz),19 9-
fluorenylmethoxycarbonyl (Fmoc),20 and allyloxycarbonyl (Alloc)21 substituents are among the 
most common and versatile amine protecting groups used across all branches of chemistry. 
Importantly, carbamate derived PGs find widespread use in the protection of amines due to their 
 3 
robustness, ease of deployment and removal, and orthogonal nature. Consequently, new chemical 
variants are continually being developed.22,23 Typical deprotection conditions involve acidic (Boc), 
basic (Fmoc) or hydrogenolytic (Cbz) conditions and numerous methods have been published, 
such as TFA,24 HCl,25 H2/Pd,
26 Et3SiH/Pd,
27 and Mg/MeOH.28 Unfortunately, deprotection with 
these conditions can promote numerous side reactions (for example, over-reductions,29 
rearrangements,30 and epimerizations31). 
1.1.2  First use of Tempoc as a protecting group 
In McCabe’s recent total synthesis of (–)-cycloclavine, a base-stable amine protecting 
group that could be subjected to tin-lithium transmetallation followed by 1,2-addition on enone 1-
14 was required, and it was strategized that the protecting group would ideally be cleaved during 
a subsequent intramolecular Diels-Alder furan (IMDAF) cycloaddition (Scheme 2).32 Following a 
survey of carbamate protecting groups identified 2,2,6,6-tetramethylpiperidin-1-yloxycarbonyl 
(Tempoc) group as a superior protecting group. Specifically, Tempoc derivative 1-16 resulted in 
the best yield and chemoselectivity in the transmetallation/addition step to furnish prerequisite 
amino alcohol 1-17, and could be cleaved during the subsequent Diels-Alder reaction using milder 
conditions of 135 °C in toluene versus microwave irradiation at 180 °C required for Boc derivative 
1-15. With this utility in mind, we sought to develop the Tempoc group as a synthetically useful 
tool for the protection of primary, secondary, and heterocyclic amines. 
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Scheme 2 The first use of the Tempoc protecting group in the 2017 synthesis of  (−)-cycloclavine 
1.2 RESULTS AND DISCUSSION 
1.2.1  Development of Tempoc transfer reagent 4-nitrophenyl (2,2,6,6-
tetramethylpiperidin-1-yl) carbonate (NPTC) 
While in McCabe’s synthesis of cycloclavine, Tempoc was installed through a 
diphenylphorhoryl azide (DPPA) mediated Curtius rearrangement of furan carboxylic acid 1-19 in 
the presence of TEMPO hydroxylamine 1-22 (TEMPO-H), this would not be practical for the 
general installation of Tempoc on a variety of amines (Scheme 3). Therefore, studies towards a 
new Tempoc transfer agent were conducted.  
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Scheme 3 The Curtius rearrangement used to form Tempoc in McCabe’s 2017 synthesis of  (−)-cycloclavine 
Amines are typically protected through a carbamolyation reaction with an activated form 
of the target protecting group. For instance, the Boc protection of benzylamine 1-26 can be 
achieved through reaction with di-tert-butyl dicarbonate 1-25 (Boc anhydride or Boc2O) (Scheme 
4). Alternatively, Cbz protection is conveniently achieved upon treatment of the amine with benzyl 
chloroformate 1-27 (CbzCl).   
 
Scheme 4 The use of Boc anhydride and benzyl chloroformate for amine protection 
While these reagents are generally stable and convenient for synthetic use, we hypothesized 
that Tempoc equivalents would be too unstable to storage, thereby limiting their convenience and 
practicality (Scheme 5). Tempoc anhydride 1-29 was discarded as a feasible substrate due to 
expected energetic decomposition. Tetramethylpiperidine chloroformate 1-30 was appealing as 
chloroformates react readily across a variety of basic and weakly nucleophilic amines.33 However, 
after reduction of stable free radical 1-28 (TEMPO) to hydroxylamine 1-22, and treatment with 
phosgene or triphosgene, the chloroformate quickly decomposed, forming a dark, complex 
reaction mixture with no isolable traces of the chloroformate.  
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Scheme 5 Planned synthesis of Tempoc anhydride and TMP chloroformate 
 
Next, attention was turned to activated mixed carbonates, which have a long history of use 
for peptide couplings and amine protections.34,35 Since mixed carbonates are easily prepared from 
alcohols and their respective chloroformates, we set out to synthesis a variety of mixed carbonates 
as potential Tempoc transfer reagents (Scheme 6). While keeping the impending workup in mind, 
we first sought to prepare the methyl and iso-butyl Tempoc carbonates 1-31 and 1-32, expecting 
that the resulting alcohols could readily be removed during the reaction workup. Reduction of 1-
28 in water or methanol with sodium ascorbate or ascorbic acid gave resulting hydroxylamine 1-
22, which after extraction was treated with corresponding chloroformates to give mixed carbonates 
1-31 and 1-32 in good to excellent yield. These carbonates were exposed to phenethylamine 1-37 
in DMF with triethylamine as base; however, no product was detected by LC-MS or NMR 
analysis.  
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Scheme 6 Synthes of Tempoc mixed carbonates and their reaction with phenethylamine 1-37 
 
Next, we sought to increase the leaving group ability of the carbonate, thus, phenyl 
carbonate 1-33, N-hydroxylsuccinimidyl (NHS) carbonate 1-36, and 4-nitrophenyl carbonate 1-34 
were synthesized. Phenyl analog 1-33 and NHS-carbonate 1-36 were unreactive towards 
phenethylamine, the latter being unstable and decomposing in solution without giving any 
detectable product. Nitrophenyl carbonate 1-34, however, cleanly afforded Tempoc protected 
phenethylamine 1-38 in 84% isolated yield. Tempoc transfer reagent 4-nitrophenyl (2,2,6,6-
tetramethylpiperidin-1-yl) carbonate (NPTC, Figure 1) is a bench stable crystalline solid that has 
been synthesized in 100 g quantities. While NPTC bears a nitro group and weak N–O bond, 
differential scanning calorimetry showed only a minor exotherm of 70 cal/g at an onset temperature 
of 135 °C, showing that NPTC is a relatively stable compound. In fact, at this time of this writing, 
NPTC, via licensing from the University of Pittsburgh, has been made commercially available for 
purchase by the chemical supplier Millipore Sigma. 
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Figure 1 The structure of Tempoc transfer reagent NPTC 
       
1.2.2  The use of NPTC to protect amines 
With transfer agent NPTC in hand, we sought to optimize a set of conditions for installment 
of the Tempoc group onto amines. Using 2-phenethylamine 1-37 as a test substrate, we first 
explored typical Boc protection conditions (Table 1, Entry 1–2). Further screening showed that 
polar solvents were critical for good conversions (Table 1, Entries 3–5) with DMF providing the 
highest isolated yield. Next, screening of bases (Table 1, Entries 6–9) indicated that triethylamine 
was more effective than pyridine and inorganic bases. Interestingly, while potassium carbonate 
(Table 1, Entry 8) showed comparable yields, trace amounts of bis-Tempoc amine were detected 
by LC-MS. In attempts to increase conversion by heating, we were surprised to see the yields of 
Tempoc phenethylamine 1-38 decrease (Experimental Part, Table 15). We hypothesize that these 
conditions are met with NPTC degradation. However, excellent yields of 1-38 were obtained with 
increased loading of NPTC with 1.2 equivalents being ideal (Table 1, Entry 11).  
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Table 1 Optimization for the protection of phenethylamine with NPTC 
 
entry stoichiometrya solventb  base yieldc (%) 
1 1:1:3 DCM  Et3N 28 
2 1:1:3 THF  Et3N 60 
3 1:1:3 MeCN  Et3N 57 
4 1:1:3 MeOH  Et3N 64 
5 1:1:3 DMF  Et3N 77 
6 1:1:3 DMF  py 67 
7 1:1:3 DMF  NaHCO3 64 
8 1:1:3 DMF  K2CO3 79d 
9 1:1:3 DMF  Et3N/DMAPe 76e 
10 1:1.1:3 DMF  Et3N 84 
11 1:1.2:3 DMF  Et3N 91 
aamine:NPTC:base; b0.5 M in amine cisolated yields; dtrace bis-Tempoc amine detected by HPLC-MS; e0.25 equiv DMAP 
With these optimized conditions, we sought to demonstrate PG utility by exploring a range 
of primary, secondary, and heterocyclic amines as potential substrates (Figure 2). Unhindered 
primary amines were protected smoothly in high yields. Unprotected hydroxyl groups were 
tolerated in the protection, 1-45 and 1-46 were isolated with no traces of O-acylation. Tryptamine 
1-47 and amino benzylamine 1-48 gave complete selectivity towards the more basic amine. 
Primary amine 1-49, bearing α-substitution, showed decreased reactivity towards NPTC, giving 
75% yield respectively. Sterically encumbered tert-butyl amine only afforded 32% of the desired 
product 1-50. Tempoc hydrazide 1-51 was isolated as a highly crystalline solid in 95% yield. Using 
sodium hydride as base, we were able to cleanly bis-protect phenethylamine 1-52 in 90% isolated 
yield. Arylamines such as naphthylamine 1-53 showed no reactivity towards NPTC under 
standard, or even under forcing conditions. 
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Figure 2 The scope of Tempoc protected primary, secondary, and heterocyclic amines 
 
Generally, cyclic secondary amines are excellent substrates for Tempoc protection. L-
Proline methyl ester gave facile protection, albeit with slightly lower yield, likely do the steric 
interactions. Sodium hydride was needed for indole 1-60 as the there was no observed product 
formation under standard conditions. Importantly, we were able to selectively protect the indole-
N on tryptamine 1-61 by treatment first with sodium hydride, followed by addition of NPTC as a 
solution in THF. Imidazole was a highly compatible substrate for acylation, giving Tempoc 
protected analog 1-62 in 91% yield. Acyclic amine 1-63 gave excellent yield, however bulkier 
dipropyl amine 1-64 suffered from a decreased reaction rate, only giving 56% of the desired 
Tempoc amine. Sulfoximine 1-65 was also protected in 82% yield under sodium hydride 
conditions.  
Driven to extend the scope to aryl amines, we hoped to accelerate the reaction of NPTC 
and weakly nucleophilic arylamines by other means. Increasing reaction temperature only led to 
decomposition of the transfer reagent, even upon switching solvents. HFIP has been known to 
activate Boc2O for protection of weakly nucleophilic or hindered amines. However, in the case of 
NPTC only slow decomposition was observed.36 Stronger bases such as sodium hydride or n-
butyllithium, again, only led to slow decomposition of the transfer reagent and no isolable 
products. Lewis acids37–39 such as MgBr2 and various metal triflates have also been used for 
activation during the Boc protection, however, no desired product was observed after screening 
many Lewis acids (i.e., MgCl2, Sc(OTf)2, TMSOTf). There are even reports in the literature of 
activation of transfer reagents using Brønsted acids.40,41 These attempts also failed, likely due to 
deactivation of the aniline through protonation rather than activation of the transfer reagent. 
Nucleophiles such as DBU,42 N-methylimidazole,43 and DABCO44 have been used for acyl-
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transfer activation, as well as other nucleophilic reagents such as sodium azide45 and sodium 
iodide.46 However, when these reagents were tested, either no desired product was formed or 
decomposition of NPTC was observed. 
1.2.3  Deprotection of the Tempoc group 
Carbamate cleavage typically takes advantage of the unstable nature of the carbamic acids, 
thus, after cleavage of the O-substituent on the carbamate, the resulting carbamic acid will 
spontaneously release carbon dioxide to generate the free amine. The deprotections of Boc and 
Fmoc are typically conducted in the presence of a strong acid or base respectively. The former, 
follows a mechanism where protonation of the carbamate oxygen generates the stable tert-butyl 
cation 1-68 and carbamic acid 1-67 (Scheme 7, Eq. 1).47 Cation 1-68 can either undergo 
elimination to the give isobutylene, a gas, or the tert-butyl cation can be trapped with solvent or 
the acid counter-ion. Carbamic acid 1-67 then undergoes spontaneous decomposition to evolve 
CO2 and free amine 1-69. Fmoc, on the other hand, undergoes decomposition via a E1cb mechanism 
(Scheme 7, Eq. 2).48 The nucleophilic amine base, typically used in high excess, deprotonates the 
9-fluorenylmethyl ring giving intermediate anion 1-72, which then collapses down on the 
carbamate to release carbon dioxide and free amine 1-73. Dibenzofulvene 1-74 is a reactive 
electrophile and is typically trapped quickly by the base.  
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Scheme 7 The acid and basic deprotection mechanisms of Boc and Fmoc respectively 
Exploitation of the entropic driving force of CO2 extrusion in conjunction with a relatively 
stable by-product (i.e., tert-butyl cation or dibenzofulvene) allows some carbamate deprotections 
to be mild and facile. It is with this in mind that we envisioned the scission of the labile N–O bond 
in Tempoc to release carbon dioxide and generate hindered 2,2,6,6-tetramethylpiperidine 1-77 and 
deprotected amine 1-70.  
 
Scheme 8 Tempoc deprotection hypothesis 
1.2.3.1 Tempoc deprotection - copper 
With a broad scope of primary and secondary amines efficiently protected, many in gram-
scale or larger, we next sought to exact a mild set of conditions for the selective deprotection of 
Tempoc, and thereby significantly differentiate its deprotection conditions from that of other PGs. 
In order to develop an orthogonal deprotection strategy, we first thought to exploit the reductive 
lability of the N–O bond in the carbamate moiety. N–O bonds are known to undergo metal-
catalyzed reduction in the presence of copper(I) (Scheme 9).49–51  
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Scheme 9 Literature examples of N–O bond cleavage with copper(I) salts 
With Tempoc indole 1-60 as test substrate, we found that copper(I) chloride effectively 
cleaved the Tempoc group (Table 2, Entry 1). However, while stoichiometric Cu(I) was effective, 
we sought to use copper catalytically, while also removing the need for air-sensitive copper(I) salts 
via the use of copper(II) chloride and the introduction of a reductant, such as ascorbic acid.  
Treatment of Tempoc indole with other sources of Cu(II) were effective. However, we chose 
copper(II) chloride as it exhibited the best solubility and cost effectiveness (Table 2, Entries 6–
10). Using optimized conditions, we found that other Tempoc substrates were sparingly soluble in 
the DMF/H2O mixture. After testing various binary solvent mixtures it was found that a ternary 
mixture of MeCN/THF/H2O exhibited excellent solubilizing properties for all Tempoc substrates, 
while concomitantly allowing for lower copper and reductant loading, and shorter reaction times 
that we attributed to the stabilizing effects of acetonitrile on the reduced Cu(I) species (Table 2, 
Entry 11). Further reduction of copper and ascorbic acid, while effective, was met with increased 
reaction times (Table 2, Entry 12). 
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Table 2 Optimization for the copper mediated deprotection of Tempoc indole 
 
entry CuX (equiv) reductant (equiv) solvent yieldb (%) 
1a CuCl (2.2) - MeCN 83 
2 a CuI (2.2) - MeCN trace 
3 a Cu2O (1.1) - MeCN 11 
4 a CuCl2 (1.1) - MeCN 2 
5 a CuCl2 (0.20) NaAsc (1.1) MeCN/H2O (2:1) 29 
6 a CuCl2 (0.20) Asc (5) MeCN/H2O (2:1) 29 
7 a CuCl2 (0.20) Asc (5) MeOH/H2O (5:1) 63 
8 a CuCl2 (0.20) Asc (5) DMF/H2O (5:1) 84, 84c 
9 CuSO4 (0.20) Asc (5) DMF/H2O (5:1) 84 
10 CuCl2 (0.05) Asc (2) DMF/H2O (5:1) 67d 
11 CuCl2 (0.05) Asc (2) MeCN/THF/H2O (4:1:1) 84d 
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CuCl2 (0.10) Asc (2) MeCN/THF/H2O (4:1:1) 83d 
acontribution (MB); bHPLC yield; cisolated yield after 12 h; disolated yield after 24 h 
 
Using these optimized reductive conditions, we explored the application for primary, 
secondary, and heterocyclic Tempoc amines (Figure 3). Tempoc piperidine 1-56 and 
cyclohexylamine trans-1-44 deprotected cleanly at room temperature to afford free amines 1-83 
and 1-84 in excellent yield. Primary amine trans-1-44 required mild heating to achieve 
deprotection, presumably due to the less hindered carbamate coordinating to copper. Deprotections 
were scaled to >1 mmol with no decrease in yield. 
 
Figure 3 Copper deprotection  of Tempoc piperidine 1-56 and cyclohexylamine trans-1-44 
 16 
1.2.3.2 Tempoc deprotection - thermolysis and mechanism 
During McCabe’s 2017 synthesis of (−)-cycloclavine,32 Tempoc was cleaved during 
thermal IMDAF reaction conditions. Interested in applying this property of thermal Tempoc 
deprotection more generally, we explored the possibility of a thermolysis of Tempoc as another 
method of deprotection. A survey of the literature shows precedents for the thermal deprotection 
of carbamates, namely Boc.52–54  
 
Scheme 10 Tandem IMDAF cyclization and thermolysis of Tempoc in McCabe’s synthesis of (−)-cycloclavine 
With Tempoc piperidine 1-56 as test substrate, we switched from Dr. McCabe’s conditions 
of 135 °C in toluene under microwave irradiation to the higher boiling chlorobenzene (Table 3). 
Under microwave irradiation at 165 °C for 1 hour, only a trace amount of product 1-83 was 
observed (Table 3, Entry 1). Switching to more polar pyridine and increasing temperature to 175 
°C again only produced trace amounts of detectable 1-83 by LC-MS (Table 3, Entry 2). Increasing 
solvent polarity further to proprionitrile showed a dramatic increase in the rate of deprotection, 
and after 2 h at 165 °C we isolated 48% of desired free piperidine 1-83 (Table 3, Entry 4). The 
highly polar solvent 1,1,3,3-hexafluroisopropanol (HFIP) has been shown to enhance the 
deprotection of carbamates.24,55,56 Thus, using a 9:1 mixture of PhCl/HFIP indeed increased the 
rate of deprotection, and in 2 h 42% of amine 1-83 was isolated (Table 3, Entry 5). Using neat 
HFIP enabled the temperature to be reduced to 135 °C and in 8 h 85% of the deprotected amine 
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was isolated (Table 3, Entry 7). Swapping HFIP to the less acidic TFE was met with a substantial 
reduction in yield (Table 3, Entry 8).  
Table 3 The optimization of Tempoc thermolysis of piperidine 1-56 
 
entry solvent temperature (°C) time (h) yielda (%) 
1 PhCl 165 1 trace 
2 pyridine 
 
175 1 trace 
3 NMP 165 1 decompb 
4 EtCN 
 
165 2 48 
5 PhCl-HFIP (9:1) 165 2 42 
6 HFIP 135 6 73 
7 HFIP 135 8 85 
8 TFE 135 6 30 
aisolated; bno recovered starting material or desired products 
These optimized deprotection conditions, 135 °C in HFIP for 8 h under microwave 
irradiation, were also applied to indole 1-60, which only required 30 min for complete conversion, 
affording indole 1-82 in 88% yield (Scheme 11).  
 
Scheme 11 Thermal deprotection of Tempoc indole 1-60 
Surprisingly, extension of this method to Tempoc protected primary amines only gave the 
symmetrical urea. When Tempoc benzylamine 1-42 was heated in HFIP, after 30 min only urea 1-
86 was isolated (Scheme 12). Numerous attempts to discourage this side-reaction were met with 
disappointing results. However, Maximilian Bremerich (MB) discovered that potassium 
trimethylsilanoate (KOTMS) inhibited the urea formation. Indeed, when Tempoc amine 1-42 was 
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heated in 1,4-dioxane for 30 min at 135 °C in the presence KOTMS the desired primary amine 1-
87 was cleanly isolated in 93% yield after filtration through a pad of silica. 
 
Scheme 12 The thermolysis of primary amines and their products 
Curious about the reaction mechanism of the thermolytic deprotection, Dr. McCabe used 
NMR analysis.1 Identification of the by-products of the thermal Tempoc cleavage (Table 4) 
showed the presence of tetramethylpiperidine 1-77, dimethylpyrrolidine 1-88, and enamine 1-90.  
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Table 4 The thermal deprotection products of Tempoc indole 1-60 
 
  product ratiosa 
entry conditions 1-77 1-88 1-89 1-90 
1 150 °C, toluene-d8, 20 h 1 1 ND 0 
2 150 °C, toluene-d8 (1 M degassed), 9 h 
150 °C, toluene-d8 (1 M degassed), 9 h 
150 °C, toluene-d8 (1 M 
degassed), 9 h 
1 2.3 ND 0.98 
3 150 °C, toluene-d8 (1 M), H2O (4 eq), 9 h 1 3.4 ND 0 
4 135-140 °C, toluene-d8 (1 M), 32.5 h 1 1.8 ND trace 
abased on NMR analysis; ND = not detected 
With these data a plausible mechanism was proposed, where the deprotection followed 
radical and ionic pathways (Scheme 13). Under thermal conditions, the ionic pathway begins with 
ring contraction of the piperidine ring, affording carbamic acid 1-91 and cationic pyrrolidine 1-92. 
Loss of CO2 affords indole 1-82, and pyrrolidine 1-92 eliminates to afford enamine 1-90, which is 
hydrolyzed to give acetone and dimethyl pyrrolidine 1-88. In the ionic mechanism, we suspect 
homolysis of the N–O bond produces 2,2,6,6-tetramethylpiperidine radical and 1-91. After 
hydrogen atom transfer from solvent and extrusion of CO2 tetramethylpiperdine 1-77 and indole 
1-82 are formed. 
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Scheme 13 The proposed ionic and radical pathways of thermal Tempoc deprotection 
1.2.4  Orthogonality study of Tempoc deprotection 
One of the key properties of a protecting group is orthogonality. Selective deprotection of 
one group in the presence of multiple other PGs is routinely carried out in a synthetic sequence. 
An example of such a selective deprotection is from Namba’s 2015 synthesis of palau’amine 1-96 
(Scheme 14).57with 
 
Scheme 14 The selective deprotection of Fmoc in the presence of 4 other protecting groups 
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The Fmoc protected pendant amine needed to be removed prior to conversion to 
pyrrolamide 1-95. This was accomplished with standard conditions, 5% piperidine in acetonitrile, 
while leaving the Boc, trifluoroacetamide, silyl ether, and methyl ester groups intact.  
With respect to assessing the orthogonality of Tempoc deprotection against the popular 
Boc and Cbz groups, we set out the explore conditions under which selective deprotection of Boc, 
Cbz, and Tempoc could be employed with strategic, synthetic compatibility (Scheme 15). 
 
Scheme 15 Orthogonality studies with Cbz/Tempoc and Boc/Tempoc protected piperazines 
Bis-protected piperazines 1-54 and 1-99 were synthesized for this demonstration. Tempoc 
amine 1-54 and 1-99 deprotected cleanly using the optimized copper(I) conditions at room 
temperature to afford free amines 1-98 and 1-101 in 95% and 92% yields, respectively. Standard 
TFA in methylene chloride conditions removed Boc in the presence of Tempoc in 94% yield, 
affording the monoprotected piperazine 1-97 as the trifluoroacetate salt. Cbz was removed using 
a modified literature protocol, Pd/C and H2 (balloon) in the presence of 0.5 equivalents of 
 22 
ammonia, gave Tempoc piperazine 1-100 in quantitative yield. Attempts to run the reaction in the 
absence of ammonia led to partial cleavage of the Tempoc group. 
1.3 CONCLUSIONS 
In conclusion, these studies indicated that the 2,2,6,6-tetramethylpiperidin-1-
yloxycarbonyl (Tempoc) is an effective amino protecting group, with excellent orthogonality to 
Boc and Cbz protective groups. Treatment of amines with the crystalline Tempoc transfer reagent 
NPTC affords corresponding Tempoc protected derivatives in high yield with excellent 
chemoselectivity. Removal is mild, utilizing catalytic copper(I) generated in situ by the reduction 
of copper(II) chloride with ascorbic acid. Alternatively, thermolysis of Tempoc occurs in HFIP at 
135 °C. Mechanistic studies have been explored, indicating a predominant ionic mechanism, 
however a radical pathway cannot be ruled out. Overall, the findings from the research described 
herein clearly demonstrate a highly useful role for the straightforward and synthetically amenable 
use of Tempoc as an amino protective group. 
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2.0 TEMPOC: A USEFUL PROTECTING GROUP IN PEPTIDE SYNTHESIS 
2.1 INTRODUCTION 
2.1.1  Protection group use in peptide synthesis 
Peptides and proteins play an essential role to all biological processes, while also being an 
integral part in the design of new therapeutics.58 While peptides may be isolated from natural 
sources or specifically expressed for isolation, they are typically produced synthetically.59–61 
Furthermore, the chemical synthesis of peptides may be done without the use of protecting groups 
utilizing native chemical ligation. However, this method comes with many limitations.62–64 
Therefore, peptides are typically constructed using protective group based solution-phase65 or 
solid-phase66 peptide synthesis. While the N- and C-terminus on amino acids require protection 
during synthesis, the multitude of reactive moieties (Figure 4) contained on amino acid sidechains 
also require protection during synthetic sequences to avoid unwanted side-reactions.67 The most 
common functional groups needing protection in peptide synthesis are amines. Of the available 
amine PGs, carbamates such as tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and 9-
fluorenylmethoxycarbonyl (Fmoc) are the most common and the most synthetically useful. 
Carbamates offer excellent durability to standard peptide coupling conditions, while also being 
removed mildly and orthogonally to other protecting groups that may be present. Taken together, 
there is demand for the development of new orthogonal protective groups for successful 
construction of the complex molecules.   
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Figure 4 Representative examples of amino acid bearing reactive sidechains (green) 
2.1.2  New carbamates in peptide synthesis 
In recent years, new carbamate-based groups for N-terminus and amine side-chain 
protections have been developed. In 2018, Staderini introduced the tetrazine-labile aryl vinyl ether 
protecting group for use as lysine sidechain protecting group (Scheme 16).68 
 
Scheme 16 The tetrazine labile vinyl ether benzyloxycarbonyl (VeZ) protecting group 
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The vinyl ether benzyloxycarbonyl (Vez) protecting group is installed on Fmoc-protected 
lysine via 4-nitrophenyl mixed carbonate 2-14 after in situ protection of the free carboxyl with N-
trimethylsilyl-N-methyl trifluoroacetamide (MSTFA). Deprotection of VeZ is performed by 
microwave heating in the presence of a tetrazine in an aqueous buffer-DMF mixture (Scheme 17). 
The mechanism proposed is that of and inverse demand Diels-Alder cyclization with subsequent 
extrusion of dinitrogen to form dihydropyridazine 2-19. Aromative-elimination provides the 
phenoxide 2-20, which readily undergoes 1,6-elimination to liberate carbon dioxide and free amine 
2-18. The authors further demonstrated the utility of the VeZ group in the synthesis of two cyclic 
peptides, melanotan II and a BAD BH3 peptide.69,70  
 
Scheme 17 Mechanism for the deprotection of the VeZ protecting group 
In 2019, Okamoto showcased the polar N,N-dimethylaminoxy carbonyl (Dmaoc) 
protecting group.22 The Dmoac group, as was the aforementioned VeZ group, was designed for 
sidechain amino protection. Dmoac shares an interesting structural similarity to Tempoc in that 
also contains an N–O bond. Installation of the protecting group was accomplished via 
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carbamoylation by treatment of the amine with N,N’-carbonyldiimidazole (CDI) in the presence 
of N,N-dimethylhydroxylamine hydrochloride (Scheme 18). 
 
Scheme 18 Dmoac protection of lysine using CDI and N,N-dimethylhydroxylamine 
Deprotection was efficiently accomplished in a few hours by stirring in a pH 7.0 buffer 
containing dithiothreitol (DTT). The authors speculate that reduction of the N–O bond may be 
occurring as the deprotection does not proceed in the absence of reducing agents, however, DTT 
nucleophilicity seems to also be a major factor. Okamoto then displays Dmoac’s utility through 
the synthesis of sunflower trypsin inhibitor SFTI.71 SFTI is a cyclic peptide bearing 14 amino acid 
residues, including lysine. After cyclization of the linear peptide, Dmoac was removed utilizing 
the author’s DTT/buffer conditions.  
2.2 RESULTS AND DISCUSSION 
2.2.1  Problems with initial Tempoc protection conditions 
During our exploration of Tempoc as a protecting group for primary, secondary, and 
heterocyclic amines,1 we showed that the amino ester proline was an excellent substrate for 
protection, affording 87% of Tempoc proline 1-59 using the standard protection conditions 
(Scheme 19, Eq. 1). Interested in expanding the versatility of Tempoc’s utility for peptide 
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synthesis, we first attempted to protect phenylalanine ethyl ester. However, we were surprised to 
isolate only 19% of the desired product 2-26 (Scheme 19, Eq. 2).  
 
Scheme 19 The unexpected yield from the Tempo protection of phenylalanine ester 2-25 as compared to proline 
2.2.2  Discovery of new protection conditions and scope 
Curious about this result, we set out to elucidate the reason for the considerable drop in 
yield. First, we wanted to simplify our protection substrate to glycine ethyl ester, as an α-
unsubstituted amino ester which should be protected in high yield. However, when glycine ethyl 
ester hydrochloride was subjected to the standard protection conditions, only 65% yield of 2-28 
was isolated (Scheme 20, Eq. 1). Speculating that solubility of the hydrochloride in DMF could be 
leading to low conversion, we freebased ethyl glycinate by extraction from aqueous ammonia and 
subjected 2-29 to the same conditions. In spite of this, no change was observed, providing only 
68% of 2-28 (Scheme 20, Eq. 2). Next, we wondered if ethyl glycinate was oligomerizing under 
the basic conditions of the reaction. Therefore, we switched to tert-butyl glycinate, which should 
exhibit no propensity of oligomerization, again, only 70% of glycinate 2-31 was isolated (Scheme 
20, Eq. 3). Lastly, we speculated the proximity of the amine to electron withdrawing ester moiety 
had an inductive effect that impacted yield. As such, ethyl β-alanine 2-32 was then subjected to 
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the standard conditions, providing Tempoc amino ester 2-33 in 91% yield as expected (Scheme 
20, Eq. 4). 
 
Scheme 20 Reactions to determine cause of reduced Tempoc protection yields for amino esters 
Not yet convinced the electronic induction of the ester was the primary culprit for lower 
yields, we theorized that the Tempoc protected amino ester may be undergoing degradation in 
solution. Therefore, we subjected Tempoc glycinate 2-28 to the protection conditions and 
monitored for the expected degradations products, TEMPO 1-28 and glycine 2-29. Stirring of the 
protected amine in DMF for 12 h in the presence of 4-nitrophenol and triethylamine did not 
produce any observable degradation products (Table 5). 
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Table 5 Tempoc stability studies under the standard reaction conditions 
 
  observed products 
entry 4-NO2C6H4OH 2-28 1-28 2-29 
1 1 equiv X ND ND 
2 – X ND ND 
X = observed by TLC and LC-MS; ND = not detected by TLC and/or LC-MS 
With Tempoc stability no longer in question, this provided stronger evidence that the 
inductive effect was slowing the reaction. However, with the longer reaction times, we 
hypothesized that NPTC degradation may also be contributing the decreased conversion rates. The 
stability of NPTC under the reaction conditions in the absence of an amine was then tested for 
expected degradation products TEMPO 1-28 and symmetrical carbonate 2-34 which could arise 
from attack of 4-nitrophenoxide onto NPTC. Exposure of NPTC in DMF or methylene chloride in 
the presence of triethylamine and 4-nitrophenol did not produce any detectable degradation 
products as well (Table 6). 
Table 6 NPTC stability studies under the standard reaction conditions 
 
    observed products 
entry solvent (conc.) temp 4-NO2C6H4OH NPTC 1-28 2-34 
1 DMF (0.5 M) ambient 1 equiv X ND ND 
2 DMF (0.5 M) ambient – X ND ND 
3 CH2Cl2 (1.0 M) 40 °C 1 equiv X ND ND 
4 CH2Cl2 (1.0 M) 40 °C – X ND ND 
X = observed by TLC and/or LC-HRMS; ND = not detected by TLC or LC-HRMS 
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With enough evidence suggesting that inductive influences were the cause of the lower 
yields observed, we concluded that a more reactive Tempoc transfer reagent should be explored. 
Avoiding the redesign of crystalline, stable, and easily prepared NPTC, we sought to activate the 
reagent by means of an external activator. A survey of the literature revealed that highly polar 
solvents such as HFIP36 or additives such as sodium cyanide,72 sodium azide,73 and HOBt74 have 
been used for amine protection enhancement through reagent activation. Given the success of these 
activators, we set out to apply these conditions to amine protection with NPTC. We hypothesized 
that addition of these activators should generate a more reactive Tempoc transfer reagent in situ 
either through hydrogen bonding, or through displacement of the 4-nitrophenolate to generate a 
more reactive species (Figure 5). 
 
Figure 5 More reactive Tempoc transfer species generated in situ by addition of an activator 
First, with the recent developments in HFIP reaction rate enhancements,75 we proposed 
that switching to this highly polar solvent would activate the carbonyl of NPTC, thus making it 
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more susceptible to nucleophilic attack. However, when we tested this hypothesis, we only isolated 
decomposition products of NPTC (Scheme 21, Eq. 1). Next, sodium cyanide can act as a catalytic 
nucleophile to attack NPTC, thus forming Tempoc cyanoformate 2-36, which would react readily 
with nucleophiles, however when phenylalanine ester 2-40 was exposed to NPTC in the presence 
of sodium cyanide, once again, only decomposition products of NPTC were isolated (Scheme 21, 
Eq. 2). Thirdly, azidoformates have a long history of being acyl transfer reagents,76 and with this 
in mind, we thought the addition of catalytic amounts of sodium azide would form Tempoc 
azidoformate 2-37 in situ, and while the mass for this compound was observed by LC-MS, no 
reaction rate enhancement was observed, and only starting materials and decomposition products 
were formed (Scheme 21, Eq. 3). Finally, the use of HOBt in acylation Scheme 21 reactions is 
well known,77 and when phenylalanine ester 2-41, was treated with NPTC in DMF in the presence 
of 1.2 equivalents of HOBt, we were excited to isolate 82% of desired Tempoc amino ester 2-26 
after 24 h (Scheme 21, Eq. 4). 
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Scheme 21 Test reactions of various NPTC activating additives  
We hypothesized that the attack of HOBt onto NPTC forms small quantities of HOBt-
adduct 2-38 which is a more reactive Tempoc transfer reagent that reacts readily with an incoming 
amine. While proof of this intermediate has not been proven spectroscopically, it’s corresponding 
mass has been observed by LC-HRMS from the reaction of NPTC with HOBt in THF in the 
presence of triethylamine as base (Scheme 22). 
 
Scheme 22 Control reaction to confirm the formation of Tempoc-HOBt adduct 2-38 
With HOBt proving to be a potent NPTC activating agent, we set out to optimize the 
protection conditions of phenylalanine ethyl ester. As previously stated, in the absence of any 
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activator, protection of phenylalanine 2-25 in dry DMF with 3.0 equivalents of triethylamine, 
afforded only 19% of Tempoc amino ester 2-26 (Table 7, Entry 1). In the presence of 1.2 
equivalents of HOBt, 3.0 equivalents of triethylamine, and molecular sieves in dry DMF, 
protection of 2-41 increased to 82% (Table 7, Entry 2). Interested in utilizing the commercially 
available and more stable hydrochloride salts, exposure of phenylalanine ester hydrochloride 2-25 
to the same conditions, albeit with an extra equivalent of amine base, showed no decrease in yield, 
isolating Tempoc amine 2-26 in 84%  (Table 7, Entry 3). Furthermore, reduction of HOBt loading 
to 1.0 equivalents in the presence and absence of molecular sieves led to comparable yields (Table 
7, Entries 4 and 5). ACS grade solvents or also compatible with the reaction, even without 
molecular sieves (Table 7, Entries 6‒7). Notwithstanding, we continued to use dry DMF 
throughout the project as we have found considerable variances in ACS grade DMF quality from 
different vendors. We were driven to further reduce the loading of HOBt to catalytic amounts 
while also reducing the equivalents of base to preclude any racemization propensity (Table 7, 
Entries 8–11). With 0.5 equivalents of HOBt, and 2.5 equivalents of triethylamine, Tempoc ester 
2-26 was isolated in an acceptable 83% yield (Table 7, Entry 10).  
HOBt hydrate water content is not precisely given on reagent bottles; therefore, to be 
accurate and reproducible with our reactions, we used the anhydrous reagent. However, HOBt 
hydrate is known to exhibit greater stability and is more readily available. Consequently, we set 
out to test it as an alternative to the anhydrous version. As expected, HOBt hydrate in the presence 
and absence of molecular sieves provided clean conversion to Tempoc phenylalanine 2-26 in 80% 
and 82% yields, respectively (Table 7, Entries 12 and 13). Alternative bases, solvents, HOBt 
substitutes, and further decreasing the loading of the activator led to diminished yields 
(Experimental Part, Table 16) 
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Table 7 Optimization of Tempoc protection of phenylalanine ethyl ester through NPTC activation 
 
entry activator (equiv) Et3N (equiv) 4 Å MSa solvent isolated yield (%) 
1 - Et3N (3.0) Y dry DMF 19 
2b HOBt (1.2) Et3N (3.0) Y dry DMF 82 
3 HOBt (1.2) Et3N (4.0) Y dry DMF 84 
4 HOBt (1.0) Et3N (4.0) Y dry DMF 88 
5 HOBt (1.0) Et3N (4.0) N dry DMF 88 
6 HOBt (1.0) Et3N (4.0) Y wet DMF 88 
7 HOBt (1.0) Et3N (4.0) N wet DMF 87 
8 HOBt (0.5) Et3N (4.0) Y dry DMF 83 
9 HOBt (0.5) Et3N (3.0) N dry DMF 80 
10 HOBt (0.5) Et3N (2.5) N dry DMF 83 
11 HOBt (0.5) Et3N (2.0) N dry DMF 77 
12 HOBt hydrate (0.5)c Et3N (2.5) N dry DMF 80 
13 HOBt hydrate (0.5)c Et3N (2.5) Y dry DMF 82 
a100 mg/mmol amine; bamine 2-41 was used; cHOBt (97%) contained ≥ 20% wt. water 
Importantly, with our optimized conditions, Marfey’s analysis was conducted on Tempoc 
phenylalanine 2-26, which showed no detectable racemization under these protection 
conditions.78,79 Additionally, a large scale synthesis of Tempoc transfer reagent NPTC and 
subsequent protection of phenylalanine ethyl ester using these optimized conditions has been 
detailed (Experimental Part).  
With optimized conditions (i.e., NPTC (1.0 equiv), HOBt (0.5 equiv), and triethylamine 
(2.5 equiv), in DMF (0.5 M, rt, 24 h), we set out to explore a variety of amino-esters for Tempoc 
protection. First, we sought to show that the reaction conditions are compatible with the range of 
ester protective groups used in peptide synthesis (Figure 6). Methyl, ethyl, tert-butyl, and benzyl 
glycinates were all protected in good to excellent yield. Moreover, unprotected glycine was also 
protected to afford Tempoc glycine amino acid 2-42 in 46% yield. Next, we tested the effect of N-
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substitution on the amino ester; N-methyl ethyl glycinate was converted to its Tempoc derivative 
in 92% yield, whereas the N-benzyl analog suffered from reduced yields, only providing N-
benzylated Tempoc amino ester 2-46 in 67% yield. Furthermore, Tempoc protection was extended 
to a variety of bulky substituted amino esters that all converted to their Tempoc derivatives 2-49 
‒ 2-51 in good yields, except for α-cyclopropyl substituted amino ester 2-52, which was isolated 
in only 30% yield. As in our previous work, NPTC chemoselectivity was maintained toward 
amines in the presence of hydroxyl groups and arylamines, even under these activated conditions. 
Interestingly, we were able to leverage the slow reactivity of the α-amino moiety toward NPTC in 
the absence of HOBt to selectively protect the side-chain of lysine ethyl ester in 90% yield. 
 
Figure 6 The scope of Tempoc protected aminno esters 
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2.2.3  Synthesis of Gramicidin S monomer 
Finally, we were interested in demonstrating the utility of Tempoc as a useful protecting 
group for peptide synthesis be synthesizing a pentapeptide monomer of Gramicidin S (GS) (Figure 
7). GS is a C2-symmetric cyclic decapeptide that exhibits potent antibacterial effects against gram-
positive and gram-negative bacteria.80 GS, and its analogs have also been a compound of interest 
in our group, and we thought it appropriate to demonstrate our Tempoc methodology toward its 
synthesis.81,82 
 
Figure 7 The structure of the cyclopeptide Gramicidin S 
Our retrosynthetic analysis of Gramicidin S monomer 2-57 utilizes a 3+2 approach 
(Scheme 23). First, construction of Tempoc-protected tripeptide 2-59 would be carried out using 
typical HATU mediated coupling conditions starting with Tempoc valine 2-51. Then, Tempoc 
dipeptide 2-58 would be synthesized in the same fashion staring with phenylalanine 2-47. Final 
coupling of the tri- and dipeptide fragments would afford the pentapeptide monomer of Gramicidin 
S. Final Tempoc deprotection of 2-57 would afford the free amine, which may be further 
elaborated to Gramicidin S. 
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Scheme 23 Retorsynthetic analysis for the synthesis of Gramicidin S monomer 2-57 
With this plan, the first objective was to synthesize tripeptide 2-59. Our initial plan was to 
construct the peptide using standard solution phase methods building from the N- to the C-
terminus. And indeed, the coupling steps went as expected affording tripeptide 2-59 in 94% overall 
yield. However, upon analysis of the NMR of tripeptide 2-59, it was determined that epimerization 
had occurred, most likely at the ornithine α-carbon during the final coupling step affording tripetide 
epi-2-59 as a 1.2:1 mixture of epimers (Scheme 24, Eq. 1).  
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Scheme 24 Original synthesis of Gramicidin fragment 2-59 
To confirm that this was not due to the nature of the Tempoc group, the Boc protected 
analog was synthesized and analyzed by NMR, which similarly produced tripepetide epi-2-65 as 
a 1.2:1 mixture of epimers (Scheme 24, Eq. 2). In order to counteract the epimerization in the final 
coupling step, we switched our synthetic approach and starting from C-terminal leucine. Initially, 
we attempted our new synthetic approach on the Boc analog to confirm that our synthetic strategy 
would provide Boc-tripeptide 2-65 without any detectable racemization (Scheme 25, Eq. 1). 
Utilizing Boc, Cbz, bis-protected ornithine 2-66, HATU mediated coupling with leucine methyl 
ester provided the Boc protected dipeptide intermediate which was directly deprotected with 
standard TFA conditions and subsequently treated once again with HATU in the presence of Boc-
valine which provided tripeptide 2-65 in 89% overall yield. Tripeptide 2-65 was successfully 
synthesized without any detectible epimerization through NMR analysis.  Our decision to use Boc-
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ornithine 2-66 instead of its Tempoc equivalent was to avoid the well-known propensity of 
dipeptide cyclization under the mildly basic conditions required for Tempoc deprotection.83,84 
With our new synthetic route validated, we continued to construct Tempoc tripeptide 2-59 in the 
same manner in 83% yield over 3 steps (Scheme 25, Eq. 2).  
 
Scheme 25 Revised synthesis of Tempoc tripeptide 2-59 
2.2.4  Optimization of Tempoc deprotection 
With a successful route towards tripeptide 2-59 in hand, we turned our attention to the 
Tempoc deprotection step. In our original publication we utilized in situ generated copper(I) to 
reductively cleave Tempoc. Our optimized conditions were copper(II) chloride (0.10 equiv) and 
ascorbic acid (3.0 equiv) in a ternary mixture of MeCN/THF/H2O (0.12 M, 12 h, 40 °C). Initial 
reactions with Tempoc phenylalanine ethyl ester 2-26 led to a new peak in the LC-MS trace which 
accounted for approximately 40% of the total peak area on the UV trace at 220 nm. After careful 
analysis of the byproduct mass, and a thorough literature search of the known ascorbic acid 
byproducts, we deduced that the unidentified peak was that of the condensation product of 
deprotected phenylalanine 2-25 and xylosone. Xylosone is a known degradation product of 
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dehydroascorbic acid, which is produced stoichiometrically from the reduction of copper(II) 
chloride during the course of the deprotection.85,86 We hypothesized that this imine underwent 
acid-mediated solvolysis during our tosic acid resin workup-isolation protocol, thus, this 
byproduct was never observed. Using this result as an opportunity to modify the original conditions 
to preclude formation of this byproduct we explored alternative reducing agents such as Zn, Mn, 
Fe, In, Mg, NaHSO3, Na2SO3, and Na2S2O3 in the presence of copper(II) chloride (0.10 equiv). 
However, either no product was observed or only a small amount of deprotected amino ester 2-25 
was detected by HPLC-MS (Table 8). We believed that the reducing metals over-reduced 
copper(II) to copper(0) before the intermediate copper(I) species could enter the catalytic cycle. 
Moreover, the sulfur reducing agents either produced copper(0) as well, or precipitated the copper 
as a reddish-brown insoluble sulfite adduct believed to be Chevreul’s salt (Cu(I,II) sulfite 
dihydrate). 
Table 8 Reaction screen for alternative reducing agents for Tempoc deprotection 
 
entry reductant conversion (HPLC-MS) observations 
1 Zn trace copper(0) ppt 
2 Mg trace copper(0) ppt 
3 Fe ND copper(0) ppt 
4 In trace copper(0) ppt 
5 Mn ND copper(0) ppt 
6 1.5 M aq. NaHSO3 < 10% Chevreul’s salt ppt 
7 1.5 M aq. Na2SO3 < 10% Chevreul’s salt ppt 
8 1.5 M aq. Na2S2O3 trace copper(0) ppt 
ND = not detected; ppt = precipitate; HPLC-MS = conversion determined by AUC @ 220 nm; Chevreul’s salt = copper(I,II) sulfite 
dihydrate 
Still interested in utilizing an inorganic reductant to facilitate workup and preclude 
formation of the xylosone byproduct, we attempted to add a ligand to stabilize the copper in 
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solution and reduce formation of the insoluble Chevreul’s salt. With sodium bisulfite as the 
reductant in the presence of 0.1 equivalents of copper(II) chloride, we screened 4 common ligands, 
tetramethylethylenediamine (TMEDA), bipyridine (bpy), ethylenediamine (en), and 
dimethoxyethane (DME) (Table 9). In all cases the reaction stalled with no more than 10% 
conversion to desired free amine 2-25, even with increased heating (60 °C) and longer reaction 
time (48 h). We also utilized the commercially available copper(I) thiophenecarboxylate complex, 
which also stalled after no more than 10% conversion. In all cases we observed the formation of 
Chevreul’s salt, which precipitated as a red-brown solid, indicating that the complexation of copper 
with sulfite is quite facile. 
Table 9 Screen of copper ligands to enable utilization of inorganic reducing agents 
 
entry CuX ligand conversion (HPLC-MS) 
1 CuCl2 TMEDA < 10% 
2 CuCl2 bpy < 10% 
3 CuTC – < 10% 
4 CuCl2 en < 10% 
5 CuCl2 DME < 10% 
6 CuCl2 – < 10% 
HPLC-MS = conversion determined by AUC @ 220 nm 
Since other reducing agents proved to be inferior, we resumed the use of ascorbic acid. We 
questioned the possibility of precipitating the DHA during the reaction by performing the reaction 
under anhydrous conditions. A qualitative test showed that in DME, DMF, and MeCN ascorbic 
acid exhibited enough solubility to reduce copper(II) to colorless copper(I). With this in mind, we 
ran a screen of solvent mixtures (Table 10). In all cases, the reaction developed a deep red color 
and HPLC-MS showed the presence of the xylosone adduct, plus several additional unidentifiable 
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peaks. Moreover, the reaction rate seemed to be slowed by either the absence of water, or the 
formation of other deleterious byproducts. Therefore, we concluded that the presence of water in 
the reaction was reducing the propensity of DHA to decompose into other compounds. 
Interestingly, we did notice that the reaction in 5:1 DME/H2O (Table 10, Entry 3) was complete 
in under 12 h, while also displaying the cleanest reaction profile. This was a serendipitous 
discovery, which led us to swap DME for THF and MeCN in future optimizations. Importantly, 
we hypothesized that DME would fill two roles, 1) as a ligand to stabilize copper(I), and 2) as a 
solubilizing agent to replace THF. Additionally, DME is commonly sold inhibitor-free, thereby 
reducing yet another possible contaminant in the deprotection reactions.  
Table 10 Solvent screen for THF replacement in Tempoc deprotection 
 
entry solvent conversion after 12 h (HPLC-MS) 
1 MeCN incomplete 
2 MeCN:DME (10:1) incomplete 
3 MeCN:DME (5:1) complete 
4 MeCN:DMF (3:1) incomplete 
5 MeCN:DMF:DME (6:2:1) complete 
6 MeCN:DMF:DME (3:1:1) complete 
HPLC-MS = conversion determined by AUC @ 220 nm 
With our new goal of using ascorbic acid as the reductant, and replacing acetonitrile and 
THF with DME, we further screened a number of deprotection modifications and monitored the 
formation of byproduct 2-67 by HPLC-MS analyzed at 220 nm (Table 11). To further understand 
the kinetics of the formation of this condensation product, we monitored the reaction over time by 
sampling the reaction mixture at 90-minute intervals to see if the formation of the DHA-byproduct 
happens immediately or slowly during the reaction. We hypothesized that increasing the 
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concentration of water in the reaction would help to hydrolyze imine 2-67, thus precluding its 
accumulation during the reaction. Indeed, as water concentration increased, decreased amounts of 
imine 2-67 were observed by HPLC-MS (Table 11, Entries 1–3). Next, we hoped that lowering 
the pH of the reaction mixture would preclude formation of the imine by sequestering the nitrogen 
lone-pair via protonation, or by aiding the hydrolysis of 2-67 by acidic activation. Unfortunately, 
while lowering the pH of the mixture and increasing the water concentration did lead to a reduction 
of the impurity from 40% to 30% (Table 11, Entries 4–6), complete removal of the impurity was 
not achieved.  
Table 11 Optimization towards minimization of byproduct formation in Tempoc deprotection 
 
entry reductant solvent ratio (DME:H2O)  additive (equiv) conversion (h) 2-69 (AUC %) 
1 Asc 4:1 – 1.5 48 
2 Asc 2:1 – 1.5 44 
3 Asc 1:4 – 1.5 30 
4 Asc 4:1 AcOH (3.0) 1.5 40 
5 Asc 2:1 AcOH (3.0) 1.5 36 
6 Asc 1:1 AcOH (3.0) 1.5 30 
7 Asc 1:1 AcOH (5.0) 1.5 40 
8 NaAsc 1:1 – 1.5 0 
9 NaHSO3 4:1 – NC 0 
10 Zn 1:0 – NC 0 
11 Mg 1:0 – NC 0 
 
Furthermore, increasing the amount of acetic acid actually increased the amount of 
observed imine 2-67 (Table 11, Entry 7), leading us to believe that the imine is quite stable, and 
acid may be catalyzing the condensation rather than the hydrolysis. However, we were excited to 
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discover that when the ascorbic acid was replaced by its sodium form (sodium ascorbate, NaAsc) 
we observed no detectable quantities of imine 2-67 (Table 11, Entry 8). Possibly, nearly neutral 
pH conditions reduced the rate for the formation of xylosone to lower than the rate of Tempoc 
deprotection. Another interesting observation made during the optimization was that all reactions 
were complete within 90 min. We hypothesize that with the introduction of DME as solvent and 
ligand, the stability of the in situ generated copper(I) species was greatly increased, leading to 
faster catalyst turnover. Finally, we retested the inorganic reductants sodium bisulfite, zinc, and 
magnesium once more to see if their reactivity was also enhanced by the introduction of DME as 
solvent. However, we observed that the reactions once again stalled after only a minimal amount 
of conversion (Table 11, Entries 9–11).  
With these enhanced conditions (i.e., sodium ascorbate in 1:1 DME/H2O), we anticipated 
the ability to reduce the copper loading and equivalents of reductant needed beyond what was 
capable using ascorbic acid in the ternary solvent mixture. As such, we proceeded to switch to 
Tempoc tripeptide epi-2-59 and continue our optimization utilizing this highly functionalized 
compound (Table 12). As expected, this functionalized tripeptide deprotected at a slower rate than 
Tempoc phenylalanine 2-26, probably due to increased molecular weight and greater bulk around 
the target amine. The deprotection with 10 mol % copper(II) chloride, and 3.0 equivalents of 
sodium ascorbate was complete in under 2.5 h, as opposed to 1.5 h as was observed by HPLC-MS 
(Table 12, Entry 1). We were able to reduce the copper(II) loading to 3.5 mol % with only a 
moderate increase in reaction time to 7 h (Table 12, Entries 2–4). Further reduction in copper 
loading was met with poor reproducibility in conversion times (Table 12, Entries 5 and 6). Next, 
with 3.5 mol % copper(II) in 1:1 DME/H2O, we were able to decrease the equivalents of sodium 
ascorbate down to 1.2 before reaction instability was observed (Table 12, Entries 7–11).   
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Table 12 Optimization of copper and reductant loading for the Tempoc deprotection of epi-2-59  
 
entry CuCl2 (mol %) NaAsc (equiv) conversion time (h) 
1 10.0 3.0 < 2.5 
2 7.5 3.0 < 2.5 
3 5.0 3.0 5 
4 3.5 3.0 7 
5 2.5 3.0 6–9 
6 1.0 3.0 > 12 
7 3.5 2.5 7 
8 3.5 2.0 7 
9 3.5 1.5 7 
10 3.5 1.2 7 
11 3.5 1.0 7.5–8 
Conversion time was determined by consumption of starting material as observed by LC-MS 
 
With the deprotection conditions fully optimized (i.e. 3.5 mol % CuCl2, 1.2 equiv NaAsc, 
in 1:1 DME/H2O (0.15 M, 40 °C, 7 h)) we set out to reevaluate the reaction workup in order to 
preclude the need for chromatography. In our original publication, we utilized a catch-and-release 
method to purify the resultant amines.1 While the tosic acid functionalized resin (SiliCycle Si-
TsOH) was convenient and effective for our previous scope, we envisioned the use of this resin in 
the context of peptide synthesis to be problematic. Common protective groups used in peptide 
synthesis, such as trityl, Boc, and tert-butyl esters and ethers, could potentially be unstable to the 
strongly acidic resin.87 Therefore, we wanted to devise a milder alternative method for 
chromatography-free amine isolation. With our target impurities being copper salts in various 
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oxidation states and ascorbate (and its possible degradation products), we devised a plan to isolate 
the peptide amine in pure form (Table 13).  
Table 13 Optimization of the chomatography-free Tempoc deprotection of tripeptide epi-2-59 
 
entry workup/isolation phase result 
1 catch and release IRC-86 amine not retained 
 2 catch and release MAC-3 amine not retained 
3 catch and release CG-50 amine not retained 
4 extraction 1 M NH4OH emulsion  
5 extraction 1 M (NH4)2SO4 emulsion 
6 extraction 0.5 M Na3-citrate emulsion 
7 extraction then chromatography sat. NaCl then SiO2 phase split 
8 extraction sat. NH4Cl-NH4OH (pH=10) phase split and copper removal 
 
First, to amend our original catch-and-release method of purification, we attempted to 
switch the resin from the strong sulfonic acid to a weaker carboxylic acid functionalized resin. We 
envisioned the weaker acid being compatible with the sensitive protective groups used in peptide 
synthesis while maintaining the ability to ‘catch’ the liberated free amine. However, when the 
reaction mixture was passed through a 1.5” plug of carboxylic acid functionalized resins IRC-78, 
MAC-3, and CG-50, we observed no retention of the basic amine (Table 13, Entries 1–3). We then 
tried stirring of the crude reaction mixture for 60 min in the presence of the resin, followed by 
filtration, and once again, we observed no retention of the amine. It is worth noting that copper 
was effectively removed by stirring in all three of the resins. Next, we thought that a creative 
extractive workup could provide deprotected peptide 2-68 in pure form. Initial aqueous workups 
 47 
on 2-68 typically resulted in the formation of persistent emulsions that resulted in low mass 
recovery. In an attempt to simultaneously remove the residual copper salts, and also remove the 
ascorbate byproducts, we targeted three high-ionic strength aqueous phases, and directly washed 
our crude reaction mixtures with them after dilution with ethyl acetate (Table 13, Entries 4–6). 
High-ionic strength solutions should preclude emulsion formation while also ensuring excellent 
recovery of the possibly water-soluble peptide 2-68.88 While the 1 M ammonium hydroxide, 1 M 
ammonium sulfate, and 0.5 M trisodium citrate aqueous phases did remove the copper salts and 
ascorbate byproducts, unfortunately, persistent emulsions or complex rag-layers also formed, 
resulting in low recovery of peptide 2-68. Granted that when we then tested a saturated sodium 
chloride extraction a clean phase-split of the aqueous/organic layers was observed, copper salts 
also partitioned into the organic layer with varying amounts of ascorbate byproducts, and the 
resulting extract required subsequent chromatography (Table 13, Entry 7). Finally, utilizing the 
promising results from ammonia solutions, we sought to create a buffered ammonia solution of 
considerable ionic strength while also maintaining ease of work-up by using standard laboratory 
resources. Thus, we adjusted the pH of a saturated ammonium chloride solution to pH = 10 by the 
addition of concentrated ammonium hydroxide. After dilution of the reaction mixture with ethyl 
acetate, and treatment of the organic layer with this solution, we observed a clean phase-split, 
which after separation resulted in complete removal of the copper and ascorbate impurities, 
resulting in clean recovery of deprotected tripetide 2-68 (Table 13, Entry 8). 
2.2.5  Future directions 
With optimized deprotection conditions in hand, and synthesis of Tempoc protected 
Gramicidin fragment 2-59 completed, we propose the completion of the synthetic sequence to 2-
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57 (Scheme 26). Dipeptide 2-58 should be easily accessible using standard HATU mediated 
coupling, which after saponification with lithium hydroxide would afford the carboxylic acid. 
Subsequently, this intermediate would be coupled with the free amine of 2-59 after Tempoc 
deprotection. Finally, an orthogonal deprotection of pentapeptide 2-57 would selectively afford 
Tempoc deprotected 2-69, or alternatively, Cbz deprotected 2-70. 
 
Scheme 26 Proposed completion of Gramicidin monomer 2-57 
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3.0 EFFORTS TOWARDS THE TOTAL SYNTHESIS OF α-CYCLOPIAZONIC ACID  
3.1 INTRODUCTION 
3.1.1  α-Cyclopiazonic acid structure and activity 
α-Cyclopiazonic acid (CPA) is a mycotoxin produced by the fungi Aspergillus and 
Penicillium.89 The first isolation and structure elucidation was by Holzapfel in 1968, who isolated 
the compound from cereal grains that were infected by Penicillium cyclopium Westling.90  This 
small indole-tetramic acid molecules possesses activity against sarcoplasmic reticulum Ca2+ 
ATPases (SERCA), which has been linked to heart failure, carcinogenesis, diabetes, and cardiac 
hypertension.91,92 SERCA is a calcium pump that is essential for calcium transportation to the 
muscles, and cyclopiazonic acid has been shown to be one of a very limited number of specific 
inhibitors of this biological target.93 More recently, CPA has been shown to have antiviral activity 
against the human respiratory syncytial virus (HRSV).94  
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Figure 8 The structures of CPA and selected Speradines and Aspergillines 
The pentacyclic structure of CPA closely resembles the ergoline family of alkaloids, 
including cycloclavine and lysergic acid (Figure 8). Furthermore, highly oxygenated congeners of 
cyclopiazonic acid, such as Speradines B-F95–97 and Apergillines A-E,98 have been isolated and 
have been receiving much attention in the synthetic community.99–101 
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Scheme 27 Biosynthesis of CPA 
 
Cyclopiazonic acid is synthesized biologically from L-tryptophan.102,103 Pyrrolidinedione 
3-14, cyclo-acetoacetyl-L-tryptophan (cAATrp), is the first stable intermediate in the biosynthetic 
pathway. This is derived from the Dieckmann cyclization of acetoacetamide 3-13, which is formed 
through an acylation of tryptophan with an acetoacetyl-tethered ACP (acyl carrier protein). Next, 
C(4) alkylation of the indole ring with DMAPP, 3-15 (dimethylallyl pyrophosphate) gives β-
cyclopiazonic acid 3-16, and subsequent reductive ring closure of the pyrrolidinedione onto the 
prenyl moiety affords α-cyclopiazonic acid 3-1. This final annulation is catalyzed by the FAD-
dependent enzyme monoamine oxidase A (MaoA). 
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3.1.2  Previous syntheses of cyclopiazonic acid 
The unique biological properties of CPA have aroused the interest of synthetic chemists 
for decades. However, since its discovery in 1968 there have only been three syntheses of racemic 
CPA, and two enantioselective syntheses of (–)-CPA. The first total synthesis of racemic 
cyclopiazonic acid were reported in 1984 by Kozikowski and Greco (Scheme 28).104 
 
Scheme 28 Kozikowski and Greco’s total synthesis of racemic CPA 
 53 
Indole 3-17 was prepared in 4 steps from 1-tosyl-indole-4-carboxyaldehyde with an overall 
yield of 82%. Vilsmeier-Haack formylation and subsequent condensation with acetamidomalonic 
acid ester 3-18 gave intermediate acetal 3-19. Protection of the indole nitrogen and deacetalization 
liberated ketone 3-20. Pyrrolidine 3-24 was elaborated through trimethylsilyl iodide mediated 
thermodynamic enolization, and treatment of the enolate with phenylsulfenylchloride provided 
sulfide 3-21 in 55% yield. Under basic conditions, intramolecular Michael addition afforded 
tricycle 3-22 in good yield. Desulfurization with Raney nickel provided pyrrolidine 3-23 with cis 
configuration. Magnesium triflate-catalyzed condensation of the acetamide onto the ketone in the 
presence of thiophenol produces the pyrrolidine sulfide adduct 3-24. Treatment of the sulfide with 
dimethyl zinc in chloroform finalized construction of the gem-dimethyl substitution. Exposure of 
acetamide 3-25 to Meerwein’s reagent deprotected the amine, which reacted smoothly with 
diketene to afford the penultimate cyclopiazonic acid precursor 3-26. Sodium methoxide promoted 
the intramolecular Dieckmann condensation onto the ethyl ester, providing iso-α-cyclopiazonic 
acid 3-27, which was epimerized to desired isomer 3-1 with heating in the presence of 
triethylamine. Ultimately, the epimerization provided a 2.5:1 mixture of desired isomer 3-1 to iso-
compound 3-27. 
A year later, in 1985, Natsume published a variant of the total synthesis of racemic 
cyclopiazonic acid (Scheme 29).105 In a similar fashion to Kozikowski, he utilized an 
intramolecular Micheal addition to construct the C-ring, which led to a mixture of stereoisomers 
3-29, 3-30, and 3-31 in a ratio of 8.7:4.5:1 with an overall yield of 84%. Isomer 3-29 was exposed 
to hydrogen chloride in a mixture of ethanol and water, which produced cyclic imine 3-32 in good 
yield. Installation of the gem-dimethyl proved difficult using organometallic reagents, and after 
treatment of the imine with boron trifluoride diethyl etherate, methyl lithium was added to produce 
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dimethyl product 3-33 in 4% yield. Deprotection of indole 3-33 was accomplished using basic 
hydrolysis with KOH, and the resulting acid was re-esterified with ethyl tosylate 3-34 to afford 
amino ester 3-35. Dieckmann cyclization with diketene furnished α-cyclopiazonic acid 3-1 in 89% 
over two steps.   
 
Scheme 29 Natsume’s 1985 total synthesis of 3-1 
Another synthesis of racemic cyclopiazonic acid was published in 2005 by Haskins and 
Knight.106 In their synthesis, they utilized a creative cationic cascade reaction to construct the C- 
and D-rings (Scheme 30). Beginning with 4-hydroxylmethyl indole 3-36, protection of the free 
hydroxyl as the silyl ether followed by Vilsmeier-Haack formylation and tosylation of the indole 
nitrogen gave intermediate 3-37 in 66% yield over 3 steps. Horner-Wadswroth-Emmons 
homologation of the aldehyde afforded unsaturated ester 3-38 in good yield. Phenylthiocuprate 
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mediated conjugate addition of proprenylmagnesium bromide onto ester 3-38, followed by 
enolization and nucleophilic azidolysis provided azidoester 3-39. Staudinger reduction and 
protection of the free amine gave nosylate 3-40 in reasonable yield over 2 steps. Triflic acid 
promoted cationic cascade cyclization provided the C- and D-rings of intermediate 3-42 in 74% 
yield. Finally, deprotection of the nosylate, and tetramic acid formation utilizing treatment of the 
free amine with diketene and subsequent base-mediated condensation cleanly afforded racemic 
cyclopiazonic acid.  
 
Scheme 30 Knight’s 2005 synthesis of racemic 3-1 
An improvement of Knight’s synthesis was published by the Sherkenbeck group a few 
years later in 2012.107 The use of a chiral auxiliary on indolyl acrylate 3-43 gave complete 
stereofacial control during the isoproprenylcuprate conjugate addition (Scheme 31). This marks 
the first asymmetric total synthesis of α-cyclopiazonic acid. 
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Scheme 31 Beyer’s asymmetric total synthesis of 3-1 
More recently, in 2018 Zhurakovskyi published an asymmetric synthesis of the 
cyclopiazonic acid family of natural products utilizing their sulfur ylide aziridination chemistry 
(Scheme 32).108 Prenylated indole imine 3-45 was prepared in 67% yield over 4 steps from 4-
bromo-indole-3-carbaldehyde. Camphor derived sulfonium 3-46 was synthesized in 4 steps from 
propargyl alcohol in 43% overall yield. Sulfur ylide formation and subsequent symmetric 
aziridination to furnish intermediate was carried out at –20 °C and afforded the desired aziridine 
in a 9:1 trans:cis ratio in favor of desired trans-diastereomer 3-47 with high enantiospecificity (er 
= 98:2). The authors report that trans-aziridine 3-47 was prone to epimerization and was telescoped 
into the cycloaddition step without further purification. Upon exposure of the crude aziridine to 
triflic acid, the 3+2 cycloaddition proceeded smoothly to give pyrrolidine 3-48 in 50% yield with 
complete enantiomeric retention and a diastereomeric ratio of 3.5:1. Potassium thiolate promoted 
nosylate deprotection gave the free amine, at which point the diastereomers were separated to give 
pyrrolidine 3-49. A cascade palladium-catalyzed carbonylation of the bromo-isoxazole and 
subsequent acylation, followed by reductive cleavage of the N–O bond afforded penultimate N-
tosyl cyclopiazonic acid imine 3-51 in good yield. Tosyl deprotection and hydrolysis of the imine 
gave cyclopiazonic acid 3-1 and iso-cyclopiazonic acid 3-27 as a 2.5:1 mixture of stereoisomers, 
which were separated by HPLC to provide enantiopure CPA. The authors also note that when the 
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detosylation was carried out under anhydrous conditions, cyclopiazonic acid imine 3-52 can be 
isolated in 80% yield. 
 
Scheme 32 Zhurakovski’s asymmetric total synthesis of 3-1 
3.2 RESULTS AND DISCUSSION 
3.2.1  Retrosynthetic analysis of cyclopiazonic acid 
Since five total syntheses, two of which as asymmetric variants, have already been 
reported, we were compelled to improve on the synthetic sequence while taking on more ambitious 
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transformations. All five syntheses start with the A- and B-rings in place as functionalized indoles. 
We set out to showcase our advancements in the intramolecular Diels-Alder furan (IMDAF) 
cyclizations by constructing the indole moiety at a later stage in the synthetic sequence (Scheme 
33).32,109–111 
 
Scheme 33 Retrosynthetic analysis of cyclopiazonic acid 3-1 
We envisioned installation of C- and D-rings early in the synthetic route with a 
diastereoselective 1,3-dipolar cycloaddition of 3,3-dimethyl aziridine carboxylate 3-59 and chiral 
cyclohexanone 3-60. With this approach, all stereogenic carbon centers would be set early, along 
with the gem-dimethyl, which was proven to be difficult in Kozikowski and Natsume’s total 
syntheses, which suffered from either low yields or requiring multiple synthetic steps. 
Cycloadditions of 3,3-dialkyl aziridines are unprecedented in the literature, and we thought to 
explore this as a viable option for facile construction of highly substituted pyrrolidines. After 
formation of the C- and D-rings we envisioned a Seagusa-Ito type oxidation to form enone 3-56. 
Luche reduction of the carbonyl and acylation affords the allylic acetate, which undergoes further 
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transformation via mesylation and displacement with protected furylamine 3-57 to furnish the 
IMDAF precursor 3-55. Palladium catalyzed intramolecular Diels-Alder furan cyclization would 
form the indolinic A- and B-rings. Finally, deprotection of the pyrrolidine nitrogen tetramic acid 
formation through treatment with diketene, base, and heat would finish the synthesis of 
cyclopiazonic acid. 
3.2.2  Progress towards the total synthesis of α-cyclopiazonic acid 
The retrosynthetic design allows a key step to be very early, if not the first step, in the 
synthesis. This allows for an expeditious assessment of feasibility and troubleshooting. With this 
in mind, we set out to develop a model system before exploring this aziridine cycloaddition. In the 
mid to late 1960s, Hüisgen showed that aziridine dicarboxylates undergo thermal ring openings to 
form azomethine ylides.112–114 These ylides have since been extensively shown to undergo facile 
cycloaddition reactions with various dipolarophiles to generate substituted pyrrolidines and 
pyrroles; however, cycloadditions from 3,3-dialkyl aziridines have not been reported.115–122 As 
such, we set out to design a model system for the testing of this cycloaddition strategy. 
 
Figure 9 Competitive pathways of aziridine heterolysis based on N-protecting group 
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With the expectation that electron donating groups on the N-protecting group would 
facilitate the heterolysis of the C–C bond in the aziridine as opposed to competitive C–N cleavage 
(Figure 9), a series of N-protected 3,3-unsubstituted aziridine carboxylates were synthesized 
readily on large scale from various amines and dibromopropionate 3-65 (Scheme 34). Aziridine 
carboxylate 3-66 was prepared from 4-methoxybenzylamine in 84% yield in gram-quantities. 
Benzyl (Bn) and benzhydryl (Dpm) protected aziridines 3-68 and 3-67 were prepared from 
benzylamine and benzhydrylamine, respectively, in 77% and 86% yields. Finally, para-
methoxyphenyl (PMP) protected aziridine 3-69 was prepared in the same fashion from p-anisidine 
in 53% yield. 
 
Scheme 34 Synthesis of N-protected 3,3-unsubstituted aziridine carboxylates 
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With these aziridines in hand, we next sought to explore thermal cycloaddition with 
cyclohexenone 3-70 as a model dipolarophile. After minimal optimization we discovered that 
benzyl protected aziridine 3-68 reacted smoothly with enone 3-70 with heating to 200 °C in a 
sealed tube to afford cycloadduct 3-71 in 45% yield, which after purification, was condensed with 
4-nitrophenylhydrazine 3-72 gave hydrazone 3-73 as a single diastereomer whose structure was 
confirmed by x-ray crystallography (Figure 11). Furthermore, when benzhydryl aziridine 3-67 was 
heated in the presence of 3-70, cycloadduct 3-74 were isolated as a crystalline solid in 48% yield 
(Scheme 35, Eq. 2). The structure of this analog was also confirmed by x-ray crystallography 
(Figure 11). 
 
Scheme 35 Results of the cycloaddition of aziridines 3-68 and 3-67 with cyclohexenone 3-70 
To our surprise, however, the adducts 3-71 and 3-74 were found to display a different 
regioselectivity than expected. The adducts were formed by head-to-head coupling of the dipole 
and the dipolarophile rather than the expected head-to-tail adduct as based on the frontier 
molecular orbitals of the azomethine ylide.123 The PMP and PMB protected aziridines 3-66 and 3-
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69 also produced cycloaddition products by crude NMR and LC-MS analysis, but the reaction 
mixtures were more complex than their benzyl and benzhydryl counterparts.  
 
Figure 10 The X-ray structures of 3-73 and 3-74 
Since it was not clear if this regioselectivity also applied to the cycloaddition with the gem-
dimethyl aziridine carboxylate 3-59, we began the exploration of a viable route to synthesize the 
target 3,3-dimethyl aziridine carboxylate 3-59. A survey of the literature showed two predominant 
methods for this target molecule. A first route begins from the amino acid serine, and after 8-
chemical steps would afford N-Boc aziridine 3-82 (Scheme 36).124,125 This aziridine would have 
to undergo Boc deprotection and subsequent benzylation or benzhydrylation to afford aziridine. 
This route, while primarily amendable to large scale, was discarded due to its overall length. 
 
Scheme 36 The literature synthesis of aziridine 3-82 from serine 
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The next prevalent example used azido alcohol 3-87 and subsequent reduction and 
cyclization after treatment with triphenylphosphine (PPh3) (Scheme 37).
126 Starting with acrylic 
acid 3-84, Fisher esterification in ethanol with catalytic sulfuric acid afforded acrylic ester 3-85 in 
63% yield, which was lower than expected, most likely due to its volatility. The acrylate was then 
treated with meta-chloroperoxybenzoic acid in methylene chloride at reflux which gave 69% of 
desired epoxide 3-86. Azidolysis with sodium azide in refluxing acetone with ammonium chloride 
gave a 2:3 mixture of regioisomeric azido alcohols 3-87 and 3-88. After chromatography, the 
mixture of low molecular weight azido alcohols was used immediately in the reduction/cyclization 
step. However, no desired aziridine was observed by NMR.  
 
Scheme 37 Attempted synthesis of aziridine 3-89 from acrylic acid 3-84  
In parallel to the epoxide route, a regioselective route to azido alcohol 3-87 was being 
explored. This was accomplished using the Sharpless cyclic sulfate method for regioselective 
azidolysis (Scheme 38).127 Upjohn dihydroxylation with potassium osmate and N-
methylmorpholine oxide as the stochiometric oxidant gave vicinal diol 3-90 in excellent yield. 
Exposure of the diol to thionyl chloride gave the cyclic sulfite, which was oxidized to sulfate 3-91 
with sodium periodate and catalytic ruthenium chloride. Azidolysis of the cyclic sulfate occurs 
regioselectively with sodium azide in a 2:1 mixture of acetone/water. Hydrolysis of the sulfate to 
the alcohol typically uses acidic conditions, which gave the azido alcohol in 29% yield, however, 
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this route was abandoned due to the potentially explosive hydrazoic acid generation from the 
excess sodium azide used in the sulfate opening step. Sharpless’ method for aziridination was 
followed by lithium aluminum hydride reduction and hydrolysis of the sulfate with potassium 
hydroxide, but since both steps would not be amendable to the sensitive ethyl ester this route was 
abandoned. 
 
Scheme 38 Regioselective synthesis of azido alcohol 3-87 from acrylic ester 3-85 
At this point, a method for the iridium catalyzed aziridination of imines and ethyl 
diazoacetate was used.128 While the majority of Kubo’s work was on the aziridination of imines 
derived from aldehydes, an example existed for the aziridination of nonan-5-one. First, we needed 
to synthesize the imine from acetone, which has limited precedence in the literature, however, after 
some modification of literature protocols, we were able to isolate imine 3-92 and 3-94 
quantitatively in excellent purity after filtration and concentration (Scheme 39). The former, being 
a crystalline solid, could be stored in the freezer for months without degradation. The later, an oil, 
was more sensitive and was used immediately after being prepared. Upon treatment with ethyl 
diazoacetate (EDA), imines 3-93 and 3-94 were converted to their aziridine products in 68% and 
72% yield respectively. Aziridine 3-95 was a crystalline and was isolated without chromatography 
by recrystallization from ethanol.  
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Scheme 39 Synthesis of 3-59 and 3-95 via iridium catalyzed aziridination of imines 3-92 and 3-94 
The authors proposed a stepwise mechanism for the aziridination (Scheme 40). First, 
coordination of the imine to the iridium forms complex 3-98 which is followed by nucleophilic 
addition of the diazoacetate to the imine forms intermediate 3-99. Subsequent cyclization of this 
intermediate with the loss of dinitrogen gives aziridine 3-95. This method for construction of 3,3-
dialkyl aziridines should be further explored.  
 
Scheme 40 Mechanism for iridum catalyzed aziridination  
With the aziridine in hand, and the ability to produce multiple grams at a time, we set out 
to test the optimized cycloadditions with cyclohexenone (Scheme 41). Heating of aziridines 3-95 
and 3-59 in the presence of cyclohexenone 3-70 did not afford any isolable products, only 
decomposition of the starting materials was observed. Curious if the cycloaddition would work in 
the presence of a more reactive dipolarophile would result in product formation, we heated 
aziridines 3-95 and 3-59 in toluene with N-methylmaleimide 3-102 and acrylonitrile 3-105. While 
the benzhydryl analog did not produce product, we were excited to see that the benzyl derivative 
reacted with the dipolarophiles to produce bicycle 3-104 and pyrrolidine 3-107 in 68% and 20% 
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yield respectively as single diastereomers. The relative configurations of the of the stereocenters 
were assigned by comparison with literature examples and through 2-D NMR analysis.  
 
Scheme 41 Cycloadditions of aziridines 3-95 and 3-59 
While the model system using cyclohexenone 3-70 did react with the gem-dimethyl 
aziridines, we thought that the ester on the aziridine and hydroxylmethyl cyclohexenone 3-60 
detailed in our retrosynthetic hypothesis would allow for the possibility of in intramolecular 
cycloaddition utilizing tethered enone-ester 3-108 (Scheme 42). Solvolysis of lactone 3-109 would 
provide the free hydroxyl group for the mesylation and displacement by Boc-furanamine 3-57. 
While this would give us all-cis configuration on the pyrrolidine, we hypothesized that a late-stage 
epimerization could be performed on epi-3-54, providing the more favorable trans-isomer 3-54.  
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Scheme 42 Proposed synthetic route to cyclopiazonic acid utilizing an intramolecular aziridine cycloaddition 
Intramolecular cycloadditions are known to be more facile than their intermolecular 
counterparts.118 Before this could be explored, however, hydroxymethyl cyclohexenone 3-60 
would need to be synthesized. This was accomplished utilizing chemistry published by Rawal in 
1997 (Scheme 43).129,130 Starting with Danishefsky’s diene, we first converted the vinylogous ester 
to amide 3-112 by condensation with dimethylamine in THF. Upon treatment of amide 3-112 with 
potassium hexamethylsilazide (KHMDS), subsequent trapping of the enolate with tert-
butyldimethylsilyl chloride (TBDMSCl) gave the corresponding siloxy diene. Exposure of this 
diene to methyl acrylate gave clean conversion to the Diels-Alder adduct 3-113, which after 
reduction with lithium aluminum hydride, provided intermediate hydroxymethyl silylenol. The 
TBDMS group was deprotected with HF in acetonitrile and in situ elimination of dimethylamine 
gave racemic cyclohexenone rac-3-60, which was isolated in good yield, only requiring one 
chromatographic step. An asymmetric variant towards 3-60 has also been published.131 
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Scheme 43 Synthesis of hydroxylmethyl cyclohexenone rac-3-60 
Our intramolecular hypothesis was first tested with 3,3-unsubstituted aziridine 3-67 
(Scheme 44). Saponification of aziridine 3-67 in a mixture of ethanol/THF and a few drops of 
water to solubilize the lithium hydroxide, and after acidification and extraction, gave aziridine acid 
3-114, which was used directly in the esterification step due to stability concerns. HBTU mediated 
coupling of alcohol rac-3-60 and acid 3-114 proceeded smoothly to provide tethered aziridine 3-
115 in 61% isolated yield. Heating of this compound in toluene in a sealed tube 150 °C for 16 h 
and then to 200 °C for 12 h provided the expected tricyclic cycloadduct 3-116 as a single 
diastereomer in 40% yield. The structure of 3-116 was confirmed by x-ray crystallography.  
 
Scheme 44 Synthesis and intramolecular cyclization of tethered aziridine 3-115  
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Encouraged by this result, we synthesized the gem-dimethyl aziridine variant (Scheme 45). 
Following the same saponification-esterification procedure, we were able to synthesize tethered 
aziridine 3-116 in 72% yield. However, when this aziridine was heated in toluene to 135 °C, only 
decomposition of the starting material was observed. Attempts to synthesize the benzyl protected 
analog failed at the saponification step, as this aziridine may be more prone to decomposition under 
the basic conditions required. 
 
Scheme 45 Synthesis and attemted cycloaddition of cyclohexenone tethered gem-dimethyl aziridine 3-118 
While the direct cycloaddition onto a cyclohexenone of an azomethine ylide formed from 
thermolysis of an aziridine was unsuccessful, an alternative approach is the generation of an 
azomethine ylide from the condensation of a glycinate onto an aldehyde or ketone in the presence 
of base and a Lewis acid, such as a silver or lithium salt, or even under metal-free thermal 
conditions.132–134 While to the best of our knowledge, no examples of ylides generated from dialkyl 
ketones have been reported utilizing this method, we thought to explore this as a possible route to 
fused-bicyclic intermediate 3-58 (Scheme 46). 
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Scheme 46 Proposed mechanism of metal mediated dipolar cycloaddition of glycine imine 
Generation of the glycine-acetone imine 3-120 from ethyl glycinate hydrochloride was 
accomplished by extraction of the freebase from aqueous ammonia and concentration of the rich 
organic extract. The amine freebase was then subjected to the optimized conditions (vida supra) 
affording glycine imine 3-120 in good yield and excellent purity after extraction. Imine 3-120 was 
relatively unstable upon exposure to moisture at ambient temperatures and was used immediately 
in subsequent reactions. However, storage of the imine as a solution in toluene at −20 °C was 
accomplished for up to 5 days without significant decomposition or hydrolysis as detectable by 
NMR. 
With a route to glycine imine 3-124 accessible, we screened an array of Lewis acid 
promoted cycloadditions that are typically found in the literature.135–137 Lithium bromide, and 
various silver and copper salts have been used previously, typically on imines derived from 
benzaldehydes. However, when we exposed imine 3-124 to these conditions, in the presence of 
various ligands and bases, we observed no detectable traces of cycloadduct 3-125 (Table 14). 
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Table 14 Condition screen for the Lewis acid promoted cycloaddition of glycine imine 3-124  
 
entry metal (equiv) ligand (equiv) base (equiv) 
1 LiBr (1.5) − Et3N (1.5) 
2 LiBr (1.5) − Et3N (1.5) 
3 AgOAc (1.5) − Et3N (1.5) 
4 AgOAc (1.5) − Et3N (1.5) 
5 AgOAc (0.05) − DIPEA (0.15) 
6 AgOAc (0.05) dppe DIPEA (0.15) 
7 AgOAc (0.05) rac-BINAP DIPEA (0.15) 
8 AgOAc (0.05) (S)-tBu-Box DIPEA (0.15) 
9 AgSbF6 (0.05) − DIPEA (0.15) 
10 Cu(CN)4PF6 (0.05) − DIPEA (0.15) 
11 Cu(CN)4PF6 (0.05) dppe DIPEA (0.15) 
12 Cu(CN)4PF6 (0.05) rac-BINAP DIPEA (0.15) 
13 Cu(CN)4PF6 (0.05) (S)-tBu-Box DIPEA (0.15) 
 
  
3.2.3  Future directions 
To complete the synthesis of cyclopiazonic acid using the aziridine cycloaddition/IMDAF 
approach, we propose utilizing a cyclopropane to install the gem-dimethyl group in a late-stage 
reductive cleavage (Scheme 47). The prerequisite cyclopropyl 1,3-dipole 3-129 could be generated 
in situ through ring opening of spirocyclic aziridine 3-126, or through the in situ condensation of 
N-benzyl ethyl glycinate 3-128 and cyclopropanone in the presence of base. This dipole should be 
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less sterically encumbered and substantially more reactive due to the reactive nature of methylene 
cyclopropyl compounds. Aziridine 3-126 can be prepared from methyl 2-chloro-2-
cyclopropylidineacetate.138–141 The synthesis and utility of cyclopropanone 3-127 is also well 
known.142–144 Cycloadduct 3-131 could be further elaborated to spirocyclic intermediate 3-132, 
which could then be reductively cleaved and converted to its gem-dimethyl analog with samarium 
diiodide or with catalytic hydrogenolysis with platinum dioxide.145,146 
 
Scheme 47 Proposed route for synthesis of cyclopiazonic acid 
 73 
4.0 EXPERIMENTAL PART 
4.1 EXPERIMENTAL – TEMPOC AMINES 
4.1.1  General experimental protocols  
Reactions were performed without inert atmosphere with ACS grade solvents unless 
otherwise stated. Inert reactions were performed under a N2 or argon atmosphere and glassware 
was flame dried prior to use. Deionized water, CH2Cl2, diethyl ether, and Et3N for NPTC synthesis 
were sonicated for 1 h under a steady stream of nitrogen prior to use. DMF, THF, and Et3N used 
for alkyl amine protections were not dried prior to use, although DMF was stirred vigorously under 
vacuum (2 Torr) at ambient temperature for 5 min to remove any volatile contaminants. THF used 
for aryl amine protections was distilled over sodium/benzophenone ketyl, or dried using an 
alumina column filtration system. Commercial grade reagents were used as-is unless otherwise 
noted. Reactions were monitored by TLC analysis (pre-coated silica gel 60 F254) and spots were 
visualized by UV (254 nm), iodine, ninhydrin (1.5 g of ninhydrin in 100 mL of absolute ethanol, 
then 3.0 mL of glacial acetic acid), p-anisaldehyde (5 mL of conc. H2SO4 and 1.5 mL of glacial 
AcOH in 135 mL of absolute ethanol, then 3.7 mL of p-anisaldehyde), 2,4-DNP (12 g of 2,4-
dinitrophenylhydrazine, 60 mL of conc. H2SO4, 80 mL of water, in 200 mL of 95% ethanol) or a 
KMnO4 solution (1.5 g of KMnO4, 10 g of K2CO3, and 1.25 mL of 10% NaOH in 200 mL of 
water). It is worth noting that iodine was an excellent general visualization method for all Tempoc 
protected amines, but KMnO4 may also be used with heating. DMF was removed on a rotary 
evaporator connected to a doubly-trapped high-vac pump (4.5 Torr) in a 35 °C water-bath. 
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Purifications by chromatography were performed using SiO2 (40-60 µm). 1H/13C NMR spectra 
were recorded on Bruker Avance 300/75 MHz, Bruker Avance 400/100 MHz, Bruker Avance 
500/125 MHz instrument, or Bruker Avance 600/150 MHz instrument. Chemical shifts were 
reported in parts per million (ppm) with the residual solvent peak or tetramethylsilane (TMS) used 
as the internal standard. Chemical shifts were tabulated as follows: chemical shift, multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet, dt = doublet of triplet, m = 
multiplet, b = broad, app = apparent), coupling constants, and integration. IR spectra were obtained 
on a Perkin-Elmer 100 IR-ATR spectrometer. Microwave reactions were performed using a 
Biotage Initiator or an Anton Paar Monowave 300 reactor in glass microwave vials (cap sealed) 
with continuous magnetic stirring and internal ruby thermometer and/or external infrared surface 
temperature sensor. LC-HRMS and ELS data were obtained on a Thermo Scientific Exactive 
Orbitrap LC-HRMS (ESI positive ion mode) coupled to an Agilent Technologies 385-ELSD and 
a Thermo Scientific Accela HPLC system using a 3.5 μm Waters XTerra C18 column (2.1 x 50 
mm; 10 min gradient elution with MeCN/H2O/MeOH containing 0.1% formic acid at a flow rate 
of 500 μL/min from 3:92:5 at 0-0.5 min to 93:2:5 at 4.0 min, back to 3:92:5 from 6.0 to 7.5 min). 
Melting points (uncorrected) were obtained using a Mel-Temp instrument. DSC exotherms were 
obtained on a Perkin-Elmer Pyris 6 differential scanning calorimeter with a scan rate of 10 °C/min 
and a scan range of 80–200 °C (2 sweeps).  
4.1.2  General methods and workup protocols 
General Method 1-A: Tempoc Protection of Alkyl Amines. A round bottom flask 
containing a stirbar was charged with amine (1.00 mmol, 1 equiv) and triethylamine (3.00 mmol, 
3.00 equiv) in DMF (2.0 mL) and the 0.5 M solution was cooled to 0 °C on an ice-bath before 
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treatment with NPTC (1.20 mmol, 1.20 equiv) as a solid in two portions. The reaction mixture 
turned yellow upon addition of the reagent. The heterogeneous solution was stirred for 5 min 
before being removed from the ice-bath (NPTC undergoes dissolution upon warming) and allowed 
to stir at ambient temperature for 12 h with monitoring by TLC and LC-MS. If necessary, for 
solubility, THF or CH2Cl2 may be added. For example, addition of a co-solvent in small quantities 
was necessary for the N-Boc and 4-phenylpiperidine substrates; however, if used in larger 
quantities, reaction rate decreased vs DMF. For some optimization studies varying solvents and 
bases, see Table 1. Upon completion of the reaction, the mixture was diluted with CH2Cl2 (5 mL) 
and poured into a separatory funnel containing ice-cold 1 M aqueous NaOH (20 mL) [sat. Na2CO3 
may also be used] and CH2Cl2 (10 mL). The organic layer was separated and the aqueous phase 
was extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were successively washed 
with water (15 mL), brine (15 mL), then dried (MgSO4), filtered, and concentrated under reduced 
pressure to afford a residue which was subjected to further purification on SiO2. 
General Method 1-B: Procedure for Tempoc Protection of Heterocyclic Amines. A 
flame dried round bottom flask containing a stirbar was charged with 90% sodium hydride (1.30 
mmol, 1.30 equiv) and dry THF (6 mL), and the solution was cooled to 0 °C on an ice-bath before 
dropwise addition of heterocyclic amine (1.00 mmol, 1 equiv) by syringe as a solution in dry THF 
(2 mL). This mixture was stirred for 30 min (or until effervescence was no longer observed) at 
ambient temperature before being cooled to 0 °C. NPTC (1.20 mmol, 1.20 equiv) was added 
dropwise by syringe as a solution in dry THF (2.0 mL). The reaction mixture was stirred at ambient 
temperature for 3 h with monitoring by TLC and LC-MS, and a bright orange sodium 4-
nitrophenoxide precipitated. Crushed ice (3 g ice per gram of amine) was added and the mixture 
was concentrated to half the volume under reduced pressure before addition of CH2Cl2 (10 mL). 
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The biphasic mixture was poured into a separatory funnel containing ice-cold 1 M aqueous NaOH 
(20 mL) [sat. Na2CO3 may also be used] and CH2Cl2 (10 mL). The organic layer was separated 
and the aqueous phase was extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were 
successively washed with water (15 mL) and brine (15 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure. The residue was further purified by chromatography on SiO2. 
Work-up Procedure 1-1 for Tempoc Protection. Upon completion of the reaction, the 
mixture was poured onto a sintered vacuum funnel containing a 1” pad (for reaction scale of <1 g) 
or a 1.5” pad (for reaction scale of ≥1 g) of pre-wetted (CH2Cl2) basic alumina (Brockmann Grade 
I) to remove p-nitrophenol. The product was then eluted with 3-4 column volumes of CH2Cl2 (or 
for more polar substrates, until yellow color approaches frit), and the filtrate was concentrated to 
afford a residue which was further purified by chromatography on SiO2. 
General Method 1-C: Procedure for Copper-Catalyzed Deprotection of Tempoc 
Amines.  A sealable vessel containing a stirbar was charged with Tempoc amine (1.00 mmol, 1 
equiv), ascorbic acid (3.00 mmol, 3.00 equiv), and anhydrous copper(II) chloride (0.100 mmol, 
0.100 equiv). A 4:1:1 mixture of MeCN/THF/H2O (556 μL:139 μL:139 µL) was added, and the 
0.12 M reaction mixture was sparged with nitrogen under sonication for 1 min before being sealed 
and allowed to stir at ambient temperature (40 °C for Tempoc protected primary amines) with 
monitoring by TLC and LC-MS.    
Work-up Procedure 1-2 for Tempoc Deprotection.  Upon completion of the reaction (≈ 
12 h), the volatiles were removed under reduced pressure to afford a green solution that was 
partitioned between CH2Cl2 (10 mL) and 2 M aqueous NH4OH (10 mL). During the extraction, a 
blue color was observed to migrate to the organic layer; this is believed to be a result of a 
disproportionation of Cu(I), and the colored impurity was removed upon filtration. The organic 
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layer was separated and the aqueous phase was extracted with CH2Cl2 (2 x 10 mL). The combined 
organic layers were washed with 2 M aqueous NH4OH (5 mL), deionized water (5 mL), and brine 
(5 mL), dried (MgSO4), filtered through a pad of Celite, and concentrated to afford a mixture of 
amine product and 2,2,6,6-tetramethylpiperidine (TMP). TMP was removed at 1.5 Torr at 35 °C 
to afford the pure amine product. Purification by chromatography, if necessary, may performed 
using triethylamine deactivated SiO2 (CH2Cl2/MeOH/Et3N). Traces of copper salts were removed, 
if necessary, by stirring the concentrated residue with a 0.5 M solution of 
ethylenediaminetetraacetic acid tetrasodium salt (Na4-EDTA) [5 equiv with respect to the initial 
loading of copper] in MeOH for 30 min at ambient temperature. The mixture was concentrated 
and the aqueous residue was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers 
were washed with water (3 mL) and brine (3 mL), dried (MgSO4), filtered and concentrated to 
afford pure amine.  
Work-up Procedure 1-3 for Tempoc Deprotection. Upon completion of the reaction (≈ 
12 h), the mixture was kept sealed to prevent further oxidation of the copper and consumption of 
the reducing agent and purified by chromatography on Si-Tosic Acid (SiliCycle, R60530B) [5 g / 
mmol starting material] with MeOH. Elution with 3 column volumes of MeOH followed by 3 
column volumes of MeCN ensured that all non-basic byproducts, and some of the copper was 
washed off the column. A ca. 2 M ammonia-methanol solution (prepared by bubbling ammonia 
gas through a gas dispersion tube submerged into chilled (ice-bath) MeOH for 30 min; the gas was 
generated by dropwise addition of conc. NH4OH directly onto KOH flakes and directing the gas 
thus produced through an empty bubbler (backflow preventer) to the gas dispersion tube. This 
solution was used to elute the amine with 4 column volumes. During elution, a blue color appeared 
on the column, but did not completely elute (this was presumed to be, again, disproportionation of 
 78 
Cu(I) on the column to Cu(II) and colloidal Cu(0) which was trapped by the stationary phase). The 
eluent was concentrated to afford the amine product. Residual trace metal was removed by adding 
a 0.5 M solution of Na4-EDTA (5 equiv with respect to initial copper loading) to a solution of the 
residue in MeOH. This solution was stirred at ambient temperature for 30 min, concentrated, and 
extracted with an organic solvent (Et2O, CH2Cl2, or CHCl3). The organic layers were combined, 
dried (MgSO4), filtered, and concentrated to afford the desired amine in high purity. 
General Method 1-D:  Thermal Deprotection of Tempoc Secondary and Aryl Amines.  
A microwave tube was charged with Tempoc amine (1.00 mmol, 1 equiv) in 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP, 10 mL) and the 0.1 M mixture was sonicated under a steady stream 
of nitrogen for 1 min before the tube was sealed and heated in a microwave reactor (conventional 
heating afforded comparable results) at 135 °C for 8 h for secondary alkylamines, or for 30 min 
for heterocyclic amines. Upon consumption of the starting material, the reaction mixture was 
concentrated under reduced pressure and the residue purified by chromatography on SiO2 
(hexanes/EtOAc or CH2Cl2/MeOH). For more polar substrates, the SiO2 catch-and-release method 
mentioned below may also be utilized. 
General Method 1-E:  Procedure for Thermal Deprotection of Tempoc Primary 
Amine. A pressure tube or microwave vial was charged with a solution of Tempoc amine (1.00 
mmol, 1 equiv) in 1,4-dioxane (6.7 mL, 0.15 M) and treated with technical grade potassium 
trimethylsilanolate (3.00 mmol, 3.00 equiv). The tube was sealed and heated to 135 °C for 30 min, 
during which time the reaction mixture formed a heavy white precipitate and turned pink. Upon 
consumption of the starting material as observed by TLC, the mixture was cooled in a room 
temperature water bath, treated with SiO2 (1 g/mmol Tempoc amine) and stirred for 10 min to 
hydrolyze the silanoate ester. The reaction mixture was poured directly onto a 1”-pad of SiO2 and 
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eluted with EtOAc. Once TLC indicated that TEMPO and TEMPO-H were eluted, the amine was 
eluted with 3% Et3N in EtOAc. The filtrate was concentrated to afford the desired amine. 
Table 15 Complete optimization table for the Tempoc protection of 2-phenethylamine 
 
entry stoichiometrya solventb temp (°C)  base yieldc (%) 
1 1:1:3 DCM 23  Et3N 28 
2 1:1:3 THF 23  Et3N 60 
3 1:1:3 MeCN 23  Et3N 57 
4 1:1:3 MeOH 23  Et3N 64 
5 1:1:3 DMF 23  Et3N 77 
6 1:1:3 DMF 23  py 67 
7 1:1:3 DMF 23  NaHCO3 64 
8 1:1:3 DMF 23  K2CO3 79d 
9 1:1:3 DMF 23  Et3N/DMAPe 76e 
10 1:1:3 DMF 40  Et3N 41f 
11 1:1:3 DMF 60  Et3N 38f 
12 1:1:3 DMF 80  Et3N 14f 
13 1:1.1:3 DMF 23  Et3N 84 
14 1:1.2:3 DMF 23  Et3N 91 
15 1:1.3:3 DMF 23  Et3N 92 
4.1.3  Synthetic procedures and spectral characterization for Tempoc transfer reagents 
 
Methyl (2,2,6,6-tetramethylpiperidin-1-yl)carbonate (1-31).  A vigorously stirred 
solution of sodium ascorbate (5.02 g, 25.1 mmol, 2 equiv) in deionized water (50 mL) was treated 
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with TEMPO (2.00 g, 12.5 mmol, 1 equiv). After ca. 30 min, decolorization was observed and a 
white precipitate formed. The heterogeneous mixture was extracted with diethyl ether (3 x 25 mL), 
and the combined organic layers were washed with deionized water and brine, dried (MgSO4), and 
concentrated to afford TEMPO-H (1.59 g, 80%) as a pale-red oil which was dissolved in dry 
CH2Cl2 (10 mL). The mixture was cooled to 0 °C and treated with pyridine (1.19 g, 1.24 mL, 15.1 
mmol) and dropwise over 1 min with ethyl chloroformate (1.47 g, 1.20 mL, 15.1 mL). The reaction 
was warmed to ambient temperature, stirred for 14 h, and quenched by addition of water (10 mL). 
The aqueous layer was extracted with CH2Cl2 (2 x 20 mL), and the combined organic layers were 
washed with water and brine, dried (MgSO4), and concentrated to afford crude product that was 
purified by chromatography on SiO2 (1:19, EtOAc/hexanes) to afford 1-31 (1.73 g, 80%) as a 
colorless oil: Rf = 0.46 (1:4, EtOAc/hexanes); ATR-IR (neat) 2978, 2936, 1776, 1221, 940, 784 
cm-1; 1H NMR (300 MHz, CDCl3) δ 3.80 (s, 3 H), 1.74–1.48 (m, 5 H), 1.42–1.35 (m, 1 H), 1.16 
(s, 6 H), 1.11 (s, 6 H); 13C NMR (76 MHz, CDCl3) δ 157.3, 60.5, 54.9, 39.2, 31.5, 20.3, 16.9; 
HRMS (ESI) m/z calcd for C11H22NO3 (M+H) 216.1594, found 216.1592. 
 
iso-Butyl (2,2,6,6-tetramethylpiperidin-1-yl)carbonate (1-32).  A solution of TEMPO 
(0.500 g, 3.14 mmol, 1 equiv) in deoxygenated MeOH (26 mL) was treated with ascorbic acid 
(663 mg, 3.76 mmol, 1.2 equiv) as a solid in one portion. The clear-pink, to orange, to clear yellow 
reaction mixture was stirred for 30 min, concentrated, and the residue was partitioned between 
deoxygenated diethyl ether (15 mL) and deionized water (15 mL). The organic layer was separated 
and the aqueous layer was extracted with deoxygenated diethyl ether (4 x 10 mL). The combined 
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organic layers were dried (MgSO4) and concentrated to afford TEMPO-H (204 mg, 41%) as a 
colorless oil that was dissolved in dry deoxygenated CH2Cl2 (7.78 mL), cooled to 0 °C and treated 
with pyridine (113 mg, 117 µL, 1.43 mmol), and dropwise over 1 min with iso-butyl chloroformate 
(325 mg, 311 µL, 1.43 mmol). The reaction mixture was warmed to ambient temperature, stirred 
for 2 h, quenched with 1 M HCl (5 mL), and transferred to separatory funnel. The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic layers were washed with water and brine, dried (MgSO4), and concentrated to afford a 
residue which was purified by chromatography on SiO2 (1:19, EtOAc/hexanes) to afford 1-32 (692 
mg, 53%) as a colorless oil: Rf = 0.59 (1:4, EtOAc/hexanes); ATR-IR (neat) 2966, 2937, 1776, 
1217, 782 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.94 (d, J = 6.8 Hz, 2 H), 2.00 (nonet, J = 6.8 Hz, 
1 H), 1.73–1.51 (m, 5 H), 1.44–1.36 (m, 1 H), 1.17 (s, 6 H), 1.12 (s, 6 H), 0.95 (d, J = 6.8 Hz, 6 
H); 13C NMR (101 MHz, CDCl3) δ 157.0, 74.0, 60.4, 39.2, 31.5, 27.9, 20.4, 18.9, 16.9; HRMS 
(ESI) m/z calcd for C14H28NO3 (M+H) 258.2064, found 258.2062. 
 
Phenyl (2,2,6,6-tetramethylpiperidin-1-yl)carbonate (1-33).  A solution of sodium 
ascorbate (2.08 g, 10.4 mmol, 1.66 equiv) and TEMPO (1.00 g, 6.27 mmol, 1 equiv) in water (18.0 
mL) was vigorously stirred for 30 min while decolorization was observed and a white precipitate 
formed. The heterogeneous mixture was extracted with diethyl ether (3 x 25 mL).  The combined 
organic layers were washed with water and brine, dried (MgSO4), and concentrated to afford 
TEMPO-H (955 mg, 97%). A solution of TEMPO-H (100 mg, 0.636 mmol) in dry CH2Cl2 (0.636 
mL) was cooled to 0 °C and treated dropwise with pyridine (63.5 mg, 65.0 µL, 0.801 mmol) and 
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phenyl chloroformate (132 mg, 106 µL, 0.827 mmol). The reaction was warmed to room 
temperature and stirred for 3 h, diluted with CH2Cl2 (5 mL), and organic layer was washed with 1 
M NaOH (5 mL), 1 M HCl (5 mL), and brine (5 mL), dried (MgSO4), and concentrated to afford 
a residue which was purified by chromatography on SiO2 (1:19, EtOAc/hexanes) to afford 1-33 
(112 mg, 63%) as a colorless oil: Rf = 0.57 (1:4, EtOAc/hexanes); ATR-IR (neat) 2979, 2935, 
1791, 1198, 1177, 696 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40–7.33 (m, 2 H), 7.25–7.14 (m, 3 
H), 1.73–1.50 (m, 5 H), 1.46–1.34 (m, 1 H), 1.21 (s, 12 H); 13C NMR (126 MHz, CDCl3) δ 155.0, 
151.4, 129.4, 125.7, 120.9, 60.8, 39.3, 31.6, 20.5, 16.9; HRMS (ESI) m/z calcd for C16H24NO3 
(M+H) 278.1751, found 278.1749. 
 
4-Nitrophenyl (2,2,6,6-tetramethylpiperidin-1-yl)carbonate (1-34, “NPTC”). A three-
neck 3-L round bottom flask was fitted with an internal temperature probe and charged with a 0.35 
M solution of sodium ascorbate (145 g, 724 mmol, 2.00 equiv) in deoxygenated deionized water 
(1.03 L). The pale translucent-yellow solution was treated with TEMPO (57.2 g, 362 mmol, 1 
equiv) as a solid under vigorous mechanical stirring at ambient temperature. After ca. 30 min, 
decolorization was observed and a white precipitate formed, accompanied by a slight, yet rapid 
increase in internal temperature of ca. 5 °C. Deoxygenated diethyl ether (800 mL) was added and 
the reaction mixture was stirred for 5 min, and poured into a separatory funnel. The organic layer 
was separated and the aqueous layer was extracted with deoxygenated diethyl ether (1 x 500 mL). 
The combined organic layers were poured directly through a funnel containing anhydrous Na2SO4 
and the filtrate was concentrated to afford TEMPO-H as a pale-red oil which was dissolved in 
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deoxygenated CH2Cl2 (950 mL), transferred to a three-neck 3-L round bottom flask, and cooled to 
-15 °C. The flask was then fitted with an addition funnel and an internal temperature probe before 
addition of deoxygenated triethylamine (73.2 g, 102 mL, 724 mmol, 2.00 equiv) in one portion, 
and p-nitrophenyl chloroformate (82.7 g, 434 mmol, 1.10 equiv) as a solution in deoxygenated 
CH2Cl2 (256 mL) by addition funnel at a rate that maintained an internal temperature of <10 °C 
(≈60 min).  The solution was allowed to slowly warm to ambient temperature for 1 h, quenched 
with 1 L of ice-cold 2 M NaOH, and vigorously stirred. The organic layer was separated, dried 
(MgSO4), and concentrated to afford a solid orange residue which was dissolved in hot acetone 
(1.0 L) and allowed to slowly cool to ambient temperature, and kept at -20 °C for 12 h. The 
precipitated crystals were removed by vacuum filtration, and the filter cake was washed with ice-
cold acetone (500 mL). The mother liquor was concentrated to 400 mL and allowed to stand in a 
freezer (-20 °C) overnight to yield another crop of crystals which were filtered and washed with 
ice-cold acetone (200 mL). This procedure was again repeated to yield a third crop. The combined 
solids were washed with water (250 mL) and ice-cold acetone (100 mL) to remove any residual 
triethylamine hydrochloride, and dried under vacuum in a desiccator over CaSO4 to afford 1-34 
(97.4 g, 302 mmol, 84%) as off-white crystals: Rf = 0.53 (4:1, hexanes/EtOAc); Mp 137-140 °C; 
ATR-IR (neat) 2985, 1781, 1519, 1345, 1175, 914, 861 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.26 
(d, J = 8.8 Hz, 2 H), 7.37 (d, J = 8.8 Hz, 2 H), 1.75–1.54 (m, 5 H), 1.45–1.39 (m, 1 H), 1.22 (s, 6 
H), 1.20 (s, 6 H); 13C NMR (101 MHz, CDCl3) δ 155.8, 153.9, 145.2, 125.2, 121.6, 61.0, 39.2, 
31.5, 20.4, 16.7; HRMS (ESI) m/z calcd for C16H23N2O5 (M+H) 323.1601, found 323.1602. 
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2,5-Dioxopyrrolidin-1-yl (2,2,6,6-tetramethylpiperidin-1-yl)carbonate (1-36).  A 
solution of sodium ascorbate (2.51 g, 12.5 mmol, 2 equiv) and TEMPO (1.00 g, 6.27 mmol, 1 
equiv) in water (25 mL) was vigorously stirred for 30 min while decolorization was observed and 
a white precipitate formed. The reaction mixture was extracted with ether (100 mL) and the 
aqueous layer was discarded. The organic layer was filtered (MgSO4) and concentrated to afford 
TEMPO-H (886 mg, 90%). A solution of bis(2,5-dioxopyrrolidin-1-yl)carbonate (2.17 g, 8.45 
mmol) in deoxygenated MeCN (20.0 mL) was cooled to 0 °C and treated with triethylamine (1.15 
g, 1.60 mL, 11.3 mmol) and dropwise with a solution of crude TEMPO-H (886 mg, 5.63 mmol) 
in deoxygenated MeCN (8 mL). The reaction mixture was warmed to room temperature, stirred 
for 12 h, and concentrated to afford a residue that was purified by chromatography on SiO2 (1:19 
to 1:4, EtOAc/hexanes) to afford 1-36 (724 mg, 43%) as a viscous pale-yellow oil: Rf = 0.53 (1:1, 
EtOAc/hexanes); ATR-IR (neat) 2978, 2938, 1827, 1794, 1741, 1194, 1171, 900, 672 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 2.82 (s, 4 H), 1.70–1.54 (m, 5 H), 1.43–1.37 (m, 1 H), 1.21 (s, 6 H), 
1.19 (s, 6 H); 13C NMR (126 MHz, CDCl3) δ 168.6, 153.0, 61.6, 39.4, 31.3, 25.5, 20.3, 16.7; 
HRMS (ESI) m/z calcd for C14H23N2O5 (M+H) 299.1601, found 299.1601. 
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4.1.4  Synthetic procedures and spectral characterization for Tempoc protected amines 
 
2,2,6,6-Tetramethylpiperidin-1-yl phenethylcarbamate (1-38).  According to General 
Method 1-A, 2-phenethylamine (27.0 mg, 0.223 mmol), triethylamine (68.3 mg, 94.9 µL, 0.668 
mmol), NPTC (86.2 mg, 0.267 mmol), DMF (0.5 mL), and chromatography on SiO2 (1:19 to 1:4, 
EtOAc/hexanes) afforded 1-38 (63.6 mg, 94%) as a colorless solid: Rf = 0.60 (1:1, 
EtOAc/hexanes); Mp 95-98 °C; ATR-IR (neat) 3292, 3025, 2977, 2932, 1698, 1475, 949, 747, 
701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.36–7.28 (m, 2 H), 7.29–7.17 (m, 3 H), 6.77 (bs, 1 H), 
3.50 (td, J = 6.9, 5.6 Hz, 2 H), 2.85 (t, J = 7.0 Hz, 2 H), 1.65–1.48 (m, 3 H), 1.42–1.29 (m, 3 H), 
1.16 (s, 6 H), 0.93 (s, 6H); 13C NMR (76 MHz, CDCl3) δ 158.5, 138.7, 128.7, 128.6, 126.5, 60.6, 
41.7, 39.6, 35.5, 31.5, 20.5, 16.7; HRMS (ESI) m/z calcd for C18H29N2O2 (M+H) 305.2224, found 
305.2223. 
 
2,2,6,6-Tetramethylpiperidin-1-yl ((5-methylfuran-2-yl)methyl)carbamate (1-39).  
According to General Method 1-A, 5-methylfurfurylamine (55.0 mg, 0.485 mmol), triethylamine 
(149 mg, 207 µL, 1.46 mmol), NPTC (188 mg, 0.582 mmol), DMF (1.0 mL) and chromatography 
on SiO2 (1:19 to 1:9, EtOAc/hexanes) afforded 1-39 (131 mg, 92%) as a colorless solid: Rf = 0.70 
(1:1, EtOAc/hexanes); Mp 88-89 °C; ATR-IR (neat) 3370, 2977, 2929, 1709, 1497, 1184, 781 cm-
1; 1H NMR (300 MHz, CDCl3) δ 7.03 (bs, 1 H), 6.08 (d, J = 3.0 Hz, 1 H), 5.86 (bd, J = 3.0, 1 H), 
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4.33 (d, J = 5.9 Hz, 2 H), 2.23 (s, 3 H), 1.73–1.34 (m, 6 H), 1.20 (s, 6 H), 1.05 (s, 6 H); 13C NMR 
(76 MHz, CDCl3) δ 158.4, 151.7, 149.5, 107.9, 106.1, 60.7, 39.7, 37.9, 31.5, 20.5, 16.7, 13.4; 
HRMS (ESI) m/z calcd for C16H27N2O3 (M+H) 295.2016, found 295.2015. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (2-bromobenzyl)carbamate (1-40).  According to 
General Method 1-A, 2-bromobenzylamine (63.0 mg, 0.332 mmol), triethylamine (102 mg, 141 
µL, 0.996 mmol), NPTC (128 mg, 0.398 mmol), DMF (0.7 mL) and chromatography on SiO2 
(1:19 to 1:9, EtOAc/hexanes) afforded 1-40 (111 mg, 90%) as a fluffy colorless solid: Rf = 0.74 
(1:1, EtOAc/hexanes); Mp 165-167 °C; ATR-IR (neat) 3310, 2939, 1698, 1473, 1187, 929, 741 
cm-1; 1H NMR (300 MHz CDCl3) δ 7.54 (dd, J = 7.9, 1.3 Hz, 1 H), 7.41 (dd, J = 7.6, 1.8 Hz, 1 H), 
7.35 (bs, 1 H), 7.27 (td, J = 7.5, 1.2 Hz, 1 H), 7.13 (td, J = 7.7, 1.8 Hz, 1 H), 4.48 (d, J = 6.4 Hz, 2 
H), 1.72–1.44 (m, 5 H), 1.44–1.35 (m, 1 H), 1.20 (s, 6 H), 1.04 (s, 6 H); 13C NMR (76 MHz, 
CDCl3) δ 158.5, 137.4, 132.7, 130.3, 129.1, 127.7, 123.5, 60.7, 45.1, 39.7, 31.6, 20.6, 16.7; HRMS 
(ESI) m/z calcd for C17H26BrN2O2 (M+H) 369.1172, found 369.1173. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (4-methoxybenzyl)carbamate (1-41). According to 
General Method 1-A, 4-methoxybenzylamine (50.0 mg, 0.354 mmol), triethylamine (108 mg, 151 
µL, 1.06 mmol), NPTC (137 mg, 0.424 mmol), DMF (0.7 mL) and chromatography on SiO2 (1:19 
to 1:4, EtOAc/hexanes) afforded 1-41 (106 mg, 93%) as a colorless solid: Rf = 0.62 (1:1, 
EtOAc/hexanes); Mp 95-98 °C; ATR-IR (neat) 3321, 2930, 1697, 1510, 1249, 929, 706 cm-1; 1H 
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NMR (500 MHz, CDCl3) δ 7.17 (d, J = 8.8 Hz, 2 H), 6.95 (bs, 1 H), 6.81 (d, J = 8.6 Hz, 2 H), 4.32 
(d, J = 5.9 Hz, 2 H), 3.75 (s, 3 H), 1.65–1.30 (m, 6 H), 1.17 (s, 6 H), 1.03 (s, 6 H); 13C NMR (126 
MHz, CDCl3) δ 158.9, 158.5, 130.3, 128.9, 113.9, 60.6, 55.2, 44.3, 39.5, 31.7, 20.5, 16.6; HRMS 
(ESI) m/z calcd for C18H29N2O3 (M+H) 321.2173, found 321.2173. 
 
2,2,6,6-Tetramethylpiperidin-1-yl ([1,1'-biphenyl]-4-ylmethyl)carbamate (1-42).  
According to General Method 1-A, 4-phenylbenzylamine (1.50 g, 7.94 mmol), triethylamine (2.44 
g, 3.38 mL, 23.8 mmol), NPTC (3.07 g, 9.53 mmol), DMF (16 mL) and chromatography on SiO2 
(1:19 to 3:7, EtOAc/hexanes) afforded 1-42 (2.60 g, 89%) as a fluffy colorless solid: Rf = 0.61 
(1:1, EtOAc/hexanes); Mp 134-137 °C; ATR-IR (neat) 3252, 2971, 2930, 1694, 1484, 1254, 933, 
732 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.60–7.55 (m, 4 H), 7.44 (t, J = 7.9 Hz, 2 H), 7.39–7.33 
(m, 3 H), 7.09 (bs, 1 H), 4.48 (d, J = 6.1 Hz, 2 H), 1.71–1.44 (m, 5 H), 1.42–1.35 (m, 1 H), 1.24 
(s, 6 H), 1.11 (s, 6 H); 13C NMR (101 MHz, CDCl3) δ 158.6, 140.5, 140.2, 137.3, 128.6, 127.9, 
127.2, 127.2, 126.9, 60.7, 44.5, 39.5, 31.7, 20.5, 16.6; HRMS (ESI) m/z calcd for C23H31N2O2 
(M+H) 367.2380, found 367.2377. 
 
2,2,6,6-Tetramethylpiperidin-1-yl ((tetrahydrofuran-2-yl)methyl)carbamate (1-43).  
According to General Method 1-A, tetrahydrofurfurylamine (50.0 mg, 0.480 mmol), triethylamine 
(147 mg, 204 µL, 1.44 mmol), NPTC (186 mg, 0.575 mmol), DMF (1 mL) and chromatography 
on SiO2 (1:19 to 3:7, EtOAc/hexanes) afforded 1-43 (126 mg, 93%) as a colorless solid: Rf = 0.41 
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(1:1, EtOAc/hexanes); Mp 74-76 °C; ATR-IR (neat) 3328, 2933, 1712, 1501, 1250, 1084, 953 cm-
1; 1H NMR (300 MHz, CDCl3) δ 7.03 (bs, 1 H), 3.97–3.88 (m, 1 H), 3.83 (A of ABX2, J = 8.4, 6.6 
Hz, 1 H), 3.75 (B of ABX2, J = 8.1, 6.7 Hz, 1 H), 3.47 (A of ABMX, J = 13.9, 6.9, 3.6 Hz, 1 H), 
3.17 (B of ABMX, J = 13.9, 6.6, 5.3 Hz, 1 H), 2.01–1.82 (m, 3 H), 1.70–1.45 (m, 6 H), 1.44–1.35 
(m, 1 H), 1.20 (s, 6 H), 1.10 (2s, 6 H); 13C NMR (76 MHz, CDCl3) δ 158.9, 78.0, 68.0, 60.7, 60.6, 
44.3, 39.7, 39.6, 31.7, 31.5, 28.3, 25.8, 20.5, 16.7; HRMS (ESI) m/z calcd for C15H29N2O3 (M+H) 
285.2173, found 285.2169. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (4-phenylcyclohexyl)carbamate (1-44). According 
to General Method 1-A and Workup Procedure 1-1, 4-phenylcyclohexylamine (455 mg, 2.60 
mmol), triethylamine (796 mg, 1.11 mL, 7.79 mmol), NPTC (1.00 g, 3.12 mmol), DMF (5 mL) 
and chromatography on SiO2 (1:19 to 3:17, EtOAc/hexanes) afforded 1-44 (811 mg, 87%) as a 
fluffy colorless solid in a 1:5 cis/trans-diastereomeric mixture: Rf = 0.56 (1:1, EtOAc/hexanes); 
Mp 114-126 °C; ATR-IR (neat) 3357, 2976, 2930, 1708, 1492, 1131, 989, 755, 699 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.35–7.27 (m, 2 H), 7.22–7.17 (m, 3 H), 6.72 (bd, J = 8.5 Hz, 1 H), 3.67 (tdt, 
J = 12.3, 8.8, 4.1 Hz, 1 H), 2.50 (tt, J = 12.2, 3.5 Hz, 1 H), 2.21–2.09 (m, 2 H), 2.02–1.91 (m, 2 
H), 1.70–1.20 (m, 10 H), 1.23 (s, 6 H), 1.12 (s, 6 H); 13C NMR (101 MHz, CDCl3) δ 157.8, 146.5, 
128.4, 126.7, 126.1, 60.7, 49.6, 43.5, 39.8, 33.6, 32.9, 31.8, 20.6, 16.7; HRMS (ESI) m/z calcd for 
C22H35N2O2 (M+H) 359.2693, found 359.2692. A sample of trans-2,2,6,6-tetramethylpiperidin-1-
yl (4-phenylcyclohexyl)carbamate (trans-1-44) was isolated for characterization: Rf = 0.60 (:1, 
EtOAc/hexanes); Mp 150-152 °C; ATR-IR (neat) 3327, 2976, 2930, 1703, 1492, 1132, 989, 733, 
699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.32–7.27 (m, 2 H), 7.22–7.16 (m, 3 H), 6.72 (bd, J = 8.8 
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Hz, 1 H), 3.67 (tdt, J = 12.3, 8.8, 4.1 Hz, 1 H), 2.50 (tt, J = 12.2, 3.4 Hz, 1 H), 2.18–2.08 (m, 2 H), 
1.98–1.90 (m, 2 H), 1.70– 1.50 (m, 7 H), 1.50-1.20 (m, 3 H), 1.23 (s, 6 H), 1.12 (s, 6 H); 13C NMR 
(101 MHz, CDCl3) δ 157.8, 146.5, 128.4, 126.7, 126.1, 60.7, 49.6, 43.5, 39.8, 33.6, 32.9, 31.8, 
20.5, 16.7; HRMS (ESI) m/z calcd for C22H35N2O2 (M+H) 359.2693, found 359.2693. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (2-hydroxyethyl)carbamate (1-45).  According to 
General Method 1-A, ethanolamine (61.1 mg, 0.648 mmol), triethylamine (199 mg, 276 µL, 1.95 
mmol), NPTC (251 mg, 0.778 mmol), DMF (1.3 mL) and chromatography on SiO2 (1:19 to 1:1, 
EtOAc/hexanes) afforded 1-45 (148 mg, 94%) as a colorless, crystalline solid: Rf = 0.29 (4:1, 
EtOAc/hexanes); Mp 102-105 °C; ATR-IR (neat) 3316, 2936, 1697, 1501, 1525, 955, 734 cm-1; 
1H NMR (300 MHz, CDCl3) δ 7.14 (bs, 1 H), 3.69 (q, J = 5.0 Hz, 2 H), 3.36 (q, J = 5.2 Hz, 2 H), 
2.75 (t, J = 4.9 Hz, 1 H), 1.71–1.45 (m, 5 H), 1.43–1.34 (m, 1 H), 1.19 (s, 6 H), 1.09 (s, 6 H); 13C 
NMR (76 MHz, CDCl3) δ 159.5, 62.1, 60.7, 43.1, 39.6, 31.5, 20.5, 16.7; HMRS (ESI) m/z calcd 
for C12H25N2O3 (M+H) 245.1860, found 245.1849. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (S)-(1-hydroxy-3-phenylpropan-2-yl)carbamate 
(1-46).  According to General Method 1-A, L-phenylalaninol (0.150 g, 0.972 mmol), triethylamine 
(298 mg, 414 µL, 2.92 mmol), NPTC (376 mg, 1.17 mmol), DMF (1.9 mL), and chromatography 
on SiO2 (1:19 to 1:1, EtOAc/hexanes) afforded 1-46 (234 mg, 72%) as a fluffy colorless solid: Rf 
= 0.47 (1:1, EtOAc/hexanes); Mp 108-111 °C; ATR-IR (neat) 3370, 2976, 2933, 1698, 1494, 1030, 
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701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35–7.16 (m, 5 H), 7.01 (bs, 1 H), 4.06–3.90 (m, 1 H), 
3.75–3.58 (m, 2 H), 3.09 (bs, 1 H), 2.95 (A of ABX, J = 13.9, 6.6 Hz, 1 H), 2.82 (B of ABX, J = 
13.9, 8.2 Hz, 1 H), 1.69–1.26 (m, 6 H), 1.16 (s, 3 H), 1.12 (s, 3 H), 1.03 (s, 3 H), 0.76 (s, 3 H); 13C 
NMR (76 MHz, CDCl3) δ 159.0, 137.4, 129.2, 128.7, 126.7, 64.6, 60.7, 60.6, 54.2, 54.1, 39.6, 
39.4, 37.0, 31.6, 31.0, 20.5, 20.4, 16.6; HRMS (ESI) m/z calcd for C19H31N2O3 (M+H) 335.2329, 
found 335.2328. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (2-(1H-indol-3-yl)ethyl)carbamate (1-47).  
According to General Method 1-A, tryptamine (1.00 g, 6.12 mmol), triethylamine (1.88 g, 2.61 
mL, 18.4 mmol), NPTC (2.37 g, 7.34 mmol), DMF (12.2 mL), and chromatography on SiO2 (1:19 
to 1:4, EtOAc/hexanes) afforded 1-47 (1.92 g, 92%) as an off-white solid: Rf = 0.47 (1:1, 
EtOAc/hexanes); Mp 150-152 °C; ATR-IR (neat) 3310, 2976, 2935, 1706, 1501, 739 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 8.20 (bs, 1 H), 7.64 (d, J = 7.7 Hz, 1 H), 7.39 (d, J = 8.0 Hz, 1 H), 7.21 
(t, J = 7.5 Hz, 1 H), 7.13 (t, J = 7.4 Hz, 1 H), 7.05 (bs, 1 H), 6.83 (bs, 1 H), 3.59 (q, J = 6.5 Hz, 2 
H), 3.02 (t, J = 6.9 Hz, 2 H), 1.67–1.43 (m, 3 H), 1.37–1.22 (m, 3 H), 1.15 (s, 6 H), 0.91 (s, 6 H); 
13C NMR (76 MHz, CDCl3) δ 158.7, 136.4, 127.3, 122.1, 119.5, 118.7, 112.9, 111.2, 60.6, 41.1, 
39.5, 31.4, 25.2, 20.5, 16.7; HRMS (ESI) m/z calcd for C20H30N3O2 (M+H) 344.2333, found 
344.2329. 
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2,2,6,6-Tetramethylpiperidin-1-yl (4-aminobenzyl)carbamate (1-48).  According to 
General Method 1-A, 4-aminobenzylamine (1.18 g, 9.47 mmol), triethylamine (2.90 g, 4.03 mL, 
28.4 mmol), NPTC (3.66 g, 11.4 mmol), DMF (19 mL) and chromatography on SiO2 (1:19 to 1:1, 
EtOAc/hexanes) afforded 1-48 (2.81 g, 93%) as a yellow solid: Rf = 0.32 (1:1, EtOAc/hexanes); 
Mp 118-120 °C; ATR-IR (neat) 3450, 3362, 2977, 2933, 1688, 1493, 1255, 928, 830, 657 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.07 (d, J = 8.3 Hz, 2 H), 6.88 (bs, 1 H), 6.62 (d, J = 8.3 Hz, 2 H), 
4.29 (d, J = 5.8 Hz, 2 H), 3.67 (s, 2 H), 1.65–1.39 (m, 5 H), 1.41–1.29 (m, 1 H), 1.20 (s, 6 H), 1.05 
(s, 6 H); 13C NMR (101 MHz, CDCl3) δ 158.5, 145.8, 128.9, 128.1, 115.1, 60.7, 44.5, 39.6, 31.7, 
20.5, 16.7; HRMS (ESI) m/z calcd for C17H28N3O2 (M+H) 306.2176, found 306.2176. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (S)-(1-phenylethyl)carbamate (1-49).  According to 
General Method 1-A, (S)-(-)-1-phenethylamine (50.0 mg, 0.404 mmol), triethylamine (124 mg, 
172 µL, 1.21 mmol), NPTC (156 mg, 0.485 mmol), DMF (0.8 mL) and chromatography on SiO2 
(1:19 to 1:4, EtOAc/hexanes) afforded 1-49 (92 mg, 75%) as a fluffy colorless solid: Rf = 0.71 
(1:1, EtOAc/hexanes); Mp 127 °C; ATR-IR (neat) 3289, 2973, 2929, 1696, 1493, 1187, 986, 698 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.39–7.20 (m, 5 H), 7.03 (bd, J = 8.6 Hz, 1 H), 4.97 (p, J = 
7.2 Hz, 1 H), 1.72–1.34 (m, 6 H), 1.51 (d, J = 6.9 Hz, 1 H), 1.23 (s, 3 H), 1.19 (s, 3 H), 1.15 (s, 3 
H), 1.00 (s, 3 H); 13C NMR (76 MHz, CDCl3) δ 157.6, 143.0, 128.5, 127.3, 126.1, 60.9, 60.6, 50.2, 
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39.8, 39.7, 31.9, 31.8, 21.8, 20.6, 20.5, 16.7; HRMS (ESI) m/z calcd for C18H29N2O2 (M+H) 
305.2224, found 305.2221. 
 
2,2,6,6-Tetramethylpiperidin-1-yl tert-butylcarbamate (1-50).  According to General 
Method 1-A, tert-butylamine (35.0 mg, 0.469 mmol), triethylamine (144 mg, 0.200 mL, 1.41 
mmol), NPTC (181 mg, 0.563 mmol), DMF (1 mL) and chromatography on SiO2 (0:1 to 1:19, 
EtOAc/hexanes) afforded 1-50 (38 mg, 32%) as a colorless solid: Rf = 0.51 (1:4, EtOAc/hexanes); 
Mp 108-109 °C; ATR-IR (neat) 3290, 2976, 2923, 1704, 1494, 1263, 1021, 693 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 6.79 (bs, 1 H), 1.67–1.46 (m, 5 H), 1.45–1.34 (m, 1 H), 1.31 (s, 9 H), 1.18 
(s, 6 H), 1.08 (s, 6 H); 13C NMR (76 MHz, CDCl3) δ 156.6, 60.6, 50.1, 39.8, 31.8, 28.7, 20.5, 16.7; 
HRMS (ESI) m/z calcd for C14H29N2O2 (M+H) 257.2224, found 257.2223. 
 
2,2,6,6-Tetramethylpiperidin-1-yl hydrazinecarboxylate (1-51).  A solution of 
anhydrous hydrazine (60.3 mg, 18.6 mmol) and triethylamine (2.85 g, 3.96 mL, 28.0 mmol) in 
DMF (37 mL) was treated at 0 °C with NPTC (3.00 g, 9.31 mmol) in 2 portions over 2 min. The 
cooling bath was removed and the reaction mixture was stirred for 2 h at room temperature, diluted 
with CH2Cl2 (20 mL), and partitioned between ice-cold 1 M NaOH (20 mL) and CH2Cl2 (20 mL). 
The organic layer was separated and the aqueous phase was extracted with CH2Cl2 (2 x 20 mL). 
The combined organic layers were washed with water and brine, dried (MgSO4), and concentrated 
to afford a residue which was purified by chromatography on SiO2 (1:19 to 1:0, EtOAc/hexanes) 
to afford 1-51 (1.90 g, 95%) as transparent crystals: Rf = 0.39 (EtOAc); Mp 146-149 °C (dec.); 
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ATR-IR (neat) 3285, 2980, 2932, 1716, 1618, 1451, 1040, 718 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.66 (bs, 1 H), 3.75 (s, 2 H), 1.64–1.40 (m, 5 H), 1.39–1.31 (m, 1 H), 1.14 (s, 6 H), 1.05 (s, 6 H); 
13C NMR (101 MHz, CDCl3) δ 160.3, 60.8, 39.5, 31.4, 20.3, 16.6; HRMS (ESI) m/z calcd for 
C10H22N3O2 (M+H) 216.1707, found 216.1705. 
 
2,2,6,6-Tetramethylpiperidin-1-yl N-(2-phenylethyl)-N-{[(2,2,6,6-
tetramethylpiperidin-1-yl)oxy]carbonyl}carbamate (1-52).  A suspension of 90% sodium 
hydride (57.2 mg, 2.15 mmol) in dry THF (6 mL) was cooled to 0 °C and treated dropwise with a 
solution of 2-phenethylamine (0.100 g, 0.825 mmol) in dry THF (1 mL). The reaction mixture was 
stirred at 0 °C for 30 min, treated dropwise with a solution of NPTC (638 mg, 1.98 mmol) in dry 
THF (1.3 mL), and stirred at room temperature for 1 h while the color turned from yellow to bright 
orange. After addition of diethyl ether (50 mL) and crushed ice (20 g), the organic layer was 
washed with sat. Na2CO3 (2 x 25 mL), water, and brine, dried (MgSO4), and concentrated to give 
a residue which was purified by chromatography on SiO2 (1:19 to 1:9, EtOAc/hexanes) to afford 
1-52 (363 mg, 90%) as an off-white solid: Rf = 0.55 (1:1, EtOAc/hexanes); Mp 125-126 °C; ATR-
IR (neat) 2935, 1779, 1751, 1262, 1148, 1043, 698 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.32–7.28 
(m, 2 H), 7.28–7.19 (m, 2 H), 3.92 (AA’ of AA’XX’, JAA’ = -10 Hz, JAX = 10 Hz, JAX’ = 5.2 Hz, 2 
H), 2.99 (XX’ of AA’XX’, JXX’ = -11 Hz, JAX = 10 Hz, JAX’ = 5.2 Hz, 2 H), 1.77–1.60 (m, 7 H), 
1.58–1.53 (m, 4 H), 1.44–1.39 (m, 2 H), 1.23 (s, 12 H), 1.14 (s, 12 H); 13C NMR (126 MHz, 
CDCl3) δ 154.5, 138.2, 128.9, 128.6, 126.5, 60.6, 48.3, 39.1, 35.7, 31.7, 21.1, 16.9; HRMS (ESI) 
m/z calcd for C28H46N3O4 (M+H) 488.3483, found 488.3481. 
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1-(tert-Butyl) 4-(2,2,6,6-tetramethylpiperidin-1-yl) piperazine-1,4-dicarboxylate (1-
54).  According to General Method 1-A and Workup Procedure 1-1, tert-butyl 1-
piperazinecarboxylate (1.00 g, 5.37 mmol), triethylamine (1.65 g, 2.29 mL, 16.1 mmol), NPTC 
(2.08 g, 6.44 mmol), DMF (11 mL) and chromatography on SiO2 (1:19 to 1:4, EtOAc/hexanes) 
afforded 1-54 (1.82 g, 91%) as a colorless solid: Rf = 0.55 (1:1, EtOAc/hexanes); Mp 146-147 °C; 
ATR-IR (neat) 2974, 2931, 1733, 1698, 1410, 1218, 1170, 1001, 758 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 3.52–3.46 (m, 4 H), 3.45–3.40 (m, 4 H), 1.75–1.48 (m, 5 H), 1.46 (s, 9 H), 1.44–1.36 
(m, 1 H), 1.14 (s, 6 H), 1.09 (s, 6 H); 13C NMR (76 MHz, CDCl3) δ 156.3, 154.6, 80.1, 60.2, 44.0, 
39.0, 31.8, 28.4, 21.0, 17.0; HRMS (ESI) m/z calcd for C19H36N3O4 (M+H) 370.2700, found 
370.2699. 
 
2,2,6,6-Tetramethylpiperidin-1-yl 4-hydroxypiperidine-1-carboxylate (1-55).  
According to General Method 1-A, 4-hydroxypiperidine (51.0 mg, 0.494 mmol), triethylamine 
(152 mg, 0.210 mL, 1.48 mmol), NPTC (191 mg, 0.593 mmol), DMF (1 mL) and chromatography 
on SiO2 (1:19 to 1:1, EtOAc/hexanes) afforded 1-55 (122 mg, 87%) as a colorless solid: Rf = 0.29 
(1:4, EtOAc/hexanes); Mp 156-157 °C; ATR-IR (neat) 3422, 2937, 1708, 1420, 1214, 757 cm-1; 
1H NMR (300 MHz, CDCl3) δ 4.01–3.79 (m, 3 H), 3.11 (ddd, J = 13.3, 9.7, 3.3 Hz, 2 H), 2.25 (s, 
1 H), 1.93–1.82 (m, 2 H), 1.76–1.42 (m, 7 H), 1.41–1.32 (m, 1 H), 1.12 (s, 6 H), 1.06 (s, 6 H); 13C 
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NMR (76 MHz, CDCl3) δ 156.4, 67.3, 60.0, 41.7, 39.0, 34.3, 31.7, 20.9, 16.9; HRMS (ESI) m/z 
calcd for C15H29N2O3 (M+H) 285.2173, found 285.2171. 
 
2,2,6,6-Tetramethylpiperidin-1-yl 4-phenylpiperidine-1-carboxylate (1-56).  
According to General Method 1-A and Workup Procedure 1-1, 4-phenylpiperidine (1.00 g, 6.08 
mmol), triethylamine (1.86 g, 2.59 mL, 18.2 mmol), NPTC (2.35 g, 7.29 mmol), DMF (12 mL) 
and chromatography on SiO2 (1:19 to 1:4, EtOAc/hexanes) afforded 1-56 (2.05 g, 98%) as a 
colorless solid: Rf = 0.56 (1:1, EtOAc/hexanes); Mp 143-145 °C; ATR-IR (neat) 3002, 2972, 2933, 
1727, 1209, 1010, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36–7.27 (m, 2 H), 7.26–7.17 (m, 3 
H), 4.38–4.26 (m, 2 H), 2.95-2.85 (m, 2 H), 2.69 (tt, J = 12.2, 3.7 Hz, 1 H), 1.90–1.86 (m, 2 H), 
1.85-1.62 (m, 5 H), 1.57-1.52 (m, 2 H), 1.46–1.35 (m, 1 H), 1.17 (s, 6 H), 1.14 (s, 6 H); 13C NMR 
(101 MHz, CDCl3) δ 156.3, 145.5, 128.5, 126.7, 126.3, 60.1, 44.9, 42.6, 38.9, 33.3, 31.8, 21.0, 
17.0; HRMS (ESI) m/z calcd for C21H33N2O2 (M+H) 345.2537, found 345.2535. 
 
2,2,6,6-Tetramethylpiperidin-1-yl morpholine-4-carboxylate (1-57).  According to 
General Method 1-A, morpholine (50.0 mg, 0.568 mmol), triethylamine (174 mg, 242 µL, 1.71 
mmol), NPTC (0.220 g, 0.682 mmol), DMF (1.1 mL) and chromatography on SiO2 (1:19 to 1:4, 
EtOAc/hexanes) afforded 1-57 (151 mg, 98%) as a clear viscous oil: Rf = 0.42 (1:1, 
EtOAc/hexanes); ATR-IR (neat) 2970, 2929, 1726, 1227, 1116, 858, 757 cm-1; 1H NMR (300 
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MHz, CDCl3) δ 3.67 (2AA’ of AA’XX’, JAA’ = -12 Hz, JAX = 7 Hz, JAX’ = 4 Hz, 4 H), 3.50 (2XX’ 
of AA’XX’, JXX’ = -12 Hz, JAX = 7 Hz, JAX’ = 4 Hz, 4 H), 1.78–1.46 (m, 5 H), 1.44–1.35 (m, 1 H), 
1.13 (s, 6 H), 1.09 (s, 6 H); 13C NMR (76 MHz, CDCl3) δ 156.4, 66.7, 60.1, 44.4, 39.0, 31.8, 21.0, 
16.9; HRMS (ESI) m/z calcd for C14H27N2O3 (M+H) 271.2016, found 271.2019. 
 
2,2,6,6-Tetramethylpiperidin-1-yl pyrrolidine-1-carboxylate (1-58).  According to 
General Method 1-A, pyrrolidine (50.0 mg, 0.696 mmol), triethylamine (213 mg, 296 µL, 2.09 
mmol), NPTC (269 mg, 0.835 mmol), DMF (1.4 mL) and chromatography on SiO2 (0:1 to 1:1, 
EtOAc/hexanes) afforded 1-58 (161 mg, 91%) as a white solid: Rf = 0.44 (1:1, EtOAc/hexanes); 
Mp 74-76 °C; ATR-IR (neat) 2972, 2932, 1726, 1388, 1060, 759 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 3.40 (t, J = 6.7 Hz, 4 H), 1.95–1.77 (m, 4 H), 1.77–1.44 (m, 5 H), 1.42–1.33 (m, 1 H), 
1.13 (s, 6 H), 1.09 (s, 6 H);  13C NMR (76 MHz, CDCl3) δ 156.0, 59.9, 46.5 (b), 45.4 (b), 38.9, 
31.9, 25.9 (b), 24.7 (b), 20.8, 17.0; HRMS (ESI) m/z calcd for C14H27N2O2 (M+H) 255.2067, found 
255.2065. 
 
2-Methyl 1-(2,2,6,6-tetramethylpiperidin-1-yl) (R)-pyrrolidine-1,2-dicarboxylate (1-
59).  According to General Method 1-A and Workup Procedure 1-1, L-proline methyl ester 
hydrochloride (1.00 g, 5.98 mmol), triethylamine (2.44 g, 3.39 mL, 23.9 mmol), NPTC (2.31 g, 
7.17 mmol), DMF (12 mL) and chromatography on SiO2 (1:19 to 1:1, EtOAc/hexanes) afforded 
1-59 (1.62 g, 87%) as an off-white solid: Rf = 0.56 (1:1, EtOAc/hexanes); Mp 91-93 °C; ATR-IR 
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(neat) 2977, 2935, 1740, 1721, 1386, 1363, 1201, 1185, 1065, 759 cm-1; 1H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 4.30 (dd, J = 8.8, 3.1 Hz, 1 H), 3.66 (s, 3 H), 3.47 (t, J = 6.7 Hz, 2 H), 2.35–
2.20 (m, 1 H), 1.99–1.85 (m, 3 H), 1.52 (s, 6 H), 1.09 (s, 6 H), 1.06 (s, 6 H); 13C NMR (101 MHz, 
CDCl3, 2:3 mixture of rotamers) δ 173.3, 173.0, 155.8, 155.0, 60.0, 59.9, 59.8, 59.4, 58.4, 52.0, 
51.9, 47.3, 45.9, 39.1, 39.0, 38.9, 31.9, 31.7, 31.5, 31.4, 31.3, 29.5, 24.4, 23.2, 20.9, 20.8, 20.7, 
20.3, 16.9; HRMS (ESI) m/z calcd for C16H29N2O4 (M+H) 313.2122, found 313.2125. 
 
2,2,6,6-Tetramethylpiperidin-1-yl 1H-indole-1-carboxylate (1-60).  According to 
General Method 1-B, indole (50.0 mg, 0.423 mmol), sodium hydride 90% (14.7 mg, 0.549 mmol), 
NPTC (164 mg, 0.507 mmol), THF (0.25 mL) and chromatography on SiO2 (1:49 to 1:19, 
EtOAc/hexanes) afforded 1-60 (119 mg, 94%) as a crystalline white solid: Rf = 0.63 (1:4, 
EtOAc/hexanes); Mp 103-105 °C; ATR-IR (neat) 2973, 2935, 1761, 1452, 1321, 1227, 1114, 988, 
756 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.16 (d, J = 8.3 Hz, 1 H), 7.57 (d, J = 3.8 Hz, 1 H), 7.49 
(d, J = 7.6 Hz, 1 H), 7.26 (dt, J = 8.1, 1.5 Hz, 1 H), 7.16 (dt, J = 7.8, 1.5 Hz, 1 H), 6.54 (d, J = 3.7 
Hz, 1 H), 1.78–1.45 (m, 5 H), 1.42–1.33 (m, 1 H), 1.22 (s, 6 H), 1.10 (s, 6 H); 13C NMR (76 MHz, 
CDCl3) δ 151.8, 135.4, 130.3, 125.2, 124.5, 122.9, 120.9, 115.3, 108.1, 60.8, 39.3, 31.7, 21.3, 16.9; 
HRMS (ESI) m/z calcd for C18H25N2O2 (M+H) 301.1911, found 301.1907. 
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2,2,6,6-Tetramethylpiperidin-1-yl 3-(2-aminoethyl)-1H-indole-1-carboxylate (1-61).  
A suspension of sodium hydride (90% in mineral oil, 74.2 mg, 2.78 mmol) in freshly distilled THF 
(10 mL) was stirred vigorously under nitrogen at 0 °C on an ice-bath for 10 min, and treated 
dropwise with a solution of tryptamine (0.350 g, 2.14 mmol) in distilled THF (5.0 mL) over 1 min. 
The cooling bath was removed and the reaction mixture was stirred at ambient temperature. After 
4 h, the mixture was cooled to 0 °C and a solution of NPTC (828 mg, 2.60 mmol) in distilled THF 
(6.0 mL) was added over 1 h by syringe pump. During the addition, the reaction mixture turned 
yellow, then deep orange. The solution was stirred at 0 °C for an additional 1 h, quenched with sat. 
ammonium chloride (2 mL), concentrated, and diluted with CH2Cl2 (50 mL) and sat. sodium 
carbonate (25 mL). The organic layer was washed with sat. sodium carbonate until the aqueous 
layer remained colorless (complete removal of 4-nitrophenol, typically 2-3 washes), dried 
(MgSO4) and concentrated to give a residue that was purified by chromatography on SiO2 (0 to 
1:4, MeOH:CH2Cl2) to afford 1-60 (523 mg, 71%) as a pale yellow oil: Rf = 0.35 (1:4, 
MeOH:CH2Cl2); ATR-IR (neat) 2974, 2934, 2871, 1754, 1364, 1453, 1364, 1221, 988, 754 cm
-1; 
1H NMR (300 MHz, CDCl3) δ 8.22 (d, J = 8.2 Hz, 1 H), 7.57 (dd, J = 7.8, 1.0 Hz, 1 H), 7.50 (s, 1 
H), 7.36 (dt, J = 7.9, 1.2 Hz, 1 H), 7.27 (dt, J = 7.9, 1.2 Hz, 1 H), 3.09 (bs, 2 H), 2.89 (t, J = 6.6 
Hz, 2 H), 1.88–1.57 (m, 7 H), 1.50–1.43 (m, 1 H), 1.32 (s, 6 H), 1.19 (s, 6 H); 13C NMR (76 MHz, 
CDCl3) δ 151.7, 135.7, 130.4, 124.7, 122.6, 122.4, 119.1, 119.0, 115.4, 60.7, 41.4, 39.2, 31.7, 29.0, 
21.4, 16.9; HRMS (ESI) m/z calcd for C20H30N3O2 (M+H) 344.2333, found 344.2330. 
 99 
 
2,2,6,6-Tetramethylpiperidin-1-yl 1H-imidazole-1-carboxylate (1-62). According to 
General Method 1-A, imidazole (0.250 g, 3.66 mmol), triethylamine (1.12 g, 1.56 mL, 11.0 mmol), 
NPTC (1.42 g, 4.39 mmol), DMF (7.3 mL) and chromatography on SiO2 (1:19 to 1:4, 
EtOAc/hexanes) afforded 1-62 (838 mg, 91%) as a fluffy colorless solid: Rf = 0.48 (1:1, 
EtOAc/hexanes); Mp 133-135 °C; ATR-IR (neat) 3133, 3109, 2937, 2937, 1771, 1376, 1245, 986, 
762 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.18 (s, 1 H), 7.46 (t, J = 1.5 Hz, 1 H), 7.11 (dd, J = 1.5, 
0.9 Hz, 1 H), 1.81–1.56 (m, 5 H), 1.50–1.42 (m, 1 H), 1.25 (s, 6 H), 1.16 (s, 6 H); 13C NMR (101 
MHz, CDCl3) δ 149.4, 136.9, 130.7, 117.0, 61.2, 39.2, 31.7, 20.8, 16.8; HRMS (ESI) m/z calcd for 
C13H22N3O2 (M+H) 252.1707, found 252.1712. 
 
2,2,6,6-Tetramethylpiperidin-1-yl benzyl(methyl)carbamate (1-63).  According to 
General Method 1-A, N-methylbenzylamine (1.00 g, 8.01 mmol), triethylamine (2.46 g, 3.41 mL, 
24.0 mmol), NPTC (3.10 g, 9.61 mmol), DMF (1 mL) and chromatography on SiO2 (0:1 to 1:19, 
EtOAc/hexanes) afforded 1-63 (2.36 g, 97%) as an off-white solid: Rf = 0.58 (1:1, 
EtOAc/hexanes); Mp 56-58 °C; ATR-IR (neat) 2973, 2932, 1723, 1378, 1117, 925, 697 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.45–7.25 (m, 5 H), 4.52 (bs, 2 H), 2.90 (b, 3 H), 1.80–1.45 (m, 5 H), 
1.45– 1.30 (m, 1 H), 1.13 (b, 12 H); 13C NMR (76 MHz, CDCl3) δ 137.8, 128.5, 127.3, 60.1, 52.8 
(b), 39.0, 35.5 (b), 31.8, 20.9, 17.0; HRMS (ESI) m/z calcd for C18H29N2O2 (M+H) 305.2224, 
found 305.2222. 
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2,2,6,6-Tetramethylpiperidin-1-yl dipropylcarbamate (1-64).  According to General 
Method 1-A, di-n-propylamine (0.200 g, 1.96 mmol), triethylamine (0.600 g, 0.833 mL, 5.87 
mmol), NPTC (757 mg, 2.35 mmol), DMF (3.9 mL) and chromatography on SiO2 (1:19 to 1:4, 
EtOAc/hexanes) afforded 1-64 (310 mg, 56%) as a clear oil: Rf = 0.67 (1:1, EtOAc/hexanes); 
ATR-IR (neat) 2966, 2933, 1729, 1232, 1147, 759 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.20 (2AA’ 
of AA’XX’, JAA’ = -8 Hz, JAX = 9 Hz, JAX’ = 5 Hz, 4 H), 1.76–1.45 (m, 9 H), 1.42–1.33 (m, 1 H), 
1.13 (s, 6 H), 1.08 (s, 6 H), 0.88 (t, J = 6.6 Hz, 3 H), 0.84 (t, J = 6.6 Hz, 3 H); 13C NMR (76 MHz, 
CDCl3, 1:1 mixture of rotamers) δ 157.2, 59.9, 49.4, 48.6, 39.1, 31.7, 22.2, 21.2, 21.0, 17.0, 11.4, 
11.1; HRMS (ESI) m/z calcd for C16H33N2O2 (M+H) 285.2537, found 285.2534. 
 
2,2,6,6-Tetramethylpiperidin-1-yl (methyl(oxo)(phenyl)-λ6-sulfanylidene)carbamate 
(1-65).  A suspension of sodium hydride (60% dispersion in mineral oil, 28.4 mg, 0.709 mmol) in 
dry DMF (6.5 mL) was treated dropwise at 0 °C under nitrogen with a solution of methyl 
sulfoximine (0.100 g, 0.664 mmol) in dry DMF (0.5 mL). The reaction mixture was stirred at 0 °C 
for 1 h before a solution of NPTC (265 mg, 0.821 mmol) in dry DMF (0.5 mL) was added. The 
cooling bath was removed, and the solution was stirred at room temperature for 12 h, quenched 
with crushed ice (5 g), and partitioned between 1 M NaOH (20 mL) and CH2Cl2 (20 mL). The 
organic layer was separated and the aqueous slayer was extracted with CH2Cl2 (2 x 15 mL). The 
combined organic layers were washed with deionized water and brine, dried (MgSO4), filtered, 
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and concentrated to give a residue which was purified by chromatography on SiO2 (1:49 to 1:19, 
CH2Cl2:MeOH) to afford 1-65 (178 mg, 82%) as a fluffy white solid: Rf = 0.36 (4:1, 
EtOAc/hexanes); Mp 196-198 °C (dec.); ATR-IR (neat) 3015, 2930, 1726, 1682, 1220, 978, 743, 
518 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.02–7.95 (m, 2 H), 7.67–7.54 (m, 3 H), 3.23 (s, 3 H), 
1.65–1.23 (m, 6 H), 1.08 (s, 3 H), 1.05 (s, 3 H), 0.91 (s, 3 H), 0.64 (s, 3 H); 13C NMR (76 MHz, 
CDCl3) δ 158.1, 139.4, 133.7, 129.6, 127.3, 60.1, 59.7, 45.2, 39.0, 31.5, 31.4, 20.6, 20.2, 16.8; 
HRMS (ESI) m/z calcd for C17H27N2O3S (M+H) 339.1737, found 339.1732. 
4.1.5  Synthetic procedures and spectral characterization for Tempoc deprotections and 
orthogonality studies 
 
1H-Indole (1-82).  According to General Method 1-C and Workup Procedure 1-3, 1-60 
(475 mg, 1.58 mmol), ascorbic acid (844 mg, 4.74 mmol), and copper(II) chloride (21.5 mg, 0.158 
mmol) in MeCN/THF/H2O (8.8 mL/2.2 mL/2.2 mL) afforded 1-82 as an off-white crystalline solid 
(179 mg, 91%) that spectrally matched a commercial sample.  
 
4-Phenylpiperidine (1-83).  According to General Method 1-C and Workup Procedure 1-
3, 1-56 (1.02 g, 2.95 mmol), ascorbic acid (1.57 g, 8.84 mmol), copper(II) chloride (40.0 mg, 0.295 
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mmol), and MeCN/THF/H2O (16.4 mL/4.1 mL/4.1 mL) afforded 1-83 as an off-white solid (435 
mg, 91%) which spectrally matched a commercial sample.  
 
trans-Phenylcyclohexan-1-amine (1-84).147  According to General Method 1-C and 
Workup Procedure 1-3, trans-1-44 (132 mg, 0.368 mmol), ascorbic acid (196 mg, 1.11 mmol), 
and copper(II) chloride (5.00 mg, 0.0368 mmol) in MeCN/THF/H2O (2.0 mL/0.5 mL/0.5 mL) 
afforded 1-84 as an off-white solid (59.0 mg, 91%) which matched literature spectra: 1H NMR 
(400 MHz, CDCl3) δ 7.33–7.27 (m, 2 H), 7.23–7.15 (m, 3 H), 2.74 (tt, J = 11.1, 3.9 Hz, 1 H), 2.48 
(tt, J = 12.2, 3.6 Hz, 1 H), 2.03–1.86 (m, 4 H), 1.60–1.46 (m, 4 H), 1.27 (dq, J = 12.4, 3.2 Hz, 2 
H); 13C NMR (101 MHz, CDCl3) δ 147.0, 128.3, 126.8, 125.9, 50.4, 43.7, 37.0, 33.1; HRMS (ESI) 
m/z calcd for C12H18N ([M+H]
+) 176.1434, found 176.1434. 
 
 
4-Phenylpiperidine (1-83).  According to General Method 1-D, 1-56 (0.200 g, 0.581 
mmol), HFIP (5.8 mL) and chromatography on SiO2 (0:1 to 3:7, MeOH:CH2Cl2) afforded 1-83 
(86 mg, 85%) as a colorless solid which spectrally matched a commercial sample: 1H NMR (300 
MHz, CDCl3) δ 7.41–7.28 (m, 2 H), 7.27–7.17 (m, 3 H), 3.30–3.13 (m, 2 H), 2.76 (td, J = 12.2, 
2.6 Hz, 2 H), 2.62 (tt, J = 12.0, 3.8 Hz, 1 H), 2.02 (bs, 1H), 1.92–1.78 (m, 2 H), 1.63 (dq, J = 12.0, 
3.6 Hz, 2 H); HRMS (ESI) m/z calcd for C11H17N (M+H) 162.1277, found 162.1277. 
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1H-Indole (1-82).  According to General Method 1-D, 1-60 (0.200 g, 0.666 mmol), HFIP 
(6.7 mL) and chromatography on SiO2 (1:19 to 1:9, EtOAc/hexanes) afforded 1-82 (68.3 mg, 88%) 
as an off-white solid that spectrally matched a commercial sample: 1H NMR (300 MHz, CDCl3) δ 
8.07 (bs, 1 H), 7.70 (dd, J = 7.8, 1.2 Hz, 1 H), 7.41 (dd, J = 8.0, 1.1 Hz, 1 H), 7.31–7.11 (m, 3 H), 
6.63–6.57 (m, 1 H). 
 
1,3-Bis([1,1'-biphenyl]-4-ylmethyl)urea (1-86).  According to General Method 1-D, 1-42 
(0.100 g, 0.273 mmol), HFIP (2.7 mL), a 2 h reaction time, and trituration with hexanes/diethyl 
ether (1:1) afforded 1-86 (39.4 mg, 74%) as an off-white solid: Rf = 0.82 (1:4, MeOH/CH2Cl2); 
Mp >250 °C; ATR-IR (neat) 3355, 3326, 3034, 1628, 1576, 1486, 1254, 753 cm-1; 1H NMR (400 
MHz, DMSO-d6, 90 °C) δ 7.69–7.55 (m, 8 H), 7.49–7.42 (m, 4 H), 7.41–7.27 (m, 6 H), 6.30 (t, J 
= 6.0 Hz, 2 H), 4.32 (d, J = 6.0 Hz, 4 H); 13C NMR (101 MHz, DMSO, 90 °C) δ 157.7, 139.7, 
139.6, 138.2, 128.2, 127.1, 126.6, 126.0, 42.5; HRMS (ESI) m/z calcd for C27H25N2O (M+H) 
393.1961, found 393.1959. 
 
[1,1'-Biphenyl]-4-ylmethanamine (1-87).1  According to General Method 1-E, 1-42 
(0.550 g, 1.50 mmol), potassium trimethylsilanolate (642 mg, 4.50 mmol), 1,4-dioxane (10 mL) 
 104 
and chromatography on SiO2 (0:1 to 3:97, Et3N:EtOAc) afforded 1-87 (255 mg, 93%) as a 
colorless solid which matched literature spectra: Rf = 0.47 (15:4:1, CH2Cl2/MeOH/Et3N); 
1H NMR 
(300 MHz, CDCl3) δ 7.75–7.54 (m, 4 H), 7.52–7.30 (m, 5 H), 3.93 (s, 2 H), 1.52 (s, 2 H); 13C 
NMR (76 MHz, CDCl3) δ 142.4, 140.9, 139.8, 128.7, 127.5, 127.3, 127.1, 127.0, 46.2. 
 
2,2,6,6-Tetramethylpiperidin-1-yl piperazine-1-carboxylate trifluoroacetic acid salt 
(1-97).  A solution of piperazine 1-54 (0.250 g, 0.677 mmol) in CH2Cl2 (5.6 mL) was treated at 0 
°C dropwise with trifluoroacetic acid (1.13 mL), and stirred at room temperature for 70 min until 
starting material disappeared by TLC and LC-MS analysis. The reaction mixture was concentrated 
under reduced pressure and the oily residue was dissolved in diethyl ether (10 mL). A colorless 
precipitate formed and was filtered, washed with ice-cold diethyl ether (10 mL), and dried under 
vacuum to afford 1-97 (243 mg, 94%) as crystalline solid: Rf = 0.36 (1:9, MeOH/CH2Cl2); Mp 
164-167 °C (dec.); ATR-IR (neat) 2972, 2946, 1733, 1686, 1172, 1125, 719 cm-1; 1H NMR (500 
MHz, CDCl3) δ 9.92 (bs, 2 H), 3.85-3.82 (m, 4 H), 3.21-3.18 (m, 4 H), 1.75–1.52 (m, 5 H), 1.45–
1.39 (m, 1 H), 1.15 (s, 6 H), 1.09 (s, 6 H); 13C NMR (101 MHz, CDCl3) δ 161.8 (q, J = 37.4 Hz, 
COCF3), 155.9, 115.9 (q, J = 289.7 Hz, COCF3), 60.7, 43.4, 41.0, 39.0, 31.6, 21.0, 16.8; 
19F NMR 
(376 MHz, CDCl3) δ -75.9; HRMS (ESI) m/z calcd for C14H28N3O2 (M+H) 270.2176, found 
270.2175. 
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tert-Butyl piperazine-1-carboxylate (1-98).  According to General Method 1-C and 
Workup Procedure 1-2, 1-54 (408 mg, 1.11 mmol), ascorbic acid (0.590 g, 3.31 mmol), and 
copper(II) chloride (15.0 mg, 0.111 mmol) in MeCN/THF/H2O (6.2 mL/1.5 mL/1.5 mL) afforded 
1-98 as a white semi-solid (196 mg, 95%) which spectrally matched a commercial sample: 1H 
NMR (300 MHz, CDCl3) δ 3.28 (2AA’ of AA’XX’, JAA’ = -12 Hz, JAX = 6.2 Hz, JAX’ = 4.2 Hz, 4 
H), 2.70 (2XX’ of AA’XX’, JXX’ = -12 Hz, JAX = 6.2 Hz, JAX’ = 4.2 Hz, 4 H), 1.98 (bs, 1 H), 1.36 
(s, 9 H). 
 
1-Benzyl 4-(2,2,6,6-tetramethylpiperidin-1-yl) piperazine-1,4-dicarboxylate (1-99).  A 
solution of 1-54 (1.50 g, 4.06 mmol) in CH2Cl2 (33.8 mL) was treated at 0 °C dropwise with 
trifluoroacetic acid (6.77 mL). The reaction stirred at room temperature for 70 min until 
consumption of the starting material was observed by TLC and LC-MS analysis, concentrated in 
vacuo, and the oily residue was dissolved in diethyl ether (20 mL). A colorless precipitate formed 
and was filtered, washed with ice-cold diethyl ether (10 mL), and dried in vacuo. The residue was 
suspended in dry CH2Cl2 (41 mL), and treated dropwise at 0 °C under nitrogen with pyridine (1.61 
g, 1.66 mL, 20.3 mmol) and benzyl chloroformate (762 mg, 0.635 mL, 4.47 mmol). The reaction 
mixture was stirred at room temperature for 12 h, quenched with water (30 mL) extracted with a 
 106 
mixture of saturated NaHCO3 (100 mL) and CH2Cl2 (100 mL).  The organic layer was separated 
and the aqueous layer extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were 
washed with water and brine, dried (MgSO4), and concentrated, and chromatographed on SiO2 
(1:19 to 1:1, EtOAc/hexanes) to afford 1-99 (1.52 g, 93%) as a viscous oil which solidified to a 
colorless solid on standing: Rf = 0.50 (1:1, EtOAc/hexanes); Mp 103-105 °C; ATR-IR (neat) 2973, 
2932, 1731, 1703, 1215, 1075, 756 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39–7.27 (m, 5 H), 5.13 
(s, 2 H), 3.50 (app s, 8 H), 1.76–1.47 (m, 5 H), 1.45–1.38 (m, 1 H), 1.13 (s, 6 H), 1.08 (s, 6 H); 13C 
NMR (101 MHz, CDCl3) δ 156.2, 155.1, 136.3, 128.4, 128.0, 127.9, 67.3, 60.1, 43.8, 38.9, 31.7, 
20.9, 16.9; HRMS (ESI) m/z calcd for C22H34N3O4 (M+H) 404.2544, found 404.2538. 
 
2,2,6,6-Tetramethylpiperidin-1-yl piperazine-1-carboxylate (1-100).4  A Schlenk flask 
containing 1-99 (0.200 g, 0.496 mmol) was purged and back-filled 3 times with hydrogen gas, and 
10% Pd/C (5.0 mg, [10 mg/mmol]) was added, followed by dry MeOH (1 mL) and 2 M methanolic 
ammonia (0.124 mL, 0.5 equiv). The flask was fitted with a H2 balloon and stirred at room 
temperature for 16 h.  The reaction mixture was diluted with methanol (10 mL) and filtered through 
a pad of Celite pre-wetted with methanol. The filtrate was concentrated to afford 1-100 (135 mg, 
quant) as an off-white solid: Rf = 0.31 (1:9, MeOH/CH2Cl2); Mp 126-128 °C; ATR-IR (neat) 3304, 
2933, 1715, 1416, 1227, 1046, 756 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.49 (2AA’ of AA’XX’, 
JAA’ = -12 Hz, JAX = 6 Hz, JAX’ = 4 Hz, 4 H), 2.85 (2XX’ of AA’XX’, JXX’ = -9 Hz, JAX = 6 Hz, JAX’ 
= 4 Hz, 4 H), 2.00 (bs, 1 H), 1.77–1.46 (m, 5 H), 1.44–1.35 (m, 1 H), 1.14 (s, 6 H), 1.10 (s, 6 H); 
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13C NMR (101 MHz, CDCl3) δ 156.4, 60.1, 46.0, 45.2, 39.0, 31.8, 21.0, 17.0; HRMS (ESI) m/z 
calcd for C14H28N3O2 (M+H) 270.2176, found 270.2177. 
 
Benzyl piperazine-1-carboxylate (1-101).148  According to General Method 1-C and 
Workup Procedure 1-3, 1-99 (297 mg, 0.736 mmol), ascorbic acid (393 mg, 2.21 mmol), and 
copper(II)chloride (10.0 mg, 0.0736 mmol) in MeCN/THF/H2O (4.1 mL/1.0 mL/1.0 mL) afforded 
1-101 as a colorless oil (165 mg, 92%) which matched literature reported spectra: 1H NMR (300 
MHz, CDCl3) δ 7.40–7.28 (m, 5 H), 5.12 (s, 2 H), 3.46 (2AA’ of AA’XX’, JAA’ = -12 Hz, JAX = 
6.2 Hz, JAX’ = 4.2 Hz, 4 H), 2.88–2.76 (m, 4 H), 1.82 (bs, 1 H); HRMS (ESI) m/z calcd for 
C12H17N2O2 (M+H) 221.1285, found 221.1284. 
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4.1.6  Thermolysis of Tempoc protected indole 1-60 
 
Experiment 1.  A microwave vial containing a solution of Tempoc protected indole 1-60 
(0.150 g, 0.499 mmol) in toluene-d8 was heated at 150 °C in an oil bath. After 20 h, the brown 
reaction mixture was cooled to room temperature. 1H NMR analysis of the solution showed a 3.6:1 
ratio of pyrrolidine 1-88 (δ 0.99 ppm) to tetramethylpiperidine 1-77 (δ 1.03 ppm).   
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Experiment 2.  A microwave vial containing a solution of Tempoc protected indole 1-60 
(0.150 g, 0.499 mmol) in toluene-d8 (0.5 mL) was degassed (4 cycles of freeze-pump-thaw) and 
on the last cycle purged with nitrogen, sealed, and heated in an oil bath maintaining an external 
temperature of 150 °C for 9 h. The reaction mixture turned from clear and colorless to dark brown. 
1H NMR analysis of the solution showed a 2.3:1.0:1.0 ratio of pyrrolidine 1-88 (  1.01 ppm) to 
tetramethylpiperidine 1-77 (δ 1.03 ppm) to enamine 1-90 (δ 4.00 ppm).  
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Experiment 3.  A microwave vial containing a solution of Tempoc protected indole 1-60 
(0.100 g, 0.332 mmol) and HPLC-grade water (0.024 mL, 1.33 mmol) in toluene-d8 (0.33 mL) 
was heated in an oil bath at an external temperature of 150 °C for 21.5 h. The brown solution was 
cooled to room temperature and 1H NMR analysis showed conversion to indole 1-82 and a 3.4:1 
ratio of pyrrolidine 1-88 (δ 1.01 ppm) to tetramethylpiperidine 1-77 (δ 1.03 ppm).  The reaction 
was concentrated and the resulting brown residue was purified by chromatography on SiO2 (0:1 to 
1:9, EtOAc/hexanes) to afford indole 1-82 (0.034 g, 87%) as a tan solid. 
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Experiment 4.  A microwave vial containing a solution of Tempoc protected indole 1-60 
(0.100 g, 0.332 mmol) in toluene-d8 (0.33 mL) was heated in an oil bath at an external temperature 
of 135-140 °C for 32.5 h. The reaction mixture turned from clear and colorless to dark brown. The 
solution was cooled to room temperature and 1H NMR analysis showed a 1.8:1 ratio of pyrrolidine 
1-88 (δ 1.02 ppm) to tetramethylpiperidine 1-77 (δ 1.04 ppm). 
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2,2-Dimethylpyrrolidine (1-88).  A solution of 2,2-dimethylpyrrolidine•HCl (0.050 g, 
0.35 mmol) in 12 N NaOH (1.25 mL) was stirred vigorously at room temperature for 1.5 h, treated 
with toluene-d8 (1 mL), and stirred vigorously. The organic layer was dried (Na2SO4) to give a 
sample of 1-88: 1H NMR (400 MHz, C6D5CD3) δ 2.77 (t, J = 7.0 Hz, 2 H), 1.57 (p, J = 7.3 Hz, 2 
H), 1.30 (t, J = 7.6 Hz, 2 H), 1.01 (s, 6 H); 13C NMR (100 MHz, C6D5CD3) δ 58.8, 46.3, 39.9, 
28.9, 26.4. 
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4.2 EXPERIMENTAL – TEMPOC PEPTIDES 
4.2.1  General experimental protocols  
Reactions were performed without inert atmosphere unless otherwise stated. DMF was 
dried over 4 Å molecular sieves which were activate in a muffle furnace at 350 °C for 16 h prior 
to use. Basic alumina (Brockmann Grade I) was purchased from Acros Organics and was stored 
in an oven (140 °C) before use. Anhydrous HOBt was purchased from Amatek Chemical. 
Anhydrous HOBt was used for reactions for uniformity (different lots of HOBt hydrate contain 
varying amounts of water). Amberlite IRC-748 resin was purchased from Sigma-Aldrich and was 
washed sequentially with water, methanol, then methylene chloride, and dried before use. All other 
reagents and solvents are commercially available and were used as received. HPLC analyses were 
conducted on a Shimadzu Prominence HPLC system utilizing a Phenomenex 4.6 mm x 250 mm 
C18 column with a 5-micron particle size. Elution with water/acetonitrile (both containing 0.1% 
(v/v) trifluoroacetic acid) was conducted at a constant a flow rate of 1.0 mL/min. A linear gradient 
of 10-60% acetonitrile over 60 min and a 100-minute acquisition time. 
4.2.2  Second generation synthesis of NPTC (1-34) 
 
A 500-mL Erlenmeyer containing a magnetic stirbar and a temperature probe was charged 
with sodium ascorbate (25.4 g, 127 mmol, 2.0 equiv) and deionized water (180 mL), affording a 
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pale-yellow solution. The stirring is increased slowly until a stable vortex is established. An initial 
temperature reading is taken and the probe is removed before freshly ground TEMPO (10.0 g, 63.4 
mmol, 1.0 equiv) is added in one portion. The probe is reinserted and the red suspension is stirred 
vigorously at ambient temperature. Once the red solids are fully converted to a white precipitate, 
and internal temperature no longer increases (ca. 15 min), CH2Cl2 (100 mL) is added and stirring 
is continued for an additional 10 min. The stirbar is removed, and the biphasic mixture is 
transferred to a 500-mL separatory funnel. The organic layer is separated and the aqueous layer 
extracted with methylene chloride (100 mL). The aqueous phase is re-extracted with an additional 
aliquot of CH2Cl2 (50 mL). The combined organics are dried (Na2SO4) and decanted into a 500-
mL 3-neck flask containing a stirbar. An additional aliquot of methylene chloride (25 mL) is used 
to wash the drying agent and the flask. The 3-neck flask is clamped inside a large crystallization 
dish. One of the flask necks was fitted with a 125-mL pressure-equalizing addition funnel. A dry-
ice/brine bath is prepared around the flask and the solution is stirred until a stable internal 
temperature (−11 ± 2 °C) is achieved. The addition funnel is charged with 4-nitrophenyl 
chloroformate (14.6 g, 69.7 mmol, 1.1 equiv) as a solution in methylene chloride (55 mL). 
Triethylamine (18.0 mL, 127 mmol, 2.0 equiv) is added via syringe and the addition of the 
chloroformate solution commenced. The addition rate is continually adjusted to maintain an 
internal temperature of −11 ± 2 °C (ca. 30 min). Once addition of the reagent is complete, the 
addition funnel is washed with CH2Cl2 and the cooling bath is removed. The reaction is stirred for 
an additional 90 min. The reaction is transferred to a 1-L separatory funnel with methylene chloride 
(50 mL). Saturated sodium carbonate (250 mL) is then added, and the contents shaken vigorously. 
The organic layer is separated and the orange aqueous layer extracted with methylene chloride (1 
x 100 mL). The combined organic layers are washed sequentially with saturated sodium carbonate 
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(2 x 250 mL), water (150 mL), and brine (200 mL). Drying (Na2SO4) and filtration through a 
course fritted vacuum funnel affords a red-orange solution, which is concentrated on a rotary 
evaporator produce a solid orange residue. The solid is dried under high-vacuum for 30 min. The 
yellow-orange residue is dissolved in acetone (250 mL) with swirling to give a reddish solution 
before being sealed and placed in a freezer (−20 °C) for 16 h. The crystals thus formed are collected 
by suction filtration on a 5 cm Büchner funnel. The filter-cake is compressed and then washed 
with cold acetone (−20 °C, 2 x 25 mL). The crystallization is repeated two more times with the 
mother liquor and the crops combined to give 1-36 “NPTC” (14.4 g, 71%) as an off-white 
crystalline solid. Characterization data vida supra. 
4.2.3  General methods and workup procedures  
Caution! 1-hydroxybenzotriazole (HOBt) is potentially explosive, especially in its 
anhydrous form, however, anhydrous HOBt was used without incident. 
General Method 2-A: Tempoc Protection of Amino Esters. A round bottom flask 
containing a stirbar was charged with target amino ester freebase or hydrochloride (1.00 mmol, 
1.0 equiv), NPTC (1.20 mmol, 1.2 equiv), and anhydrous HOBt (0.500 mmol, 0.5 equiv). Dry 
DMF (2.0 mL, 0.5 M) was added ensuring that all solids are washed down the walls of the vessel.  
The mixture was stirred for 3 min before addition of triethylamine (1.50 mmol, 1.5 equiv for amine 
freebases or 2.50 mmol, 2.5 equiv for amine hydrochlorides) in one portion. Upon addition of the 
base the reaction forms a heavy precipitate which undergoes partial dissolution within a couple 
minutes and is accompanied by formation of a yellow color (4-nitrophenoxide). The reaction is 
stirred at ambient temperature for 24 h during which time the reaction turned yellow or yellow-
orange in color.  
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Workup Procedure 2-1. At this point the reaction was diluted with methylene chloride or 
ethyl acetate (4 mL) and the reaction mixture was filtered through a 2.5 cm pad of pre-wetted 
(CH2Cl2 or EtOAc) basic alumina (Brockmann Grade I) in a 4.5 cm diameter coarse-fritted funnel. 
The crude product was washed through with methylene chloride or ethyl acetate (75 mL). HOBt 
and 4-nitrophenol are effectively retained by the alumina. If desired, DMF may be removed at this 
stage by washing the organic filtrate with water. The filtrate is concentrated on a rotary evaporator 
and the residue dissolved in a minimal amount of toluene and purified by chromatography on SiO2 
using the specified solvent systems.  
Workup Procedure 2-2. At this point the reaction is poured into a separatory funnel 
containing ethyl acetate (100 mL) and water is added (30 mL).  The aqueous layer is separated and 
organic is washed with saturated sodium carbonate (2 x 30 mL) and then brine (20 mL). 
Concentration of the organic layer afforded a residue which was purified by chromatography on 
SiO2 using the specified solvent systems. 
General Method 2-B: Tempoc Deprotection of Peptides. A vial containing a stirbar was 
charged with Tempoc protected peptide (1.00 mmol, 1.0 equiv) and sodium ascorbate (1.20 mmol, 
1.2 equiv) before a 1:1 mixture of DME/H2O (6.7 mL, 0.15 M) was then added resulting in a 
colorless turbid mixture. To this suspension was added a 0.50 M aqueous CuCl2 solution (70.0 μL, 
35.0 μmol, 0.035 equiv) [Various concentrations of the aqueous metal were used depending on the 
scale of the reaction (e.g. 0.50, 0.25, 0.10 M) with identical results. Additionally, CuCl2 can be 
added as a solid for larger scale reactions]. The reaction vessel headspace was flushed with 
nitrogen for 15 seconds and placed in a pre-heated aluminum block (38–41 °C). [The reaction can 
be run in a sealed vessel or under an inert atmosphere (balloon) to preclude oxygen.] After stirring 
for a few minutes, the reaction became a yellow-green color. After 3 h of heating the reaction 
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became orange-tan and a precipitate began to collect on the glass at the solvent-headspace 
interface, this precipitate is believed to be a dehydroascorbate by-product and need not be 
mechanically removed from the vessel walls. The reaction is typically complete in 7 h as 
determined by HPLC-MS and/or TLC, at this point the reaction was cooled before being diluted 
with ethyl acetate (20 mL). 
Workup Procedure 2-3. After dilution, the biphasic mixture saturated with solid NaCl to 
increase the ionic strength of the aqueous layer and induce good partitioning of the layers. The 
mixture is then transferred to a separatory funnel and the aqueous layer is removed and discarded. 
The organic layer is dried (MgSO4), concentrated, and the residue purified by catch and release on 
a 1” pad of SiO2 (the pad was first washed with 2 column volumes of ethyl acetate, then with 15% 
methanol in ethyl acetate or 5% triethylamine in ethyl acetate for more polar substrates). During 
the elution with the more polar eluent, the copper can be seen oxidizing on the silica as made 
apparent by the appearance of a slight blue color. Concentration of the second filtrate gave the 
pure peptide freebase as a yellow oil which formed a collapsible foam under high vacuum.  
NOTE: Depending on the nature of the peptide, copper may also elute through the plug 
and contaminate the product.  The presence of copper was made apparent by line broadening in 
the NMR. Residual copper is expeditiously removed with Amberlite IRC-748 resin (iminodiacetic 
acid resin, Na-form) using the following protocol: The peptide freebase is made 0.3 M in 
chloroform of methylene chloride and to it is added Amberlite IRC-748 resin 50 mass %. Stirring 
for 1 hour at ambient temperature in an open vessel and subsequent filtration removed all traces of 
copper. 
Workup Procedure 2-4. After dilution, the mixture is transferred to a separatory funnel. 
Additional ethyl acetate is added (30 mL) and the mixture is washed with a pH 10 ammonium 
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chloride buffer of high ionic strength (to preclude the formation of an emulsion.) This buffer was 
easily prepared from 100 mL of saturated ammonium chloride and enough concentrated 
ammonium hydroxide to achieve a pH = 10 (typically 15–20 mL). The organics were washed with 
this buffer (2 x 15 mL) with swirling, which removes dehydroascorbate (and byproducts) and 
copper salts from the organic phase. The organic layer is then dried (MgSO4), filtered, and 
concentrated to give the crude tripeptide freebase in sufficient purity for subsequent couplings. 
General Method 2-C: Saponification and Peptide Coupling Procedure for N- to C-
Terminus. A round bottom flask containing a stirbar was charged with protected amino ester (1.00 
mmol, 1.0 equiv) in a 2:1 THF/H2O mixture (2.9 mL, 0.35 M). This turbid mixture is cooled to 
0°C on an ice-bath before additions of lithium hydroxide monohydrate (1.50 mmol, 1.5 equiv) as 
a solid in one portion. The cooling bath is removed and the reaction is stirred at ambient 
temperature until disappearance of the starting material is observed by TLC or LC-MS (typically 
2.5–3 h). The reaction mixture is transferred to a separatory funnel containing ethyl acetate (25 
mL). The mixture is then acidified to pH = 2 with 2 M aqueous KHSO4.  The aqueous layer is 
discarded and the organic layer is washed with brine (10 mL), then dried (NaSO4), filtered, and 
concentrated to afford the protected amino acid which was directly dissolved in dry DMF (4.0 mL, 
0.25 M) and cooled to 0°C on an ice-bath before sequential addition of HATU (1.05 mmol, 1.05 
equiv), and DIPEA base. The clear mixture becomes yellow after addition of the base. This mixture 
is stirred for 5 min before addition of the target amino ester (1.05 mmol, 1.05 equiv) as a solid in 
two portions.  The cooling bath is removed and the reaction stirred at ambient temperature for 2 h. 
At this point, the reaction is poured into a separatory funnel containing ice-cold water (15 mL). 
Ethyl acetate is then added (50 mL) and the contents shaken vigorously. The aqueous layer is 
discarded and the organic is washed with an additional 15 mL aliquot of water which is also 
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discarded. The organic layer is then washed sequentially with 2 M aqueous KHSO4 (10 mL), sat. 
sodium carbonate (10 mL), then brine (10 mL).  The organic layer is then dried (MgSO4), filtered, 
and concentrated to give a crude oil which was dissolved in toluene and loaded onto a 1.5” pad of 
silica gel (pre-wetted with 5% EtOAc/hexanes.) The compound is then washed with two volumes 
of 5% EtOAc-hexanes, then the peptide is washed through with the appropriate solvent given 
below. Concentration of the filtrate affords the desired peptide in excellent purity. Alternatively, 
the peptide may be purified by chromatography on SiO2 using the detailed solvent systems. 
General Method for Marfey’s Analysis. Tempoc amino ester (0.05 mmol) was heated 
(105–110 °C) in 6 M aqueous HCl (10 mL) on an aluminum block in a sealed vessel for 24 h. After 
cooling of the solution to ambient temperature, the bulk of the HCl gas was removed by sparging 
with nitrogen for 10 min. 0.600 mL of the mixture was transferred to a 1-dram vial and 
concentrated with heating (40 °C) under high-vacuum (5 mbar) for 60 min. The white solid residue 
was taken up in 0.060 mL of deionized water and transferred to an auto-sampler vial before being 
treated with 118 μL of a 36 mM solution of Marfey’s reagent in freshly distilled acetone. The 
solution was made alkaline by addition of 48 μL of 1.0 mM aqueous NaHCO3. The vial was sealed 
and placed in an aluminum block at 40 °C for 1 hour with exclusion of ambient light. During this 
time the bright-yellow solution becomes fluorescent orange. Once cooled, 24 μL of 2.0 M aqueous 
HCl was added and the sample was shaken before being passed through a micron-filter into an 
amber auto-sampler vial and kept refrigerated in the dark until analysis (not more than 24 h) by 
HPLC. HPLC analysis was conducted on a Shimadzu Prominence HPLC system utilizing a 
Phenomenex 4.6 mm x 250 mm C18 column with a 5-micron particle size. Elution with 
water/acetonitrile (both containing 0.1% (v/v) trifluoroacetic acid) was conducted at a constant a 
flow rate of 1.0 mL/min. A linear gradient of 10–60% acetonitrile over 60 min and a 100-minute 
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acquisition time. Injection volume should be no larger than 2 μL as larger volumes resulted in 
saturation of the detector. Under these conditions the excess FDAA reagent eluted first (tR ca. 45 
min) followed by the L-isomer (tR ca. 63 min), an unidentified peak (tR ca. 67 min), and finally 
the D-isomer (tR ca. 69 min). Standards were prepared using the aforementioned conditions of: 
Tempoc protected DL-PheOEt (synthesized correspondingly (vida supra) from the commercial 
DL-phenylalanine ethyl ester hydrochloride) and from commercial DL-PheOH and L-PheOEt 
∙HCl.  
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Table 16 Complete optimization table for the Tempoc protection of phenylalaline 2-26 
 
entry additive (equiv) base (equiv) 4 Å MSb solvent isolated yield (%) 
1 - Et3N (3.0) Y dry DMF 19 
2a HOBt (1.2) Et3N (3.0) Y dry DMF 82 
3 HOBt (1.2) Et3N (4.0) Y dry DMF 84 
4 Oxyma (1.2) Et3N (4.0) Y dry DMF 59 
5 K-Oxyma (1.2) Et3N (4.0) Y dry DMF 55 
6 HOBt (1.0) Et3N (4.0) Y dry DMF 88 
7 HOBt (1.0) Et3N (4.0) N dry DMF 88 
8 HOBt (1.0) Et3N (4.0) Y wet DMF 88 
9 HOBt (1.0) Et3N (4.0) N wet DMF 87 
10 HOBt (0.1) Et3N (3.0) Y dry DMF 60 
11 HOBt (0.15) Et3N (3.0) Y dry DMF 62 
12 HOBt (0.25) Et3N (3.0) Y dry DMF 68 
13 HOBt (0.5) Et3N (4.0) Y dry DMF 83 
14 HOBt (0.5) Et3N (3.0) N dry DMF 80 
15 HOBt (0.5) Et3N (2.5) N dry DMF 83 
16 HOBt (0.5) Et3N (2.0) N dry DMF 77 
17 HOBt (0.5) Na2CO3 (2.5) N dry DMF 71 
18 HOBt (0.5) pyridine (2.5) N dry DMF –c 
19 HOBt hydrate (0.5)d Et3N (2.5) N dry DMF 80 
20 HOBt hydrate (0.5)d Et3N (2.5) Y dry DMF 82 
21 HOBt (0.5) Et3N (2.5) N dry CH2Cl2 19 
22 HOBt (0.5) Et3N (2.5) N dry THF 40 
23 HOBt (0.5) Et3N (2.5) N dry MeCN 32 
aamine 2-41 was used; b100 mg/mmol amine; conly recovered starting materials were isolated; dHOBt (97%) contained ≥ 20% wt. 
water 
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4.2.4  Synthetic procedures and spectral characterization for Tempoc protected amino 
esters 
 
Ethyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-L-phenylalaninate(2-26). 
Following General Method 2-A and Workup Procedure 2-1, A two-neck 250-mL round-bottom 
flask containing a stirbar was charged with NPTC (12.6 g, 38.8 mmol), L-phenylalanine ethyl 
ester hydrochloride (7.50 g, 32.3 mmol), and HOBt (2.25g, 16.2 mmol). DMF (65 mL) was then 
added and the heterogeneous solution is stirred for 5 min. At this point, triethylamine (11.5 mL, 
80.8 mmol) is added in two portions over 2 min via syringe. This mixture is stirred at ambient 
temperature for 24 h, during which time the mixture turns an orange-yellow color. The reaction is 
diluted with 100 mL of toluene and transferred to a vacuum-funnel containing basic alumina which 
has been pre-wetted with toluene. Filtration through basic alumina gives a transparent light-tan 
filtrate that is concentrated on a rotary evaporator to afford a heavy liquid that begins to crystallize. 
At this point the residue is statically dried on the high-vac for an additional 10 h to afford a 
colorless solid. The solid is purified by chromatography on silica gel to afford 2-26, (9.96 g, 80%) 
as a colorless solid. Unreacted NPTC (3.35 g) is also recovered from the purification and recycled 
in subsequent protections. [α]D
23 −8.8 (c 0.12, CH2Cl2); Rf = 0.27 (4:1 hexanes/EtOAc, UV active); 
Mp 80–82 °C; ATR-IR (neat) 3353, 2979, 2936, 1726, 1492, 1183, 1030, 743, 700 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.30–7.22 (m, 3 H), 7.18–7.14 (m, 2 H), 4.64 (dt, J = 7.7, 6.3 Hz, 1 H), 4.17 
(q, J = 7.1 Hz, 2 H), 3.21–3.11 (m, 2 H), 1.67–1.49 (m, 3 H), 1.48–1.34 (m, 3 H), 1.23 (t, J = 7.1 
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Hz, 3 H), 1.16 (s, 3 H), 1.15 (s, 3H), 1.03 (s, 3 H), 0.86 (s, 3 H); 13C NMR (126 MHz, CDCl3) δ 
171.5, 157.8, 135.9, 129.3, 128.6, 127.1, 61.4, 60.8, 60.6, 54.6, 39.6, 39.6, 38.0, 31.6, 31.5, 20.6, 
20.5, 16.7, 14.1; HRMS (ESI) m/z calcd for C21H33N2O4 (M+H) 377.2435, found 377.2430. 
 
(((2,2,6,6-Tetramethylpiperidin-1-yl)oxy)carbonyl)glycine (2-42). According to 
General Method 2-A, glycine (80.0 mg, 1.07 mmol), NPTC (412 mg, 1.28 mmol), HOBt (74.2 
mg, 0.533 mmol), triethylamine (272 mg, 378 μL, 2.66 mmol), DMF (2.1 mL), after 24 h was 
diluted with diethyl ether (30 mL) and transferred to a separatory funnel. The mixture was acidified 
with 1 N KHSO4 (10 mL). The aqueous layer was separated and the organic layer washed with 1 
N KHSO4 (10 mL). The combined aqueous layers were back-extracted once with diethyl ether (30 
mL). The combined ethereal layers were dried (Na2SO4), filtered, and concentrated to afford an 
oily solid which was reslurried in toluene (30 mL). The white precipitate was filtered off under 
vacuum and the filtrate was concentrated in vacuo to afford a residue which was purified by 
chromatography on silica gel (isocratic, 99:1 EtOAc/AcOH) to afford 2-42 (132 mg, 46%) as an 
oil that foamed to a beige solid under high vacuum which contained 3.5% HOBt by mass (factored 
into yield): Rf = 0.52 (EtOAc, bromocresol green active); Mp 122.5 °C (dec.); ATR-IR (neat) 3359, 
2978, 2936, 1709, 1505, 1185, 1048, 945 cm-1; 1H NMR (400 MHz, DMSO) δ 12.57 (bs, 1 H), 
7.62 (bs,  1 H), 3.71 (d, J = 6.0 Hz, 2 H), 1.63–1.44 (m, 5 H), 1.40–1.32 (m, 1 H), 1.11 (s, 6 H), 
1.06 (s, 6 H); 13C NMR (101 MHz, DMSO) δ 171.2, 158.0, 59.8, 42.2, 38.8, 31.1, 20.3, 16.4; ; 
HRMS (ESI) m/z calcd for C12H23N2O4 (M+H) 259.1652, found 259.1648.   
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Methyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)glycinate (2-43). Following 
General Method 2-A and Workup Procedure 2-1, glycine methyl ester hydrochloride (0.150 g, 
1.17 mmol), NPTC (453 mg, 1.41 mmol), HOBt (81.6 mg, 0.585 mmol), triethylamine (299 mg, 
416 μL, 2.93 mmol), DMF (2.4 mL), and chromatography on SiO2 (19:1 to 1:1 hexanes/Et2O) 
afforded 2-43 (279 mg, 88%) as a colorless solid: Rf = 0.23 (1:1 Hexanes/Et2O, I2 active); Mp 
110.5–112 °C; ATR-IR (neat) 3298, 2979, 3943, 1763, 1702, 1505, 1171, 940, 728 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.24 (bs, 1 H), 4.04 (d, J = 5.6 Hz, 2 H), 3.74 (s, 3 H), 1.68–1.53 (m, 5 H), 
1.45–1.35 (m, 1 H), 1.21 (s, 6 H), 1.14 (s, 6 H); 13C NMR (101 MHz, CDCl3) δ 170.3, 158.4, 60.9, 
52.2, 42.4, 39.7, 31.6, 20.6, 16.7; HRMS (ESI) m/z calcd for C13H25N2O4 (M+H) 273.1809, found 
237.1807.   
 
Ethyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)glycinate (2-28). Following 
General Method 2-A and Workup Procedure 2-1, glycine ethyl ester hydrochloride (0.150 g, 1.06 
mmol), NPTC (412 mg, 1.28 mmol), HOBt (74.1 mg, 0.532 mmol), triethylamine (272 mg, 378 
μL, 2.66 mmol), DMF (2.1 mL), and chromatography on SiO2 (19:1 to 1:1 hexanes/Et2O) afforded 
2-28 (283 mg, 93%) as a colorless solid: Rf = 0.38 (1:1 hexanes/Et2O, I2 active); Mp 109–110.5 
°C; ATR-IR (neat) 3275, 2976, 2942, 1757, 1698, 1497, 1178, 1040, 945, 723 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.23 (bs, 1 H), 4.18 (q, J = 7.1 Hz, 2 H), 4.01 (d, J = 5.6 Hz, 2 H), 1.68–1.48 (m, 
5 H), 1.43–1.35 (m, 1 H), 1.25 (t, J = 7.1 Hz, 3 H), 1.20 (s, 6 H), 1.13 (s, 6 H); 13C NMR (101 
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MHz, CDCl3) δ 169.8, 158.3, 61.3, 60.8, 42.5, 39.6, 31.6, 20.5, 16.7, 14.1; HRMS (ESI) m/z calcd 
for C14H27N2O4 (M+H) 287.1965, found 287.1962.   
 
tert-Butyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)glycinate (2-31). 
Following General Method 2-A and Workup Procedure 2-1, glycine tert-butyl ester hydrochloride 
(175 mg, 1.02 mmol), NPTC (396 mg, 1.23 mmol), HOBt (71.3 mg, 0.512 mmol), triethylamine 
(261 mg, 363 μL, 2.56 mmol), DMF (2.0 mL), and chromatography on SiO2 (19:1 to 3:1 
hexanes/Et2O) afforded 2-31 (303 mg, 94%) as a colorless solid: Rf = 0.50 (1:1 hexanes/Et2O, I2 
active); Mp 152-154 °C; ATR-IR (neat) 3340, 2978, 2938, 2871, 1702, 1491, 1455, 1367, 1158, 
1133, 1041, 933, 706 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.18 (s, 1 H), 3.92 (d, J = 5.4 Hz, 2 H), 
1.68–1.56 (m, 5 H), 1.46 (s, 9 H), 1.44–1.38 (m, 1 H), 1.21 (s, 6 H), 1.14 (s, 6 H); 13C NMR (126 
MHz, CDCl3) δ 168.8, 158.3, 82.1, 60.8, 43.3, 39.7, 31.7, 28.1, 20.6, 16.8; HRMS (ESI) m/z calcd 
for C16H31N2O4 (M+H) 315.2278, found 315.2274.   
 
Benzyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)glycinate (2-44). Following 
General Method 2-A and Workup Procedure 2-1, glycine benzyl ester hydrochloride (225 mg, 1.11 
mmol), NPTC (0.430 g, 1.33 mmol), HOBt (77.3 mg, 0.555 mmol), triethylamine (284 mg, 394 
μL, 2.78 mmol), DMF (2.2 mL), and chromatography on SiO2 (19:1 to 1:1 hexanes/Et2O) afforded 
2-44 (351 mg, 91%) as a heavy oil which turned to a colorless solid on standing: Rf = 0.35 (1:1 
hexanes/Et2O, I2 active); Mp 93–94.5 °C; ATR-IR (neat) 3336, 2977, 2936, 2874, 1707, 1498, 
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1171, 940, 739, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40–7.31 (m, 5 H), 7.26 (bs, 1 H), 5.17 
(s, 2 H), 4.09 (d, J = 5.6 Hz, 2 H), 1.68–1.48 (m, 5 H), 1.45–1.37 (m, 1 H), 1.21 (s, 6 H), 1.12 (s, 
6 H); 13C NMR (101 MHz, CDCl3) δ 169.6, 158.3, 128.6, 128.5, 128.4, 67.1, 60.8, 42.6, 39.6, 
31.6, 20.5, 16.7; HRMS (ESI) m/z calcd for C19H29N2O4 (M+H) 349.2122, found 349.2123.   
 
Ethyl N-methyl-N-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)glycinate (2-45). 
Following General Method 2-A and Workup Procedure 2-1, sarcosine ethyl ester hydrochloride 
(175 mg, 1.11 mmol), NPTC (432 mg, 1.33 mmol), HOBt (77.0 mg, 0.553 mmol), triethylamine 
(282 mg, 392 μL, 2.76 mmol), DMF (2.2 mL), and chromatography on SiO2 (19:1 to 1:1 
hexanes/Et2O) afforded 2-45 (306 mg, 92%) as a heavy clear oil: Rf = 0.25 (1:1 hexanes/Et2O, I2 
active); ATR-IR (neat) 2975, 2935, 1729, 1378, 1199, 1125, 1037, 928, 763 cm-1; 1H NMR (400 
MHz, CDCl3) δ 4.20 (dq, J = 14.7, 7.1 Hz, 2 H), 4.01 (d, J = 11.5 Hz, 2 H), 3.03 (s, 3 H), 1.74–
1.34 (m, 6 H), 1.32–1.21 (m, 3 H), 1.17 (s, 3 H), 1.12 (s, 3 H), 1.09 (s, 3 H), 1.08 (s, 3 H); 13C 
NMR (101 MHz, CDCl3, mixture of rotamers) δ 169.6, 157.7, 156.8, 61.2, 61.0, 60.1, 51.2, 50.6, 
39.0, 36.7, 35.2, 31.7, 31.6, 20.9, 20.8, 17.0, 16.9, 14.2, 14.2; HRMS (ESI) m/z calcd for 
C15H29N2O4 (M+H) 301.2122, found 301.2119.   
 
Ethyl N-benzyl-N- (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl) glycinate (2-
46). Following General Method 2-A and Workup Procedure 2-1,  N-benzyl glycine ethyl ester 
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hydrochloride (0.250 g, 1.07 mmol), NPTC (417 mg, 1.28 mmol), HOBt (74.3 mg, 0.533 mmol), 
triethylamine (273 mg, 379 μL, 2.67 mmol), DMF (2.1 mL), and chromatography on SiO2 (19:1 
to 1:1 hexanes/Et2O) afforded 2-46 (303 mg, 94%) as a heavy clear oil: Rf = 0.39 (1:1 
hexanes/Et2O, I2 active); ATR-IR (neat) 2974, 2936, 1732, 1453, 1364, 1183, 1091, 1028, 928, 
760, 700 cm-1; 1H (400 MHz, CDCl3) δ 7.41–7.23 (m, 5 H), 4.62 (d, J = 2.6 Hz, 2 H), 4.18 (q, J = 
7.2 Hz, 2 H), 3.99 (s, 1 H), 3.87 (s, 1 H), 1.77–1.35 (m, 6 H), 1.25 (td, J = 7.2, 3.4 Hz, 3 H), 1.14 
(s, 6 H), 1.09 (s, 3 H), 1.04 (s, 3 H); 13C NMR (101 MHz, CDCl3, mixture of rotamers) δ 169.7, 
157.5, 157.1, 137.3, 137.3, 128.7, 128.6, 128.2, 127.6, 127.5, 127.1, 61.2, 61.1, 60.2, 60.2, 52.0, 
51.5, 49.0, 47.5, 39.1, 31.7, 31.6, 20.9, 17.0, 14.2, 14.1; HRMS (ESI) m/z calcd for C21H33N2O4 
(M+H) 377.2435, found 377.2429.   
 
Methyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-D-phenylalaninate (2-47). 
Following General Method 2-A and Workup Procedure 2-1, D-phenylalanine methyl ester 
hydrochloride (785 mg, 3.64 mmol), NPTC (1.41 mg, 4.37 mmol), HOBt (254 mg, 1.82 mmol), 
triethylamine (0.930 g, 1.29 mL, 9.10 mmol), DMF (19 mL), and chromatography on SiO2 (19:1 
to 1:1 hexanes/Et2O) afforded 2-47 (1.07 g, 81%) as a colorless solid: [α]D
23 +17.4 (c 0.16, CH2Cl2); 
Rf = 0.33 (1:1 hexanes/Et2O, I2 active); Mp 84–85.5 °C; ATR-IR (neat) 3346, 2935, 1721, 1491, 
1181, 988, 700 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.32–7.21 (m, 3 H), 7.21–7.10 (m, 3 H), 4.66 
(dt, J = 7.6, 6.2 Hz, 1H), 3.73 (s, 3H), 3.21–3.10 (m, 2H), 1.66–1.50 (m, 3 H), 1.47–1.34 (m, 3 H), 
1.16 (s, 3 H), 1.15 (s, 3 H), 1.02 (s, 3 H), 0.86 (s, 3 H); 13C NMR (126 MHz, CDCl3) δ 172.0, 
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157.9, 135.8, 129.2, 128.6, 127.1, 60.8, 60.6, 54.5, 52.2, 39.6, 39.6, 37.9, 31.5, 20.6, 20.5, 16.7; 
HRMS (ESI) m/z calcd for C20H31N2O4 (M+H) 363.2278, found 363.2279.   
 
Ethyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-L-tryptophanate (##). 
Following General Method 2-A and Workup Procedure 2-1, L-tryptophan ethyl ester 
hydrochloride (0.300 g, 1.08 mmol), NPTC (423 mg, 1.30 mmol), HOBt (75.4 mg, 0.541 mmol), 
triethylamine (277 mg, 384 μL, 2.71 mmol), DMF (2.2 mL), and chromatography on SiO2 (19:1 
to 2:1 hexanes/Et2O) afforded 2-48 (371 mg, 83%) as a colorless foam which collapsed to a clear 
oil on standing:  [α]D
23 +4.9 (c 0.292, CH2Cl2); Rf = 0.48 (1:1 hexanes/Et2O, UV active); ATR-IR 
(neat) 3340, 2978, 2936, 2244, 1708, 1491, 1250, 986, 912, 735 cm-1; 1H NMR (601 MHz, CDCl3) 
δ 8.19 (s, 1 H), 7.60 (d, J = 7.9 Hz, 1 H), 7.36 (d, J = 8.1 Hz, 1 H), 7.19 (t, J = 7.6 Hz, 1 H), 7.2 
(overlapped, 1 H), 7.13 (t, J = 7.5 Hz, 1 H), 7.05 (d, J = 2.3 Hz, 1 H), 4.66 (q, J = 6.7 Hz, 1 H), 
4.20–4.09 (m, 2 H), 3.33 (qd, J = 15.0, 6.4 Hz, 2 H), 1.59–1.39 (m, 3 H), 1.32–1.21 (m, 3 H), 1.19 
(t, J = 7.2 Hz, 3 H), 1.13 (s, 3 H), 1.10 (s, 3 H), 0.99 (s, 3 H), 0.73 (s, 3 H); 13C (151 MHz, CDCl3) 
δ 172.0, 158.1, 136.0, 127.6, 122.6, 122.2, 119.7, 118.5, 111.2, 110.2, 61.3, 60.6, 60.5, 54.5, 39.5, 
39.3, 31.6, 31.1, 27.5, 20.5, 20.5, 16.6, 14.0; HRMS (ESI) m/z calcd for C23H34N3O4 (M+H) 
416.2544, found 416.2553.   
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Methyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-L-alaninate (2-49). 
Following General Method 2-A and Workup Procedure 2-1, L-alanine methyl ester hydrochloride 
(0.200 g, 1.18 mmol), NPTC (462 mg, 1.42 mmol), HOBt (82.3 mg, 0.591 mmol), triethylamine 
(302 mg, 419 μL, 2.95 mmol), DMF (2.4 mL), and chromatography on SiO2 (19:1 to 2:1 
hexanes/Et2O) afforded 2-49 (310 mg, 92%) as a colorless solid:  [α]D
24 +10.2 (c 0.248, CH2Cl2); 
Rf = 0.30 (1:1 hexanes/Et2O, I2 active); Mp 66–67.5 °C; ATR-IR (neat) 3367, 2979, 2937, 1716, 
1495, 1454, 1167, 1023, 758 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.33 (bd, J = 8.0 Hz, 1 H), 4.55–
4.39 (m, 1 H), 3.74 (s, 3 H), 1.67–1.52 (m, 5 H), 1.41 (d, J = 7.2 Hz, 3 H), 1.41 (overlapped, 1 H), 
1.21 (s, 6 H), 1.14 (s, 3 H), 1.10 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 173.3, 157.6, 60.8, 60.8, 
52.3, 49.3, 39.7, 39.6, 31.6, 31.5, 20.5, 20.5, 18.8, 16.7; HRMS (ESI) m/z calcd for C14H27N2O4 
(M+H) 287.1965, found 287.1990.   
 
Methyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-L-leucinate (2-50). 
Following General Method 2-A and Workup Procedure 2-1, L-leucine methyl ester hydrochloride 
(225 mg, 1.21 mmol), NPTC (474 mg, 1.46 mmol), HOBt (84.5 mg, 0.607 mmol), triethylamine 
(0.310 mg, 431 μL, 3.04 mmol), DMF (2.4 mL), and chromatography on SiO2 (19:1 to 17:3 
hexanes/Et2O) afforded 2-50 (355 mg, 89%) as a colorless solid: [α]D
25 −7.0 (c 0.141, CH2Cl2); Rf 
= 0.53 (1:1 hexanes/Et2O, I2 active); Mp 90–91.5 °C; ATR-IR (neat) 3281, 2951, 1757, 1697, 
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1504, 1187, 991, 922, 736 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.15 (bs, 1 H), 4.48 (td, J = 9.0, 
4.5 Hz, 1 H), 3.72 (s, 3 H), 1.71–1.52 (m, 8 H), 1.46–1.39 (m, 1 H), 1.22 (s, 6 H), 1.16 (s, 3 H), 
1.11 (s, 3 H), 0.95 (d, J = 5.9 Hz, 3  H), 0.93 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
173.4, 157.9, 60.9, 60.8, 52.2, 52.1, 42.1, 39.8, 39.7, 31.8, 31.6, 24.8, 22.9, 21.8, 20.6, 20.6, 16.8; 
HRMS (ESI) m/z calcd for C17H33N2O4 (M+H) 329.2435, found 329.2434.   
 
Methyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-L-valinate (2-51). 
Following General Method 2-A and Workup Procedure 2-1, L-valine methyl ester hydrochloride 
(3.24 g, 19.1 mmol), NPTC (7.48 g, 23.0 mmol), HOBt (1.33 g, 9.57 mmol), triethylamine (6.79 
mL, 4.89 g, 47.9 mmol), DMF (38 mL), and chromatography on SiO2 (19:1 to 1:1 hexanes/Et2O) 
afforded 2-51 (5.18 g, 86%) as a heavy clear oil which solidified on standing to a colorless solid:  
[α]D
24 −6.5 (c 0.318, CH2Cl2); Rf = 0.40 (1:1 hexanes/Et2O, I2 active); Mp 78–79.5 °C; ATR-IR 
(neat) 3371, 2967, 2935, 1729, 1492, 1211, 1148, 991, 764 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.30 (s, 1 H), 4.38 (dd, J = 9.2, 4.6 Hz, 1 H), 3.73 (s, 3 H), 2.20 (heptd, J = 6.9, 4.8 Hz, 1 H), 1.71–
1.54 (m, 5 H), 1.46–1.38 (m, 1 H), 1.23 (s, 3 H), 1.22 (s, 3 H), 1.17 (s, 3 H), 1.15 (s, 3 H), 0.97 (d, 
J = 6.9 Hz, 3 H), 0.90 (d, J = 6.9 Hz, 3 H); 13C NMR (126 MHz, CDCl3) δ 172.3, 158.2, 77.3, 
76.7, 60.9, 60.7, 58.8, 52.0, 39.8, 39.7, 32.3, 31.5, 20.6, 20.6, 19.1, 17.7, 16.8; HRMS (ESI) m/z 
calcd for C16H31N2O4 (M+H) 315.2278, found 315.2296.   
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Ethyl 1-((((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)amino)cyclopropane-1-
carboxylate (2-52). Following General Method 2-A and Workup Procedure 2-1, ethyl-1-
aminocyclopropanecarboxylate hydrochloride (135 mg, 1.02 mmol), NPTC (0.400 g, 1.23 mmol), 
HOBt (71.3 mg, 0.512 mmol), triethylamine (262 mg, 364 μL, 2.56 mmol), DMF (2.0 mL), and 
chromatography on SiO2 (19:1 to 1:1 hexanes/Et2O) afforded 2-52 (97 mg, 30%) as a fluffy 
colorless solid:  Rf = 0.35 (1:1 hexanes/Et2O, I2 active); Mp 125–128 °C; ATR-IR (neat) 3272, 
2981, 2941, 1725, 1709, 1472, 1175, 1030, 954, 753 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33 (bs, 
1 H), 4.13 (q, J = 7.1 Hz, 2 H), 1.70–1.48 (m, 7 H), 1.45–1.38 (m, 1 H), 1.25–1.16 (m, 11 H), 1.13 
(s, 6 H); 13C NMR (101 MHz, CDCl3) δ 172.4, 158.1, 61.4, 60.9, 39.7, 33.9, 31.7, 20.6, 18.1, 16.7, 
14.1; HRMS (ESI) m/z calcd for C16H29N2O4 (M+H) 313.2122, found 313.2118.   
 
Methyl (((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-L-serinate (2-53). 
Following General Method 2-A and Workup Procedure 2-2, L-serine methyl ester hydrochloride 
(0.200 g, 1.26 mmol), NPTC (492 mg, 1.51 mmol), HOBt (87.8 mg, 0.630 mmol), triethylamine 
(322 mg, 447 μL, 3.15 mmol), DMF (2.5 mL), and chromatography on SiO2 (19:1 to 1:1 
hexanes/Et2O) afforded 2-53 (311 mg, 82%) as a heavy oil which solidified to colorless solid on 
standing:  [α]D
25 +16.8 (c 0.268, CH2Cl2); Rf = 0.54 (EtOAc, KMnO4 active); Mp 93.5–95.5 °C; 
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ATR-IR (neat) 3377, 2978, 2934, 1705, 1500, 1211, 1035, 752 cm-1; 1H NMR (500 MHz, CDCl3) 
δ 7.65 (s, 1 H), 4.50 (dt, J = 7.6, 3.6 Hz, 1 H), 4.01 (ddd, J = 11.1, 5.7, 3.7 Hz, 1 H), 3.90 (ddd, J 
= 11.1, 5.9, 3.5 Hz, 1 H), 3.78 (s, 3 H), 2.42 (td, J = 5.9, 1.7 Hz, 1 H), 1.67–1.55 (m, 5 H), 1.45–
1.38 (m, 1 H), 1.21 (s, 6 H), 1.16 (s, 3 H), 1.14 (s, 3 H); 13C NMR (126 MHz, CDCl3) δ 170.8, 
158.4, 63.4, 60.9, 55.8, 52.6, 39.6, 39.6, 31.6, 31.5, 20.5, 20.5, 16.7; HRMS (ESI) m/z calcd for 
C14H27N2O5 (M+H) 303.1914, found 303.1937.   
 
(Aminooxy)diphenylphosphine oxide (S-1).149 Hydroxylamine hydrochloride (1.98 g, 
28.2 mmol) was charged into a round bottom flask and dissolved in water (4.25 mL). This solution 
was vigorously stirred and treated with NaOH (0.970 g NaOH, 24.3 mmol) in water (3.5 mL). This 
mixture was then immediately transferred into a NaCl/ice bath (1:3) and to it was added 1,4-
dioxane (15 mL). The solution was allowed to cool for 5 min before diphenylphosphinyl chloride 
(2.50 g, 2.02 mL, 10.5 mmol) which was diluted to 12.5 mL in 1,4-dioxane, was ran in by syringe. 
A white precipitate was immediately formed. This precipitate thickened over the next 5 min to the 
point where the reaction seized. After 5 min, ice-cold water (15 mL) was added and the solids were 
removed by vacuum filtration and the filter cake washed with ice-cold water (15 mL). The filter 
cake was then transferred to a vacuum desiccator and dried over calcium sulfate under reduced 
pressure overnight. The tacky solids were then slurried in ice-cold 0.25 M aq. NaOH (25 mL) for 
30 min in an ice-bath before being filtered one more time and washed with ice cold water (15 mL). 
This filter cake was dried in a vacuum desiccator for 24 h to afford S-1 (1.20 g, 49%) as a colorless 
solid which matched literature reported spectra: 1H NMR (400 MHz, CDCl3) δ 7.89–7.81 (m, 4H), 
7.59–7.53 (m, 2H), 7.52–7.44 (m, 4H); 31P NMR (162 MHz, CDCl3) δ 37.6. 
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tert-Butyl aziridine-2-carboxylate (S-2).149  A flame dried flask was charged with 
(aminooxy)diphenylphosphine oxide (1.14 g, 4.87 mmol) in dry MeCN (77 mL, 0.06 M). This 
solution was then treated with NMM (55 μL, 502 mg, 4.87 mmol) dropwise over 3 min. The white 
mixture stirred for 30 min before sequential addition of NaOH (371 mg, 9.27 mmol) and tert-butyl 
acrylate (68 µL, 0.600 g, 4.64 mmol). After stirring for an additional 16 h at ambient temperature, 
the reaction was quenched with sat. NH4Cl. Extraction with diethyl ether, and concentration gave 
a residue which was purified by chromatography on silica gel (gradient,1:19 to 1:0 Et2O/hexanes) 
to afford S-2 as a slightly volatile yellow liquid which matched literature reported spectra: 1H 
NMR (400 MHz, CDCl3) δ 2.42 (dd, J = 5.5, 3.0 Hz, 1 H), 1.92 (dd, J = 3.0, 1.6 Hz, 1 H), 1.79 (d, 
J = 5.4 Hz, 1 H), 1.48 (s, 9 H), 1.45 (d, J = 6.2 Hz, 1 H). 
 
(±) 2-(tert-Butyl) 1-(2,2,6,6-tetramethylpiperidin-1-yl) aziridine-1,2-dicarboxylate (2-
24). Following General Method 2-A and Workup Procedure 2-1, tert-butyl aziridine-2-carboxylate 
(269 mg, 1.79 mmol), NPTC (697 mg, 2.14 mmol), HOBt (124 mg, 0.892 mmol), triethylamine 
(274 mg, 363 μL, 2.56 mmol), DMF (3.6 mL), and chromatography on SiO2 (19:1 to 17:3 
hexanes/Et2O) afforded 2-54 (475 mg, 82%) as a heavy clear oil: Rf = 0.26 (3:1 hexanes/Et2O); 
ATR-IR (neat) 2977, 2935, 1761, 1733, 1367, 1319, 1146, 992, 846, 745 cm-1; 1H NMR (500 
MHz, CDCl3) δ 3.01 (dd, J = 5.5, 3.2 Hz, 1 H), 2.55 (dd, J = 3.3, 1.4 Hz, 1 H), 2.43 (dd, J = 5.5, 
1.4 Hz, 1 H), 1.74–1.59 (m, 5 H), 1.49 (s, 9 H), 1.42–1.36 (m, 1 H), 1.18 (s, 3 H), 1.15 (s, 3 H), 
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1.13 (s, 3 H), 1.11 (s, 3 H);13C NMR (75 MHz, CDCl3, 1:1 mixture of rotamers) δ 167.2, 161.9, 
82.6, 60.5, 39.2, 35.3, 31.6, 31.6, 31.0, 28.0, 20.4, 16.9; HRMS (ESI) m/z calcd for C17H31N2O4 
(M+H) 327.2278, found 327.2276.   
 
Methyl Nε-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)carbonyl)-L-lysinate (2-55). 
Following General Method 2-A and Workup Procedure 2-1, L-valine methyl ester hydrochloride 
(3.24 g, 19.1 mmol), NPTC (7.48 g, 23.0 mmol), HOBt (1.33 g, 9.57 mmol), triethylamine (6.79 
mL, 4.89 g, 47.9 mmol), DMF (38 mL), and chromatography on SiO2 (19:1 to 1:1 hexanes/Et2O) 
afforded 2-55 (5.18 g, 86%) as a heavy clear oil which solidified on standing to a colorless solid 
(conversion to the hydrochloride salt by means of HCl-ether gave a white precipitate which 
deliquesced rapidly on the filter paper): [α]D
24 +3.7 (c 0.297, CH2Cl2); Rf = 0.52 (4:1 
EtOAc:MeOH, ninhydrin active); ATR-IR (neat) 3367, 2935, 3871, 1706, 1603, 1499, 1251, 1186, 
956, 734 cm-1; 1H NMR (601 MHz, CDCl3) δ 6.81 (bs, 1 H), 3.72 (s, 3 H), 3.44 (dd, J = 7.5, 5.4 
Hz, 1 H), 3.23 (q, J = 6.8 Hz, 2 H), 1.78–1.72 (m, 1 H), 1.67–1.49 (m, 10 H), 1.41 (ddq, J = 12.6, 
6.3, 2.9 Hz, 3 H), 1.21 (s, 6 H), 1.09 (s, 6 H); 13C NMR (151 MHz, CDCl3) δ 176.4, 158.6, 60.7, 
54.3, 52.0, 40.5, 39.7, 34.4, 31.7, 29.7, 22.9, 20.5, 16.7; HRMS (ESI) m/z calcd for C17H33N3O4 
(M+H) 343.2471, found 343.2543.  
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(S)-2-amino-5-(((benzyloxy)carbonyl)amino)pentanoic acid hydrochloride (H-
Orn(Z)-OH) (S-3). An Erlenmeyer flask was charged with L-ornithine hydrochloride (10.0 g, 
58.7 mmol, 1.0 equiv) in water (47 mL) and to it was added solid sodium hydroxide (4.70 g, 117 
mmol, 2.0 equiv). Upon complete dissolution a mixture of copper(II) sulfate pentahydrate (7.33 g, 
29.4 mmol, 0.5 equiv) was added as a solution in water (24 mL) resulting in a deep blue solution.  
The blue mixture was stirred for 15 min before being cooled to 0°C on an ice-bath and receiving 
benzyl chloroformate (11.2 mL, 13.4 g, 76.3 mmol, 1.3 equiv) dropwise over 10 min. After 
addition was complete the reaction was slowly allowed to warm to ambient temperature and stir 
for 12 h.  The blue copper complex that precipitated was collected by suction filtration and the 
filter cake was washed with water (2 x 100 mL) and acetone (2 x 100 mL) then air dried to give 
the copper complex as a light blue powder which was used directly without purification. In a large 
Erlenmeyer flask, a suspension of EDTA dihydrate (21.6 g, 64.6 mmol, 1.1 equiv) in water (235 
mL) was brought to reflux and the pH was adjusted to 7 by addition of solid sodium hydroxide.  
To this refluxing solution was added the powdered complex (the complex should be free of large 
chunks) portion-wise with vigorous stirring (polygon stirbar necessary). The complex tends to 
float on top of the vortex so periodically a scoopula was inverted and inserted down the wall of 
the flask into the vortex to act as a baffle.  Once the blue powder has been converted into a white 
precipitate (typically 2 h), the pH is checked and adjusted to 7 if necessary. The slurry is cooled to 
ambient temperature and the white precipitate is collected by filtration. The filter-cake washed 
with liberally with water and then with methanol (200 mL).  The cake was then dried under vacuum 
to afford the neutral amino acid S-3 (13.4 g, 86%) as a white solid. The neutral Cbz amino acid is 
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insoluble in DMSO, CHCl3, and methanol and therefore a sample was converted to the 
hydrochloride salt for NMR analysis: a small amount of the above product is dissolved in a 
minimal amount of 4 M aqueous HCl and dried to a colorless solid under vacuum before being 
dissolved in DMSO-d6 which spectrally matched commercial material:  
1H NMR (400 MHz, 
DMSO) δ 13.80 (bs, 1 H), 8.29 (bs, 3 H), 7.41–7.29 (m, 5 H), 5.01 (s, 2 H), 3.90 (s, 1 H), 3.01 (q, 
J = 6.5 Hz, 2 H), 1.85–1.68 (m, 2 H), 1.63–1.39 (m, 2 H).   
 
methyl (S)-2-amino-5-(((benzyloxy)carbonyl)amino)pentanoate hydrochloride (H-
Orn(Z)-OMe) (2-61).150 A suspension of S-3 (10.0 g, 37.2 mmol, 1.0 equiv) in dry methanol (148 
mL, 0.25 M) was cooled to 0 °C on an ice-bath before dropwise addition of thionyl chloride (16.6 
mL, 22.1 g, 186 mmol, 5.0 equiv) by addition funnel over 10 min (the suspension underwent 
dissolution on addition). The reaction mixture was stirred at this temperature for 1 hour and before 
the cooling bath was removed and stirring continued for an addition 24 h. The reaction was 
concentrated and the residue chased with methanol twice then once with toluene. The waxy solid 
was reslurried in diethyl ether (500 mL) under vigorous stirring for 1 hour (any large chunks were 
granulated manually with a teflon stirbar retriever). Collection of the liberated solids on a vacuum 
funnel gave a cake which was washed with ether (150 mL) and dried under vacuum to give 2-61 
(10.5 g, quant) as a fluffy colorless solid that matched literature reported spectra: [α]D
20 +17.0 (c 
4.018, CH2Cl2) 
1H NMR (500 MHz, DMSO) δ 8.58 (bs, 3 H), 7.40–7.31 (m, 5 H), 4.02 (t, J = 6.4 
Hz, 1 H), 3.73 (s, 3 H), 3.00 (q, J = 6.5 Hz, 2 H), 1.78 (dtd, J = 9.3, 6.3, 2.8 Hz, 2 H), 1.59–1.38 
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(m, 2 H); 13C NMR (126 MHz, DMSO) δ 169.9, 156.1, 137.2, 128.3, 127.7, 127.7, 65.2, 52.7, 
51.6, 27.4, 24.9. 
 
Methyl (S)-5-(((benzyloxy)carbonyl)amino)-2-((S)-3-methyl-2-((((2,2,6,6-
tetramethylpiperidin-1-yl)oxy)carbonyl)amino)butanamido)pentanoate (Tempoc-Val-
Orn(Cbz)-OMe) (2-63).  Following General Method 2-C.  2-51 (1.53 g, 4.87 mmol, 1.0 equiv), 
lithium hydroxide monohydrate (313 mg, 7.30 mmol, 1.5 equiv), in a 2:1 mixture of THF/H2O (15 
mL, 0.35 M), gave the acid after which was used immediately in the next step. 2-61 (1.70 g, 5.35 
mmol, 1.1), HATU (2.08 g, 5.35 mmol, 1.1 equiv) in dry DMF (8.2 mL, 0.25 M) afforded an oil 
which was purified by chromatography on SiO2 (gradient, 19:1 to 1:1, hexanes/EtOAc) to give 2-
63 (2.63 g, 95%) as a colorless foam: [α]D
24 +5.0 (c 0.274, CH2Cl2); Rf = 0.63 (1:4 hexanes/EtOAc, 
I2 active); ATR-IR (neat) 3320, 2965, 2935, 2874, 1711, 1666, 1497, 1250, 1132, 1021, 733 cm
-1; 
1H NMR (601 MHz, CDCl3) δ 7.39–7.29 (m, 5 H), 6.46 (d, J = 7.9 Hz, 1 H), 5.09 (s, 2 H), 4.91 (t, 
J = 6.2 Hz, 1 H), 4.57 (td, J = 7.9, 5.0 Hz, 1 H), 4.01 (dd, J = 9.0, 6.8 Hz, 1 H), 3.74 (s, 3 H), 3.21 
(qd, J = 6.8, 3.1 Hz, 2 H), 2.11 (h, J = 6.8 Hz, 1 H), 1.87 (tt, J = 10.1, 4.9 Hz, 1 H), 1.70–1.45 (m, 
9 H), 1.44–1.38 (m, 1 H), 1.22 (s, 3 H), 1.19 (s, 3 H), 1.16 (s, 3 H), 1.08 (s, 3 H), 1.00–0.95 (m, 6 
H); 13C NMR (151 MHz, CDCl3) δ 172.2, 170.9, 158.5, 156.5, 136.5, 128.5, 128.1, 128.0, 66.6, 
60.9, 60.7, 60.4, 52.4, 51.8, 40.2, 39.7, 39.4, 32.1, 31.4, 31.3, 29.1, 25.9, 20.6, 19.2, 18.2, 16.7; 
HRMS (ESI) m/z calcd for C29H47N4O7 (M+H) 563.3439, found 563.3432.   
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Methyl (5-(((benzyloxy)carbonyl)amino)-2-((S)-3-methyl-2-((((2,2,6,6-
tetramethylpiperidin-1-yl)oxy)carbonyl)amino)butanamido)pentanoyl)-L-leucinate (epi-2-
59). Following General Method 2-C, 2-63 (6.90 g, 12.3 mmol), lithium hydroxide monohydrate 
(788 mg, 18.4 mmol), in a 2:1 mixture of THF/H2O (35 mL) gave the acid after extraction which 
was used immediately in the coupling step. 2-62•HCl (2.50 g, 13.5 mmol), HATU (5.18 g, 13.5 
mmol), and DIPEA (7.16 mL, 5.60 g, 42.9 mmol) in dry DMF (49 mL) afforded an oil which was 
purified by chromatography on SiO2 (gradient, 19:1 to 1:1, hexanes/EtOAc) to give epi-2-59 (8.29 
g, 99%) as a colorless foam in a 1.2:1 mixture of epimers: [α]D
23 +5.9 (c 0.576, CH2Cl2); Rf = 0.55 
(1:4 hexanes/EtOAc, I2 active); ATR-IR (neat) 3304, 2960, 1706, 1645, 1497, 1248, 1156, 1132, 
1022, 848, 696 cm-1; 1H (601 MHz, DMSO, mixture of epimers) δ 8.43–8.13 (m, 2 H), 7.46–7.20 
(m, 7 H), 5.08–4.95 (m, 2 H), 4.38–4.22 (m, 2 H), 4.15–3.99 (m, 1 H), 3.60 (s, 3 H), 3.07–2.87 (m, 
2 H), 2.02–1.90 (m, 1 H), 1.65–1.34 (m, 12 H), 1.31–1.21 (m, 1 H), 1.14–1.07 (m, 9 H), 0.98–0.96 
(m, 3 H), 0.91–0.73 (m, 12 H),13C NMR (126 MHz, DMSO, mixture of epimers) δ 173.2, 172.0, 
171.8, 170.9, 170.7, 157.8, 157.6, 156.6, 156.5, 137.7, 128.8, 128.2, 128.2, 128.1, 65.6, 65.6, 60.5, 
60.3, 60.3, 59.3, 59.0, 52.4, 52.3, 52.3, 52.3, 50.6, 50.6, 40.0, 32.2, 32.2, 32.2, 32.0, 31.5, 31.4, 
30.3, 29.7, 26.4, 24.7, 24.6, 23.3, 21.6, 20.8, 20.7, 19.8, 19.6, 18.0, 17.9, 16.8; HRMS (ESI) m/z 
calcd for C35H58N5O8 (M+H) 676.4280, found 676.4283.   
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Methyl (5-(((benzyloxy)carbonyl)amino)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-
methylbutanamido)pentanoyl)-L-leucinate (epi-2-65). Following General Method 2-C, 2-64 
(0.600 g, 2.76 mmol), lithium hydroxide monohydrate (174 mg, 4.14 mmol), in a 2:1 mixture of 
THF/H2O (7.9 mL) gave the acid after extraction which was used immediately in the coupling 
step. 2-61 (928 mg, 2.90 mmol), HATU (1.10 g, 2.90 mmol), and DIPEA (1.60 mL, 9.67 mmol) 
in dry DMF (11 mL) and filtration through a 1.5” plug of SiO2 afforded the dipeptide as a 
hygroscopic colorless foam which was used in the next step without further purification. Following 
General Method 2-C, (0.600 g, 2.76 mmol), lithium hydroxide monohydrate (174 mg, 4.14 mmol), 
in a 2:1 mixture of THF/H2O (7.9 mL) gave the acid after extraction which was used immediately 
in the coupling step. 2-62•HCl (538 mg, 2.90 mmol), HATU (1.10 g, 2.90 mmol), and DIPEA 
(1.60 mL, 9.67 mmol) in dry DMF (11 mL) and purification by chromatography on SiO2 (gradient, 
19:1 to 1:1, hexanes/EtOAc) to give epi-2-65 (1.44 g, 88%) as a colorless foam in a 1.2:1 mixture 
of epimers: ATR-IR (neat) 3298, 2960, 2871, 1692, 1641, 1524, 1247, 1160, 1019, 698 cm-1; 1H 
NMR (601 MHz, DMSO, mixture of epimers) δ 8.33–8.17 (m, 1 H), 8.01–7.77 (m, 1 H), 7.43–
7.21 (m, 6 H), 6.79–6.66 (m, 1 H), 5.07–4.92 (m, 2 H), 4.36–4.22 (m, 2 H), 3.85–3.74 (m, 1 H), 
3.67–3.53 (m, 3 H), 3.04–2.91 (m, 2 H), 1.98–1.86 (m, 1 H), 1.66–1.32 (m, 16 H), 0.90–0.76 (m, 
12 H); 13C NMR  (151 MHz, DMSO, mixture of epimers) δ 173.2, 172.0, 171.9, 171.7, 171.5, 
156.6, 156.5, 156.0, 155.9, 137.7, 128.8, 128.2, 128.2, 78.5, 78.5, 65.6, 65.6, 60.3, 60.2, 52.3, 52.3, 
52.2, 50.6, 50.6, 40.0, 34.7, 31.5, 30.8, 30.8, 30.2, 28.7, 28.6, 26.3, 25.3, 24.7, 24.6, 23.3, 23.2, 
22.6, 21.8, 21.6, 19.7, 18.6, 18.6.  
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(S)-5-(((Benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino)pentanoic acid 
(2-66). To a suspension of S-3 (4.20 g, 15.8 mmol) in water (48 mL) and 1,4-dioxane (18 mL) was 
cooled on an ice-bath before addition potassium carbonate (2.41 g, 17.4 mmol) followed by 
dropwise addition of Boc anhydride (3.65 g, 16.6 mmol) as a solution in 1,4-dioxane (40 mL) over 
30 min via addition funnel. After the addition was complete the cooling bath was removed and the 
reaction (still heterogeneous) was stirred at ambient temperature for 14 h. During this time the 
solid underwent dissolution. The bulk of the dioxane was removed by rotary evaporation and the 
aqueous mixture poured into a separatory funnel containing ice. 2 M KHSO4 was then added to 
pH = 2, resulting in a milky precipitate which was dissolved in ethyl acetate (200 mL). The aqueous 
layer was separated and the organic was washed with saturated ammonium chloride (100 mL). The 
rich extract was then dried (MgSO4), filtered, and concentrated to afford 2-66 (4.88 g, 84%) as a 
hygroscopic amorphous solid. This crude material was used in subsequent couplings without 
further purification: 1H NMR (400 MHz, DMSO) δ 12.45 (bs, 1 H), 7.39–7.28 (m, 5 H), 7.25 (t, J 
= 5.6 Hz, 1 H), 7.07 (d, J = 8.0 Hz, 1 H), 5.00 (s, 2 H), 3.94–3.73 (m, 1 H), 3.12–2.86 (m, 2 H), 
1.72–1.59 (m, 1 H), 1.58–1.41 (m, 3 H), 1.38 (s, 9 H). 
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Methyl ((S)-5-(((benzyloxy)carbonyl)amino)-2-((S)-2-((tert-butoxycarbonyl)amino)-
3-methylbutanamido)pentanoyl)-L-leucinate (2-65). A flask was charged with 2-66 (484 mg, 
1.32 mmol), in dry DMF (5.3 mL). This clear solution was cooled to 0 °C on an ice-bath before 
sequential addition of HATU (533 mg, 1.39 mmol) and DIPEA base (604 mg, 772 µL, 1.39 mmol). 
This pale-yellow solution was stirred for a few minutes before addition of 2-62•HCl (245 mg, 1.32 
mmol) as a solid in 1 portion. The reaction turned yellow and the cooling bath was removed. The 
reaction was stirred for 2 h before being diluted with ethyl acetate (30 mL) and transferred to a 
separatory funnel. The organic was washed with water (2 x 15 mL), 2 M KHSO4 (10 mL), sat. 
Na2CO3 (10 mL), then brine (10 mL). The organic layer was then dried (MgSO4), filtered and 
concentrated to give a foam which was taken up in ether and passed through a 1.5" pad of silica. 3 
plug-volumes was used to washed the product through. Concentration of the filtrate gave the 
dipeptide methyl ((S)-5-(((benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino) 
pentanoyl)-L-leucinate (S-4) as a colorless foam which was used in the next step without further 
purification. A sample gave the following data: 1H NMR (500 MHz, CDCl3) δ 7.35–7.22 (m, 5 H), 
7.08 (bd, J = 8.0 Hz, 1 H), 5.44–5.30 (m, 2 H), 5.04 (AB, J = 12.3 Hz, 2 H), 4.61–4.42 (m, 1 H), 
4.38–4.19 (m, 1 H), 3.64 (s, 3 H), 3.41–3.24 (m, 1 H), 3.18–3.02 (m, 1 H), 1.89–1.45 (m, 7 H), 
1.39 (s, 9 H), 0.87 (t, J = 6.2 Hz, 6 H); 13C NMR (126 MHz, CDCl3) δ 173.1, 172.2, 156.9, 155.6, 
136.4, 128.3, 127.9, 79.6, 66.4, 52.8, 52.0, 50.6, 40.8, 39.6, 29.8, 28.1, 25.9, 24.5, 22.7, 21.5. S-4 
was taken up in methylene chloride (2.7 mL) and the solution was cooled to 0 °C on an ice-bath 
before addition of TFA (2.7 mL) dropwise by syringe. The cooling bath was removed and the 
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reaction stirred at ambient temperature until consumption of the starting material was observed 
(HPLC-MS, about 1.5 h). At this point the reaction was concentrated and the oily residue taken up 
in fresh methylene chloride and washed with sat. Na2CO3. The free amine was dried (MgSO4) and 
concentrated to give the amine methyl ((S)-2-amino-5-(((benzyloxy)carbonyl)amino)pentanoyl)-
L-leucinate (S-5) as a pale-yellow oil which was used immediately in the next step. A vial was 
charged with Boc-Val-OH (287 mg, 1.32 mmol) in dry DMF (3.0 mL). This clear solution was 
cooled to 0 °C on an ice-bath before sequential addition of HATU (533 mg, 1.39 mmol) and 
DIPEA base (604 mg, 772 µL, 1.39 mmol). This pale-yellow solution was stirred for a few minutes 
before addition of S-4 as a solution in dry DMF (2.3 mL). The reaction turned bright-yellow and 
the cooling bath was removed. The reaction was stirred for 2 h before being diluted with ethyl 
acetate (30 mL) and transferred to a separatory funnel. The organic was washed with water (2 x 
15 mL), 2 M KHSO4 (10 mL), sat. Na2CO3 (10 mL), then brine (10 mL). The organic layer was 
then dried (MgSO4), filtered and concentrated to give a foam which was purified by reslurrying in 
Et2O to give 2-65 (699 g, 89%) as a colorless solid after filtration: [α]D
24 -16.4 (c 0.061, CH2Cl2); 
Rf = 0.65 (1:4 hexanes/EtOAc; UV active); Mp 154–156 °C; ATR-IR (neat) 3291, 3079, 2958, 
1690, 1636, 1525, 1245, 1167, 1026, 695 cm-1; 1H  NMR (601 MHz, DMSO) δ 8.29 (d, J = 7.7 Hz, 1 
H), 7.81 (d, J = 8.1 Hz, 1 H), 7.44–7.21 (m, 6 H, ArH overlapping TempocNH), 6.75 (d, J = 9.0 Hz, 1 H), 
5.00 (s, 2 H), 4.40–4.19 (m, 2 H), 3.78 (dd, J = 9.0, 6.7 Hz, 1 H), 3.59 (s, 3 H), 2.98 (q, J = 6.5 Hz, 2 H), 
1.91 (h, J = 6.8 Hz, 1 H), 1.65–1.39 (m, 7 H), 1.37 (s, 9 H), 0.87 (d, J = 6.6 Hz, 3 H), 0.83–0.77 (m, 9 H); 
13C NMR (151 MHz, DMSO) δ 173.2, 172.0, 171.5, 156.6, 155.9, 137.7, 128.8, 128.2, 78.5, 65.6, 
60.2, 52.3, 52.2, 50.6, 30.8, 30.2, 28.6, 26.3, 24.6, 23.3, 21.6, 19.7, 18.6; HRMS (ESI) m/z calcd 
for C30H49N4O8 (M+H) 593.3545, found 593.3555. 
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Methyl ((S)-5-(((benzyloxy)carbonyl)amino)-2-((S)-3-methyl-2-((((2,2,6,6-
tetramethylpiperidin-1-yl)oxy)carbonyl)amino)butanamido)pentanoyl)-L-leucinate (2-59). 
A flask was charged with 2-66 (484 mg, 1.32 mmol), in dry DMF (5.3 mL). This clear solution 
was cooled to 0 °C on an ice-bath before sequential addition of HATU (533 mg, 1.39 mmol) and 
DIPEA base (604 mg, 772 µL, 1.39 mmol). This pale-yellow solution was stirred for a few minutes 
before addition of 2-62•HCl (245 mg, 1.32 mmol) as a solid in 1 portion. The reaction turned 
yellow and the cooling bath was removed. The reaction was stirred for 2 h before being diluted 
with ethyl acetate (30 mL) and transferred to a separatory funnel. The organic was washed with 
water (2 x 15 mL), 2 M KHSO4 (10 mL), sat. Na2CO3 (10 mL), then brine (10 mL). The organic 
layer was then dried (MgSO4), filtered and concentrated to give a foam which was taken up in 
ether and passed through a 1.5" pad of silica. 3 plug-volumes was used to washed the product 
through. Concentration of the filtrate gave the dipeptide methyl S-4 as a colorless foam which was 
used in the next step without further purification. S-4 was taken up in methylene chloride (2.7 mL) 
and the solution was cooled to 0 °C on an ice-bath before addition of TFA (2.7 mL) dropwise by 
syringe. The cooling bath was removed and the reaction stirred at ambient temperature until 
consumption of the starting material was observed (HPLC-MS, about 1.5 h). At this point the 
reaction was concentrated and the oily residue taken up in fresh methylene chloride and washed 
with sat. Na2CO3. The free amine was dried (MgSO4) and concentrated to give the amine S-5 as a 
pale-yellow oil which was used immediately in the coupling step. Following General Method 2-
C, 2-51 (416 mg, 1.32 mmol), lithium hydroxide monohydrate (84.9 mg, 1.98 mmol), in a 2:1 
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mixture of THF/H2O (3.6 mL) gave the acid Tempoc-Val-OH after extraction which was used 
immediately in the coupling step. Tempoc-Val-OH was combined with S-5, HATU (1.10 g, 2.90 
mmol), and DIPEA (1.60 mL, 9.67 mmol) in dry DMF (5.3 mL) gave the crude tripeptide after 
extraction which was purified by reslurrying in Et2O to give 2-59 (743 mg, 83%) as a colorless 
amorphous solid after filtration: [α]D
24 -6.5 (c 0.185, CH2Cl2); Rf = 0.63 (100% EtOAc; UV active); 
ATR-IR (neat) 3293, 2958, 2873, 1707, 1640, 1497, 1250, 1017, 910, 729 cm-1; 1H NMR 1H NMR 
(601 MHz, CDCl3) δ 7.38–7.27 (m, 6 H; ArH overlapping TempocNH), 6.98 (d, J = 8.0 Hz, 1 H), 
6.68 (d, J = 8.3 Hz, 1 H), 5.14–5.03 (m, 3 H), 4.70 (td, J = 8.5, 4.3 Hz, 1 H), 4.52 (ddd, J = 9.4, 
8.0, 5.1 Hz, 1 H), 4.04 (dd, J = 8.9, 6.8 Hz, 1 H), 3.68 (s, 3 H), 3.47 (dq, J = 14.0, 7.3 Hz, 1 H), 
3.11–3.04 (m, 1 H), 2.07 (h, J = 6.8 Hz, 1 H), 1.93–1.84 (m, 1 H), 1.72–1.45 (m, 11 H), 1.43–1.38 
(m, 1 H), 1.20 (s, 3 H), 1.18 (s, 3 H), 1.15 (s, 3 H), 1.06 (s, 3 H), 0.96–0.88 (m, 12 H); 13C NMR 
(151 MHz, CDCl3) δ 173.2, 171.5, 171.0, 158.4, 157.3, 136.4, 128.5, 128.1, 128.0, 66.7, 60.9, 
60.6, 60.4, 52.2, 51.2, 50.8, 40.9, 39.7, 39.5, 39.2, 32.1, 31.4, 31.4, 29.8, 26.1, 24.7, 22.8, 21.7, 
20.5, 19.3, 18.2, 16.7; HRMS (ESI) m/z calcd for C35H58N5O8 (M+H) 676.4280, found 676.4283.   
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4.3 EXPERIMENTAL – CYCLOPIAZONIC ACID 
4.3.1  General experimental protocols 
Reactions were performed without inert atmosphere with ACS grade solvents unless 
otherwise stated. Inert reactions were performed under a N2 or argon atmosphere and glassware 
was flame dried prior to use. Absolute ethanol was stored over 4 Å molecular sieves.  Diethyl ether 
and THF were distilled over sodium/benzophenone ketyl. Dry toluene was distilled from CaH2 or 
dried by passage through an alumina filtration system. Acetone for imine formations was pre-dried 
with MgSO4, decanted, then distilled under an inert atmosphere. DMF was dried over 4 Å 
molecular sieves which were activate in a muffle furnace at 350 °C for 16 h prior to use. 
Commercial reagents were used as-is unless otherwise noted. 
4.3.2  Synthetic procedures and spectral characterization 
 
Ethyl 1-(4-methoxybenzyl)aziridine-2-carboxylatecarbonate (3-66).151 A flame dried 
sealable flask was charged with ethyl 2,3-dibromopropanoate (3.79 g, 2.12 mL, 14.1 mmol) in 
absolute ethanol (70.7 mL) and the mixture cooled to 0 °C on an ice-bath under nitrogen. The 
cooled solution then received sequentially 4-MeO-benzylamine (1.00 g, .952 mL, 7.07 mmol) and 
triethylamine (2.17 g, 3.01 mL, 21.2 mmol) drop-wise by syringe. The flask was removed from 
the bath and the reaction was allowed to warm to ambient temperature, and then was sealed and 
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heated to 50 °C for 3 h. Upon completion of the reaction, the solvent was removed under reduced 
pressure and the residue thus obtained was purified by chromatography on SiO2 (gradient, 19:1 to 
4:1 hexanes/EtOAc) to afford 3-66 (1.48 g, 84%) as a yellow liquid that matched literature reported 
spectra: Rf = 0.49 (1:1 hexanes/EtOAc, UV active); 
1H NMR (300 MHz, CDCl3) δ 7.36–7.17 (m, 
2 H), 6.94–6.75 (m, 2 H), 4.30–4.06 (m, 2 H), 3.80 (s, 3 H), 3.49 (s, 2 H), 2.23 (dd, J = 3.2, 1.2 
Hz, 1 H), 2.17 (dd, J = 6.5, 3.2 Hz, 1 H), 1.72 (dd, J = 6.5, 1.2 Hz, 1 H), 1.26 (t, J = 7.1 Hz, 3 H); 
13C NMR (76 MHz, CDCl3) δ 170.8, 158.9, 129.9, 129.3, 113.8, 63.3, 61.1, 55.3, 37.4, 34.3, 14.2. 
 
Ethyl 1-benzylaziridine-2-carboxylate (3-68).151  A flame dried flask was charged with 
ethyl 2,3-dibromopropanoate (3.68 g, 2.06 mL, 13.7 mmol) in absolute ethanol (125 mL, 0.11 M) 
and the mixture was cooled to 0 °C under nitrogen and stirring before sequential addition of 
benzylamine (1.50 g, 1.53 mL, 13.7 mmol) and triethylamine (2.81 g, 3.90 mL, 27.4 mmol) by 
syringe. The reaction mixture was then heated to 60 °C in a sealed flask (septum secured with 
wire) and stirred for 16 h. The resulting yellow solution was concentrated in vacuo to give an oily 
solid. The solid was suspended in ether and stirred for 30 min. The solids were then removed by 
filtration and washed with ether. The filtrate was concentrated to afford a residue which was 
purified by chromatography on SiO2 (gradient, 19:1 to 17:3 hexanes/EtOAc) to afford 3-68 (2.15 
g, 77%) as a yellow liquid which matched literature reported spectra: Rf = 0.49 (1:1 
hexanes/EtOAc, UV-active); 1H NMR (300 MHz, CDCl3) δ 7.74–6.56 (m, 5 H), 4.82–3.79 (m, 2 
H), 3.70–3.45 (m, 2 H), 2.26 (dd, J = 3.2, 1.2 Hz, 1 H), 2.19 (dd, J = 6.4, 3.1 Hz, 1 H), 1.74 (dd, J 
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= 6.5, 1.1 Hz, 1 H), 1.27 (t, J = 7.1 Hz, 3 H); 13C (76 MHz, CDCl3) δ 170.7, 137.8, 128.4, 128.0, 
127.3, 63.9, 61.1, 37.5, 34.4, 14.2. 
 
Ethyl 1-benzhydrylaziridine-2-carboxylate (3-67).  A flame dried flask was charged 
with ethyl 2,3-dibromopropanoate (2.84 g, 1.59 mL, 10.6 mmol) in absolute ethanol (96 mL, 0.11 
M) and the mixture was cooled to 0 °C under nitrogen and stirring before sequential addition of 
benzhydrylamine (2.00 g, 1.88 mL, 10.6 mmol) and triethylamine (2.16 g, 3.01 mL, 21.2 mmol) 
by syringe. The reaction mixture was then slowly heated to 60 °C in a sealed flask (septum secured 
with wire) and stirred for 16 h. The resulting yellow solution was concentrated in vacuo to give an 
oily solid. The solid was suspended in ether and stirred for 30 min. The solids were then removed 
by filtration and washed with ether. The filtrate was concentrated to afford a residue which was 
purified by chromatography on SiO2 (gradient, 19:1 to 17:3 hexanes/EtOAc) to afford the 3-67 
(2.57 g, 86%) as off-white crystals: Rf = 0.54 (1:1 hexanes/Et2O, UV-active); ATR-IR (neat) 3062, 
2983, 1740, 1493, 1453, 1189, 1075, 1031, 862 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.47–7.40 
(m, 4 H), 7.37–7.20 (m, 6 H), 4.19 (qd, J = 7.1, 1.6 Hz, 2 H), 3.63 (s, 1 H), 2.32 (dd, J = 3.2, 1.0 
Hz, 1 H), 2.25 (dd, J = 6.4, 3.2 Hz, 1 H), 1.84 (dd, J = 6.4, 1.0 Hz, 1 H), 1.26 (t, J = 7.1 Hz, 3 H); 
13C NMR (76 MHz, CDCl3) δ 170.5, 142.5, 142.5, 128.4, 127.6, 127.4, 127.2, 127.1, 77.8, 61.0, 
38.3, 34.7, 14.1; HRMS (ESI) m/z calcd for C18H20NO2 (M+H) 282.1489, found 282.1495. 
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Ethyl 1-(4-methoxyphenyl)aziridine-2-carboxylate (3-69).151  A flame dried flask was 
charged with ethyl 2,3-dibromopropanoate (3.00 g, 1.68 mL, 11.2 mmol) in absolute ethanol (102 
mL, 0.11 M) and the mixture was cooled to 0 °C under nitrogen and stirring before sequential 
addition of p-anisidine (1.39 g, 11.2 mmol) and triethylamine (2.29 g, 3.18 mL, 22.4 mmol) by 
syringe. The reaction mixture was then slowly heated to 60 °C in a sealed flask (septum secured 
with wire) and stirred for 16 h. The resulting yellow solution was concentrated in vacuo to give an 
oily solid. The solid was suspended in ether and stirred for 30 min. The solid was partitioned 
between ethyl acetate (100 mL) and water (100 mL). The aqueous layer was removed and the 
organic layer was washed with water (100 mL), then brine. The organic was dried (MgSO4), 
filtered, and the filtrate was concentrated to afford a residue which was purified by 
chromatography on SiO2 (gradient, 19:1 to 3:1 hexanes/EtOAc) to afford 3-69 (1.32 g, 53%) as a 
yellow oil which freezes at −20 °C and matched literature reported spectra: Rf = 0.32 (1:1 
hexanes/Et2O, UV active); 
1H NMR (500 MHz, CDCl3) δ 6.94 (d, J = 8.9 Hz, 2 H), 6.79 (d, J = 
8.9 Hz, 2 H), 4.33–4.20 (m, 2 H), 3.76 (s, 3 H), 2.71 (dd, J = 6.4, 3.1 Hz, 1 H), 2.62 (dd, J = 3.2, 
1.7 Hz, 1 H), 2.25 (dd, J = 6.4, 1.8 Hz, 1 H), 1.32 (t, J = 7.2 Hz, 3 H); 13C NMR (126 MHz, CDCl3) 
δ 170.2, 155.7, 145.8, 121.4, 114.3, 61.4, 55.5, 37.9, 34.0, 14.2; HRMS (ESI) m/z calcd for 
C12H16NO3 (M+H) 221.1125, found 222.1123. 
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(±)-Ethyl (1S,3aS,7aR)-2-benzyl-7-oxooctahydro-1H-isoindole-1-carboxylate (3-71). 
A flame dried microwave tube was charged with 3-70 (1.08 g, 1.08 mL, 11.0 mmol) and 4 as a 2.6 
M solution in dry toluene (0.750 g, 1.41 mL, 3.65 mmol), in dry toluene (10.8 mL). The mixture 
was sparged with argon under sonication for 2 min before being sealed under argon and heated to 
195 °C on an aluminum block for 6 h then the heat was turned off and the reaction was allowed to 
cool to ambient temperature in the block slowly. The reaction mixture was concentrated and placed 
on the high vacuum for an hour before being purified by chromatography on SiO2 (gradient, 19:1 
to 3:1 PhMe/Et2O) gave  3-71 (0.500 g, 45%) as a pale yellow oil: Rf = 0.33 (1:1 hexanes/Et2O, 
UV active); ATR-IR (neat) 3028, 2936, 2805, 1722, 1701, 1183, 1029, 744, 699 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.34–7.28 (m, 4 H), 7.26–7.22 (m, 1 H), 4.13 (qd, J = 7.1, 2.9 Hz, 2 H), 3.79 
(d, J = 9.0 Hz, 1 H), 3.76 (d, J = 13.1 Hz, 1 H), 3.64 (d, J = 13.2 Hz, 1 H), 3.17 (t, J = 9.3 Hz, 1 
H), 2.81–2.74 (m, 2 H), 2.66–2.57 (m, 1 H), 2.39–2.26 (m, 2 H), 2.00–1.93 (m, 1 H), 1.85–1.79 
(m, 1 H), 1.74–1.66 (m, 2 H), 1.25 (t, J = 7.2 Hz, 3 H); 13C NMR (126 MHz, CDCl3) δ 211.6, 
171.7, 138.4, 128.7, 128.1, 127.0, 67.6, 60.5, 57.5, 56.9, 53.5, 39.9, 38.5, 27.1, 22.0, 14.2; HRMS 
(ESI) m/z calcd for C18H24NO3 (M+H) 302.1751, found 302.1747. 
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(±)-Ethyl (1S,3aS,7aR,E)-2-benzyl-7-(2-(4-nitrophenyl)hydrazono)octahydro-1H-
isoindole-1-carboxylate (3-73). A flame dried 2 mL microwave tube was charged with 3-71 (50.0 
mg, 0.158 mmol) in abs. EtOH (790 µL, 0.2 M) and to it was added 4-nitrophenylhydrazine (25.9 
mg, 0.166 mmol) in one portion and the tube was sealed under nitrogen and heated to 80 °C until 
consumption of the starting material was visualized (TLC, ≈ 18 h). The reaction mixture was 
concentrated and purified by chromatography on SiO2 (isocratic, CH2Cl2) to afford 3-73 (22 mg, 
32%) as a yellow solid. Single crystals were grown by liquid-liquid diffusion (hexanes/CH2Cl2) 
which were isolated as prisms and submitted for x-ray analysis: Rf = 0.61 (1:1 hexanes/EtOAc, I2 
active); Mp 154-158 °C; ATR-IR (neat) 3328, 2933, 1724, 1592, 1315, 1261, 1107, 844, 731 cm-
1; 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 9.3 Hz, 1 H), 7.63 (s, 1 H), 7.37–7.27 (m, 4 H), 7.25 
(d, J = 4.9 Hz, 1 H), 7.01 (d, J = 9.2 Hz, 2 H), 3.98–3.82 (m, 2 H), 3.76 (dd, J = 13.3, 11.3 Hz, 2 
H), 3.57 (d, J = 13.0 Hz, 1 H), 3.51 (td, J = 9.6, 1.6 Hz, 1 H), 2.81 (dd, J = 9.1, 3.5 Hz, 1 H), 2.74 
(dd, J = 9.1, 6.8 Hz, 1 H), 2.51–2.40 (m, 2 H), 2.17 (dddd, J = 16.4, 9.4, 6.6, 1.7 Hz, 1 H), 2.10–
1.99 (m, 1 H), 1.77–1.61 (m, 3 H), 1.48 (dtdd, J = 13.2, 9.7, 5.9, 3.2 Hz, 1 H), 1.07 (t, J = 7.1 Hz, 
3 H);  13C NMR (126 MHz, CDCl3) δ 172.3, 151.8, 150.2, 140.0, 138.4, 128.9, 128.2, 128.1, 127.1, 
126.0, 111.7, 70.4, 60.2, 58.8, 57.6, 46.7, 37.4, 27.7, 24.7, 20.7, 14.2.; HRMS (ESI) m/z calcd for 
C24H29N4O4 (M+H) 437.2183, found 437.2182. 
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(±)-Ethyl (1R,3aR,7aS)-2-benzhydryl-7-oxooctahydro-1H-isoindole-1-carboxylate (3-
75). A flame dried microwave tube was charged with 3-70 (209 mg, 211 µL, 2.13 mmol) and 3-
67 (0.200 g, 0.711 mmol) in dry PhMe (2.4 mL). The mixture was sparged with argon under 
sonication for 2 min before being sealed under argon and placed in a preheated (200 °C) aluminum 
block for 9 h then heat was turned off and the reaction was allowed to cool to ambient temperature 
in block slowly. The reaction was concentrated and by chromatography on SiO2 (gradient, 5-30% 
Et2O/hexanes) gave a small forerun of unreacted aziridine (40 mg) and 3-74 (130 mg, 48%) as off-
white crystals.  A single crystal was grown from absolute ethanol and submitted for X-ray analysis: 
Rf = 0.36 (1:1 hexanes/Et2O, UV active); ATR-IR (neat) 3062, 2938, 1724, 1702, 1453, 1453, 
1186, 1029, 707 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.41 (ddd, J = 8.1, 2.7, 1.3 Hz, 4 H), 7.25 
(ddd, J = 14.9, 8.1, 6.8 Hz, 4 H), 7.21–7.14 (m, 2 H), 4.60 (s, 1 H), 3.99 (d, J = 9.4 Hz, 1 H), 3.98–
3.88 (m, 2 H), 3.21 (t, J = 9.8 Hz, 1 H), 2.90 (dd, J = 9.6, 7.3 Hz, 1 H), 2.83 (dd, J = 9.5, 6.1 Hz, 
1 H), 2.61 (td, J = 10.4, 6.5 Hz, 1 H), 2.36 (ddd, J = 17.6, 5.1, 3.7 Hz, 1 H), 2.22 (ddd, J = 17.7, 
11.2, 6.3 Hz, 1 H), 2.01–1.93 (m, 1 H), 1.87–1.61 (m, 3 H), 1.11 (t, J = 7.2 Hz, 3 H).; 13C NMR R 
(76 MHz, CDCl3) δ 212.1, 172.3, 142.8, 142.2, 128.4, 128.3, 127.9, 127.6, 127.1, 71.4, 65.8, 60.2, 
57.2, 53.5, 39.8, 38.3, 27.2, 22.3, 14.0; HRMS (ESI) m/z calcd for C24H28NO3 (M+H) 378.2064, 
found 378.2062. 
 152 
 
Ethyl 3-methylbut-2-enoate (3-85). A flask was charged with 3,3-dimethyacrylic acid 
(10.0 g, 96.9 mmol) in absolute EtOH (48.5 mL, 2.0 M) and the mixture was stirred until complete 
dissolution took place. The flask then received H2SO4 (0.950 g, 516 µL, 9.69 mmol) dropwise by 
syringe. The mixture was then heated to reflux for 18 h, after which point the solution was allowed 
to cool to ambient temperature and was poured into a separatory funnel containing CH2Cl2 (100 
mL) and ice-water (100 mL). The phases were separated and the aqueous phase extracted with 
CH2Cl2 (2 x 100 mL). The pooled organics were successively washed with sat NaHCO3, water, 
brine, then dried (MgSO4), filtered, and concentrated to afford a pale green liquid which was 
purified by chromatography on SiO2 (gradient, 1:0 to 19:1 hexanes/EtOAc) to afford 3-85 (8.56 g, 
65%) as a light green liquid which spectrally matched commercial material: Rf = 0.48 (4:1 
hexanes/EtOAc, KMnO4 & UV active); 
1H NMR (300 MHz, CDCl3) δ 5.83–5.42 (m, 1 H), 4.07 
(q, J = 7.1 Hz, 2 H), 2.10 (d, J = 1.4 Hz, 3 H), 1.82 (d, J = 1.5 Hz, 3 H), 1.20 (t, J = 7.2 Hz, 3 H); 
13C NMR (76 MHz, CDCl3) δ 166.5, 156.0, 116.0, 59.2, 27.1, 19.9, 14.1. 
 
Ethyl 3,3-dimethyloxirane-2-carboxylate (3-86).152 A flame dried flask was charged 
with 3-85 (1.00 g, 1.09 mL, 7.41 mmol) in dry CH2Cl2 (29.6 mL, 0.2 M) and the solution was 
cooled to 0 °C on an ice-bath. The cooled solution was then treated with m-CPBA (2.05 g, 8.90 
mmol) as a solid, portion-wise over 5 min. The cooling bath was removed and the reaction stirred 
at ambient temperature overnight. Conversion was slow so after 12 h the reaction was fitted with 
an oil bath and heated at reflux for an additional 12 h. After 12 h of heating the acrylate was almost 
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consumed (TLC). Reaction was cooled, diluted with CH2Cl2 (20 mL) and quenched with sat. 
sodium bisulfite and washed with sat. sodium bicarbonate (2 x 20 mL). The organics were dried 
(MgSO4) and concentrated to afford a clear liquid that was purified by chromatography on SiO2 
(gradient, 19:1 to 9:1 hexanes/EtOAc) to afford 3-86 (737 mg, 69%) as a clear liquid which 
matched literature reported spectra: 1H NMR (300 MHz, CDCl3) δ 4.25 (qd, J = 7.1, 4.5 Hz, 2 H), 
3.33 (s, 1 H), 1.42 (s, 3 H), 1.38 (s, 3 H), 1.31 (t, J = 7.2 Hz, 3 H). 
 
Ethyl 2,3-dihydroxy-3-methylbutanoate (3-90). A flask was charged with 3-85 (3.00 g, 
3.26 mL, 22.2 mmol) in tert-butanol (67 mL) and to it was added water (22 mL) and 4-
methylmorpholine N-oxide (3.49 g, 28.9 mmol), citric acid (4.67 g, 22.2 mmol), and potassium 
osmate (82.8 mg, 0.222 mmol). The reaction was stirred at ambient temperature for 12 h during 
which time the reaction color changed from translucent green to tan. The reaction was then diluted 
with water (20 mL) and tert-butanol was removed under reduced pressure. The residue was 
extracted with ethyl acetate (3 x 50 mL). The combined organics were washed with brine, dried 
(MgSO4), filtered, and concentrated to afford a residue which was purified by chromatography on 
SiO2 (gradient, 19:1 to 1:1 hexanes/EtOAc) to afford 3-90 (3.50 g, 97%) as a colorless oil: Rf = 
0.45 (1:4 hexanes/EtOAc, KMnO4 active); ATR-IR (neat) 3450, 2980, 2939, 1729, 1201, 1090, 
744 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.39–4.21 (m, 2 H), 3.96 (d, J = 6.6 Hz, 1 H), 3.15 (d, J 
= 6.7 Hz, 1 H), 2.59 (s, 1 H), 1.33 (t, J = 7.1 Hz, 3 H), 1.30 (s, 3 H), 1.22 (s, 3 H).; 13C NMR (76 
MHz, CDCl3) δ 173.2, 77.1, 72.0, 62.0, 25.6, 24.9, 14.2; HRMS (ESI) m/z calcd for C7H15O4 
(M+H) 163.0965, found 163.0963. 
 154 
 
Ethyl 5,5-dimethyl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide (3-91). To a stirred 
solution of 3-90 (0.650 g, 4.01 mmol) in CH2Cl2 (13.4 mL) at 0 °C was added SOCl2 (722 mg, 
443 µL, 6.01 mmol) and Et3N (1.02 g, 1.42 mL, 10.0 mmol). After 30 min, a saturated solution of 
NaHCO3 (15 mL) was added. After separation of the layers, the organic layer was dried (Na2SO4) 
and concentrated to dryness. The residue was dissolved in the mixture of MeCN (13.4 mL) and 
H2O (6.68 mL). To the stirred mixture at room temperature, NaIO4 (874 mg 4.09 mmol) and 
RuCl3ꞏH2O (8.31 mg, 0.0401 mmol) was added. H2O was added to the reaction after 30 min and 
the mixture was extracted with EtOAc (2 x 25 mL). The combined organic layers were dried 
(Na2SO4) and concentrated to dryness under reduced pressure. The residue was purified by 
chromatography on SiO2 (gradient, 19:1 to 4:1 hexanes/EtOAc) to afford 3-91 (676 mg, 75%) as 
a clear oil: Rf = 0.55 (1:1 hexanes/EtOAc, KMnO4 active); ATR-IR (neat) 2989, 1764, 1742, 1375, 
1209, 1054, 827 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.36 (q, J = 7.2 Hz, 2 H), 1.79 (s, 3 H), 1.58 
(s, 3 H), 1.36 (t, J = 7.2 Hz, 3 H); 13C NMR (76 MHz, CDCl3) δ 163.5, 91.8, 83.8, 63.1, 26.1, 22.1, 
14.1; HRMS (ESI) m/z calcd for C7H13O6 (M+H) 225.0427, found 225.0431. 
 
Ethyl 2-azido-3-hydroxy-3-methylbutanoate (3-88). A flask was charged with 3-91 
(0.670 g, 2.99 mmol) in 9:1 acetone/water (18 mL/ 2.0 mL) and to it was added sodium azide (294 
mg, 4.48 mmol) in one portion and the mixture was stirred at 50 °C for 5 h or until consumption 
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of the SM as visualized by TLC. Acetone was removed under reduced pressure and diethyl ether 
(58 mL) and water (1.7 mL) was added and then the solution was chilled on an ice bath before 
dropwise addition of 20% H2SO4 (1.6 mL/mmol, 4.8 mL) and the mixture stirred vigorously 
overnight.  Separation of the organics and washing with saturated sodium carbonate, followed by 
drying with MgSO4, and concentration afforded 3-88 (164 mg, 29%) as a clear oil which was used 
immediately in the next step as it is a low molecular weight azide: 1H NMR (300 MHz, CDCl3) δ 
4.32 (qd, J = 7.1, 0.7 Hz, 2 H), 3.79 (s, 1 H), 2.81 (bs, 1 H), 1.35 (t, J = 7.1 Hz, 3 H), 1.30 (s, 3 H), 
1.30 (s, 3 H). 
 
N-benzylpropan-2-imine (3-92). A flame-dried flask was charged with a 1:2 mixture of 
dry ether and distilled acetone (12.2 mL:6.1 mL) and anhydrous calcium sulfate (2.75 g, about 0.3 
g/mmol). This mixture was then treated with benzylamine (1.00 g, 1.02 mL, 9.15 mmol). The 
reaction was stirred vigorously at ambient temperature for 18 h after which point it was filtered 
through a pad of dried HyFlo Celite. The Celite was washed with dry ether and the filtrate 
concentrated to afford 3-92 (1.40 g, quant) as a clear oil which was used immediately in the next 
step without further purification: 1H NMR (500 MHz, CDCl3) δ 7.34–7.30 (m, 4 H), 7.25–7.21 (m, 
1 H), 4.46 (s, 2 H), 2.09 (t, J = 1.3 Hz, 3 H), 1.94 (s, 3 H); 13C NMR (126 MHz, CDCl3) δ 168.1, 
140.4, 128.4, 127.8, 126.5, 77.3, 77.0, 76.7, 55.4, 29.4, 29.2, 18.7. 
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Ethyl 1-benzyl-3,3-dimethylaziridine-2-carboxylate (3-59). A flame dried flask was 
charged with [Ir(cod)Cl]2 catalyst in the glovebox (322 g, 0.476 mmol) and the flask was placed 
in a -10 °C bath (15 wt % aq. NaCl/dry-ice, bath temp remains −11 °C as long as a slush is 
maintained by slow addition of dry-ice) and to it was added freshly distilled THF (6.0 mL) under 
and argon atmosphere. The mixture was stirred for 5 min before the red solution received 3-92 
(1.40 g, 9.51 mmol) as a solution in distilled THF (3.5 mL) in one portion which turned the solution 
bright yellow. This mixture was stirred for an additional 10 min before ethyl diazoacetate (2.49 g, 
2.27 mL, 19.0 mmol) was added dropwise by syringe over 1 minute. The reaction was stirred at 
this temperature for 60 min, then the reaction was allowed to warm slowly to ambient temperature 
and stir for an additional 12 h during which time the mixture turned from yellow to brown. Wet 
diethyl ether was then added and the reaction was poured through a 1" pad of SiO2 and the silica 
was washed with diethyl ether (3 x column volumes). Concentration under reduced pressure and 
1 hour on the high vacuum gave a residue which was purified by chromatography on SiO2 
(gradient, 19:1 to 3:1 hexanes/Et2O) to afford 3-59 (1.51 g, 68%) as a yellow liquid: Rf = 0.44 (1:1 
hexanes/Et2O, KMnO4 & I2 active); ATR-IR (neat) 3063, 2982, 2930, 1741, 1302, 1175, 1037, 
732, 697 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 7.2 Hz, 2 H), 7.31 (dd, J = 8.4, 6.8 Hz, 
2 H), 7.25–7.21 (m, 1 H), 4.20 (qd, J = 7.1, 5.1 Hz, 2 H), 3.83–3.74 (m, 2 H), 2.12 (s, 1 H), 1.35 
(s, 3 H), 1.33 (s, 3 H), 1.27 (t, J = 7.1 Hz, 3 H); 13C NMR (126 MHz, CDCl3) δ 170.2, 139.2, 128.3, 
127.3, 126.7, 60.7, 56.0, 49.3, 44.6, 21.8, 17.9, 14.3; HMRS (ESI) m/z calcd for C14H20NO2 (M+H) 
234.1489, found 234.1487. 
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N-benzhydrylpropan-2-imine (3-94). A flame dried flask was charged with a 1:2 mixture 
of dry ether and distilled acetone (13 mL:40 mL) and anhydrous calcium sulfate (8.00 g, about 0.3 
g/ mmol). This mixture was then treated with benzhydrylamine (5.00 g, 4.72 mL, 26.5 mmol). The 
reaction was stirred vigorously at ambient temperature for 18 h after which point it was filtered 
through a pad of dried HyFlo Celite. The Celite was washed with dry ether and the filtrate 
concentrated to afford 3-94 (4.55 g, 77%) as an off-white solid that can be recrystallized from dry 
hexanes but was >95% pure by 1H NMR and was used directly in the next step: 1H NMR (500 
MHz, CDCl3) δ 7.39–7.36 (m, 4 H), 7.34–7.30 (m, 4 H), 7.26–7.19 (m, 2 H), 5.66 (s, 1 H), 2.16 
(s, 3 H), 1.94 (s, 3 H); 13C NMR (126 MHz, CDCl3) δ 167.2, 144.5, 128.3, 127.6, 126.6, 68.0, 
29.7, 19.1. 
 
Ethyl 1-benzhydryl-3,3-dimethylaziridine-2-carboxylate (3-95). A flame dried flask 
was charged with [Ir(cod)Cl]2 catalyst in the glovebox (.250 g, 0.369 mmol) and the flask was 
placed in a −10 °C bath (15 wt % aq. NaCl/dry-ice) and to it was added freshly distilled THF (2.94 
mL, 1.0 M) under and argon atmosphere. The mixture was stirred for 5 min before the red solution 
received 3-94 (1.65 g, 7.37 mmol) as a solid in one portion which turned the solution yellow. This 
mixture was stirred for an additional 10 min before ethyl diazoacetate (1.93 g, 1.76 mL, 14.7 
mmol) by syringe over 1 minute. The reaction was stirred at this temperature for 30 min then the 
reaction was allowed to warm slowly for 30 min to about 0 °C during which time the mixture 
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turned from yellow to brown. Wet diethyl ether was then added and the reaction was poured 
through a 1" pad of silica gel and eluted with diethyl ether. Concentration under reduced pressure 
and 1 hour on the high vacuum gave dark brown solid which was dissolved in 95% ethanol (25 
mL) at 60 °C and allow to slowly cool to ambient temperature, then was placed in the freezer (−20 
°C) for 12 h. The crystals thus formed were collected by filtration and the filter cake was washed 
with water and ice-cold 95% ethanol. Drying of the solids afforded 3-95 (1.65 g, 72%) as tan 
crystals in >95% purity: Rf = 0.23 (9:1 hexanes/Et2O, UV active); Mp = 120-122 °C; ATR-IR 
(neat) 3061, 3027, 2983, 1742, 1454, 1180, 1032, 746, 703 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.54–7.50 (m, 4 H), 7.31–7.25 (m, 4 H), 7.22–7.17 (m, 2 H), 4.34 (s, 1 H), 4.15 (qq, J = 10.8, 7.1 
Hz, 2 H), 2.17 (s, 1 H), 1.34 (s, 3 H), 1.29 (s, 3 H), 1.23 (t, J = 7.1 Hz, 3 H); 13C NMR (126 MHz, 
CDCl3) δ 170.0, 144.0, 143.4, 128.3, 128.3, 127.3, 126.9, 126.9, 126.8, 70.1, 60.5, 48.3, 45.8, 21.9, 
18.0, 14.3; HRMS (ESI) m/z calcd for C20H24NO2 (M+H) 310.1802, found 310.1809. 
 
(±)-Ethyl (1S,3aR,6aS)-2-benzyl-3,3,5-trimethyl-4,6-dioxooctahydropyrrolo[3,4-
c]pyrrole-1-carboxylate (3-103). A flame dried microwave tube was charged with N-
methylmaleimide (146 mg, 1.29 mmol) and 3-59 (0.100 g, 0.429 mmol) in dry PhMe (1.4 mL). 
The mixture was sparged with argon under sonication for 2 min before being sealed under argon 
and placed in a preheated (135 °C) aluminum block for 18 h. The heat was then turned off and the 
reaction was allowed to warm to ambient temperature in block slowly. The reaction was then 
concentrated and the residue purified by chromatography on SiO2 (gradient, 19:1 to 1:1 
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hexanes/EtOAc) to afford 3-103 (101 mg, 68%) as a colorless solid: Rf = 0.41 (1:1 hexanes/EtOAc, 
UV active); Mp 122-124 °C; ATR-IR (neat) 2969, 1694, 1433, 1379, 1284, 1129, 1021, 729 cm-
1; 1H NMR (400 MHz, CDCl3) δ 7.31–7.26 (m, 2 H), 7.25–7.15 (m, 3 H), 3.79 (d, J = 13.6 Hz, 1 
H), 3.90–3.69 (m, 3 H), 3.46 (d, J = 14.6 Hz, 1 H), 3.44 (d, J = 17.3 Hz, 1 H), 2.96 (s, 3 H), 2.88 
(d, J = 8.2 Hz, 1 H), 1.27 (s, 3 H), 1.14 (s, 3 H), 1.08 (t, J = 7.2 Hz, 3 H); 13C NMR (101 MHz, 
CDCl3) δ 176.0, 175.9, 170.3, 139.1, 128.6, 127.8, 126.9, 66.9, 63.9, 60.9, 54.3, 51.1, 45.6, 24.9, 
24.6, 21.2, 13.7; HRMS (ESI) m/z calcd for C19H25N2O4 (M+H) 245.1809, found 345.1806.  
 
(±)-Ethyl (2R,4S)-1-benzyl-4-cyano-5,5-dimethylpyrrolidine-2-carboxylate (3-106). A 
flame dried microwave tube was charged with 3-59 (0.100 g, 0.429 mmol) in dry PhMe (1.4 mL). 
The mixture was sparged with nitrogen under sonication for 2 min before addition of acrylonitrile 
[MEHQ removed by Brockmann 1 basic alumina and degassed with N2 sparging (69.6 mg, 87 µL, 
1.29 mmol)] The mixture was sealed under argon and placed in a preheated (135 °C) aluminum 
block for 18 h. The heat was then turned off and the reaction was allowed to warm to ambient 
temperature in block slowly. The reaction was then concentrated and the residue purified by 
chromatography on SiO2 (gradient, 19:1 to 1:1 hexanes/EtOAc) to afford 3-106 (25.1 mg, 20%) 
as a clear oil: Rf = 0.61 (1:1 hexanes/EtOAc, UV  active); ATR-IR (neat) 2975, 2238, 1728, 1452, 
1368, 1187, 1150, 1027, 749, 697 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.30–7.24 (m, 4 H), 7.22–
7.17 (m, 1 H), 3.92 (d, J = 14.2 Hz, 1 H), 3.84 (q, J = 7.2 Hz, 2 H), 3.69 (d, J = 14.3 Hz, 1 H), 3.55 
(dd, J = 9.2, 6.1 Hz, 1 H), 2.80 (dd, J = 8.4, 6.7 Hz, 1 H), 2.51 (dt, J = 13.5, 8.8 Hz, 1 H), 2.23 (dt, 
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J = 13.2, 6.4 Hz, 1 H), 1.38 (s, 3 H), 1.22 (s, 3 H), 1.09 (t, J = 7.2 Hz, 3 H); 13C NMR (126 MHz, 
CDCl3) δ 173.00, 138.98, 128.32, 128.06, 126.97, 119.86, 63.69, 62.54, 60.70, 49.98, 40.23, 31.02, 
23.37, 23.18, 13.85; HRMS (ESI) m/z calcd for C17H23N2O2 (M+H) 287.1754, found 287.1751. 
 
4-(Hydroxymethyl)cyclohex-2-en-1-one (rac-3-60).153 A flame dried flask was charged 
with solid KHMDS (1.95 g, 9.28 mmol) in the glove box. The solid was then dissolved in distilled 
THF (35 mL, 0.25 M) and the solution cooled to −78°C on a dry-ice/acetone bath. This cooled 
mixture was treated with trans-4-(dimethylamino)-3-buten-2-one (1.00 g, 8.84 mmol) as a solution 
in distilled THF (8.9 mL, 1.0 M) over a period of 30 min (syringe pump). The mixture was then 
allowed to warm to −30 °C over 30 min before being cooled back down to −78 °C and treated with 
TBDMSCl (1.48 g, 7.72) as a solution in THF (7.7mL, 1.0 M). The reaction was warmed to 
ambient temperature before being diluted with diethyl ether and passed through a pad of celite and 
concentrated to afford the aminosiloxydiene in good purify for the next step.  A flame dried flask 
was charged with this siloxydiene (2.00 g, 8.79 mmol) in distilled Et2O (11 mL, 0.8 M) and the 
yellow solution was cooled to 0 °C on an ice-bath before being treated with deinhibited (Brockann 
1 basic alumina) methyl acrylate (1.53 g, 1.60 mL, 17.6 mmol) dropwise by syringe under nitrogen. 
The reaction was warmed slowly to ambient temperature and stirred for 24 h. The reaction was 
then concentrated and re-dissolved in ether and polish filtered through a 1" pad of silica.  
Concentration of the eluent afforded the crude cycloadduct (2.32 g) as a 1.3:1 mixture of exo:endo 
products containing 10 mass % TBDMSCl. This crude material was dissolved in distilled THF (17 
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mL). The mixture was cooled to 0 °C on an ice-bath before dropwise addition of LAH 1M in Et2O 
(10.9 mL, 10.9 mmol) over 30 min. The reaction stirred for an additional 30 min at this temperature 
before being diluted with ether (30 mL) and quenched by addition of water (3.3 mL; 0.3 mL/mmol 
LAH) dropwise by syringe with good ventilation. This turbid mixture was then warmed to ambient 
temperature before addition of anhydrous Na2SO4. The inorganics were removed by filtration and 
the ethereal portion was concentrated to afford the desired alcohol as a colorless oil which was 
used in the next step without further purification. This material (1.67 g, 5.38 mmol) was taken up 
in MeCN (5.4 mL, 1 M) and cooled to 0 °C on an ice-bath. To this cooled mixture was added 10% 
HF in MeCN (2.5 mL, 2.2 mL/mmol) dropwise by syringe over 3 min. Upon addition of HF, the 
reaction mixture turned colorless to yellow. The reaction was warmed to ambient temperature and 
stirred for 1.5 h with monitoring by TLC. Upon completion of the reaction, the reaction mixture 
was loaded directly on to a column layered with sodium sulfate for purification by chromatography 
on SiO2 (isocratic, diethyl ether) to rac-3-60 (645 mg, 59% over 4 steps) as a viscous clear oil 
which matched literature spectra: 1H NMR (500 MHz, CDCl3) δ 6.10–6.04 (m, 1 H), 3.78–3.64 
(m, 2 H), 2.69–2.59 (m, 1 H), 2.55 (dt, J = 16.8, 4.7 Hz, 1 H), 2.40 (ddd, J = 16.9, 12.6, 5.1 Hz, 1 
H), 2.14 (dqd, J = 13.4, 4.9, 1.4 Hz, 1 H), 1.82 (tdd, J = 12.9, 9.7, 4.5 Hz, 1 H), 1.69 (d, J = 5.0 
Hz, 1 H). 13C NMR (126 MHz, CDCl3) δ 199.5, 151.1, 130.4, 77.3, 76.7, 65.3, 39.0, 36.6, 25.4. 
 
(4-Oxocyclohex-2-en-1-yl)methyl 1-benzhydrylaziridine-2-carboxylate (3-115). Ethyl 
1-benzhydrylaziridine-2-carboxylate (0.350 g, 1.24 mmol) was suspended in EtOH (1.24 mL) and 
cooled to 0 °C on an ice-bath. Bench grade THF was added until dissolution of the starting material 
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was visualized (about 300 µL). Lithium hydroxide monohydrate (79.9 mg, 1.87 mmol) was added 
in one portion followed by a drop of water. The reaction was stirred while warming to ambient 
temperature. After about 3 h the reaction mixture had seized and the white solid was slurried in 
ether and collected by filtration. The solids were washed with ether, dried on the filter, then 
dissolved in 6 mL of water and to it was added and equal volume of half-saturated aqueous citric 
acid resulting in a formation of a white precipitate. Methylene chloride was added, and the two 
layers were transferred to a separatory funnel. The organic layer was separated, and the aqueous 
layer extracted with methylene chloride (2 x 25 mL). The organic extracts were combined, dried 
(Na2SO4), filtered and concentrated to afford an oil which foamed to a light colorless solid under 
high vacuum. This material was charged into a flame-dried vial with HBTU (383 mg, 0.999 mmol), 
and DIPEA (258 mg, 330 µL, 2.00 mmol) in dry DMF (2.5 mL, 0.4 M). The mixture was stirred 
for 30 min at ambient temperature before rac-3-60 (139 mg, 1.10 mmol) was added as a solution 
in dry DMF (1 mL). Stirring was continued for 16 h at which point the reaction was diluted with 
diethyl ether 100 mL and washed with water (2 x 25 mL), brine (25 mL), dried (MgSO4), filtered, 
and concentrated to afford a yellow oil which was purified by chromatography on SiO2 (gradient, 
1:1 to 0:1 hexanes/Et2O) to afford 1 (275 mg, 61%) as a colorless solid:  Rf = 0.41 (1:1 
hexanes/EtOAc, UV active); Mp 91.5–93 °C; ATR-IR (neat) 3062, 3028, 2953, 1742, 1677, 1177, 
749, 703 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.44–7.39 (m, 4 H), 7.34–7.21 (m, 6 H), 6.79–6.74 
(m, 1 H), 6.05 (dt, J = 10.2, 3.0 Hz, 1 H), 4.29–4.05 (m, 2 H), 3.62 (s, 1 H), 2.80–2.73 (m, 1 H), 
2.53 (ddt, J = 17.2, 8.8, 4.7 Hz, 1 H), 2.42–2.32 (m, 2 H), 2.28 (ddd, J = 6.4, 3.2, 1.1 Hz, 1 H), 
2.11–2.02 (m, 1 H), 1.88 (d, J = 6.4 Hz, 1 H), 1.75 (qdd, J = 12.9, 9.7, 4.5 Hz, 1 H); 13C NMR 
(126 MHz, CDCl3, 1:1 diastereomers) δ 198.8, 198.8, 170.4, 170.4, 149.5, 149.4, 142.5, 142.2, 
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130.7, 128.5, 128.5, 127.5, 127.4, 127.2, 127.1, 77.9, 77.9, 66.3, 66.3, 37.9, 37.9, 36.5, 35.9, 35.9, 
35.1, 35.1, 25.6, 25.5; HRMS (ESI) m/z calcd for C23H24NO3 (M+H) 362.1751, found 362.1760.   
 
(±)–(2aS,2a1R,5aR,8aS)-1-Benzhydryloctahydro-3H-pyrano[3,4,5-cd] isoindole-3,8 
(1H)-dione (3-116). A flame dried 30 mL microwave vial was charged with 3-115 (0.100 g, 0.277 
mmol) in distilled PhMe (9.2 mL, 0.03 M), and the mixture was sparged with nitrogen under 
sonication for 2 min before the vial was sealed and placed in a preheated aluminum block (150 
°C) for 34 h. At this point the reaction was directly purified by chromatography on SiO2 (gradient, 
0:1 to 1:9 acetone/CH2Cl2) to afford 3-116 (40 mg, 40%) as an off-white solid: Rf = 0.75 (9:1 
CH2Cl2/acetone, UV active); Mp 195–196 °C; ATR-IR (neat) 3058, 3025, 2900, 1737, 1709, 1493, 
1453, 1125, 1072, 750, 708 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.37–7.27 (m, 9 H), 7.24–7.18 
(m, 1 H), 5.52 (s, 1 H), 4.39 (dd, J = 11.0, 6.7 Hz, 1 H), 4.20 (dd, J = 11.0, 2.7 Hz, 1 H), 3.46 (dd, 
J = 9.8, 3.7 Hz, 1 H), 3.43 (d, J = 10.0 Hz, 1 H), 3.19 (td, J = 10.1, 7.9 Hz, 1 H), 2.76 (ddd, J = 
10.5, 6.9, 3.6 Hz, 1 H), 2.50–2.33 (m, 4 H), 2.09 (dtd, J = 14.4, 7.0, 4.0 Hz, 1 H), 1.95 (dtd, J = 
14.3, 8.3, 5.8 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ 209.3, 171.4, 141.7, 137.7, 130.2, 128.1, 
128.1, 127.6, 127.5, 126.8, 69.3, 66.1, 60.7, 48.3, 47.3, 40.5, 36.6, 32.6, 22.9; HRMS (ESI) m/z 
calcd for C23H24NO3 (M+H) 362.1751, found 362.1751.   
 164 
 
(4-Oxocyclohex-2-en-1-yl)methyl 1-benzhydryl-3,3-dimethylaziridine-2-carboxylate 
(3-118). 3-95 (0.400 g, 1.29 mmol) was dissolved in 3:1 EtOH/THF (2.0 mL:0.60 mL) and cooled 
to 0 °C on an ice-bath. Lithium hydroxide monohydrate (83.0 mg, 1.94 mmol) was added in one 
portion followed by a 12 drops of water from a glass pipette (about 3 drops/20 mg LiOH). The 
reaction was stirred while warming to ambient temperature and stirred for 12 h during which time 
the reaction seized. The solid was transferred to a separatory funnel and half-saturated aqueous 
citric acid (20 mL) was then added which resulted in a white precipitate. 30 mL of methylene 
chloride was added to the funnel and the contents was shaken vigorously. The organics were 
separated, and aqueous layer extracted with methylene chloride (2 x 30 mL) ensuring the aqueous 
layer remained acidic (pH < 2). The cloudy combined organics were washed with brine (20 mL) 
resulting in a transparent pale-yellow solution which was dried (Na2SO4), filtered, and 
concentrated to produce an oil which foamed to a solid on the high vacuum. Diethyl ether (10 mL) 
was added to this foam and swirled under the high vacuum. One more chasing of ether gave the 
aziridine carboxylic acid as a white solid which was used immediately due to instability. This 
crude acid (363 mg, 1.29 mmol) was charged into a flame dried vial with HBTU (494 mg, 1.29 
mmol) in dry DMF (5.0 mL). The mixture was cooled to 0 °C on an ice-bath before addition of 
and DIPEA (258 mg, 330 µL, 2.00 mmol). The bath was removed and the mixture was stirred for 
30 min at ambient temperature before rac-3-60 (171 mg, 1.36 mmol) was added as a solution in 
dry DMF (2 mL). Stirring was continued for 16 h at which point the reaction was diluted with 
ethyl acetate (120 mL) and washed with water (2 x 30 mL), brine (25 mL), dried (MgSO4), filtered, 
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and concentrated to afford a yellow oil which was purified by chromatography on SiO2 (gradient, 
1:0 to 1:1 hexanes/Et2O) to afford 3-118 (361 mg, 72%) as an off-white solid: Rf = 0.68 (Et2O, UV 
active); Mp 95–96 °C; ATR-IR (neat) 3062, 3027, 2956, 2870, 1743, 1678, 1453, 1169, 1134, 748, 
704 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.51–7.46 (m, 4 H), 7.32–7.16 (m, 6 H), 6.78–6.71 (m, 1 
H), 6.03 (ddd, J = 10.3, 7.8, 2.5 Hz, 1 H), 4.32 (s, 1 H), 4.18 (dt, J = 11.1, 6.1 Hz, 1 H), 4.07 (ddd, 
J = 11.0, 6.5, 2.2 Hz, 1 H), 2.78–2.67 (m, 1 H), 2.52 (ddt, J = 12.3, 8.3, 4.4 Hz, 1 H), 2.41–2.31 
(m, 1 H), 2.18 (d, J = 1.4 Hz, 1 H), 2.10–1.98 (m, 1 H), 1.81–1.62 (m, 1 H), 1.35 (s, 3 H), 1.29 (s, 
3 H); 13C NMR 126 MHz, CDCl3, 1:1 diastereomers) δ 198.9, 198.9, 170.1, 170.1, 149.7, 149.7, 
143.7, 143.3, 130.6, 128.4, 127.4, 127.4, 127.1, 127.0, 126.8, 70.3, 66.0, 66.0, 48.0, 48.0, 46.5, 
46.5, 36.5, 36.5, 36.0, 35.9, 25.6, 25.6, 22.1, 18.0, 18.0; HRMS (ESI) m/z calcd for C25H28NO3 
(M+H) 390.2064, found 390.2056. 
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 : X-RAY CRYSTALLOGRAPHY DATA 
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Figure 11 ORTEP strucuture of 3-73 
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Table 17 Sample and crystal data for 3-73 
Chemical formula C24H28N4O4 
Formula weight 436.50 g/mol 
Temperature 150(2) K 
Wavelength 1.54178 Å 
Crystal size 0.030 x 0.050 x 0.130 mm 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 10.5702(3) Å α = 105.875(2)° 
 b = 11.2776(3) Å β = 109.9772(16)° 
 c = 11.4692(4) Å γ = 108.8025(18)° 
Volume 1097.46(6) Å3  
Z 2 
Density (calculated) 1.321 g/cm3 
Absorption coefficient 0.744 mm-1 
F(000) 464 
 
Table 18 Data collection and structure refinement for 3-73 
Theta range for data collection 4.55 to 70.20° 
Index ranges -12<=h<=12, -13<=k<=13, -13<=l<=13 
Reflections collected 17806 
Independent reflections 4046 [R(int) = 0.0377] 
Coverage of independent reflections 96.7% 
Absorption correction Multi-Scan 
Max. and min. transmission 0.9800 and 0.9100 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2017/1 (Sheldrick, 2017) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4046 / 0 / 294 
Goodness-of-fit on F2 1.486 
Final R indices 3499 data; I>2σ(I) R1 = 0.0448, wR2 = 0.1350 
 all data R1 = 0.0515, wR2 = 0.1398 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0680P)2] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.716 and -0.344 eÅ-3 
R.M.S. deviation from mean 0.051 eÅ-3 
 
 
Table 19 Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 3-73 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
  x/a y/b z/c U(eq) 
C1 0.78797(17) 0.97374(16) 0.17860(16) 0.0242(3) 
C2 0.81594(17) 0.11089(16) 0.28163(16) 0.0237(3) 
C3 0.91762(17) 0.14674(18) 0.43175(17) 0.0285(4) 
C4 0.83191(17) 0.06555(17) 0.48986(16) 0.0267(4) 
 255 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
  x/a y/b z/c U(eq) 
C5 0.71509(17) 0.11316(16) 0.50222(15) 0.0224(3) 
C6 0.62968(16) 0.12938(15) 0.37760(15) 0.0198(3) 
C7 0.65267(16) 0.08993(15) 0.25225(15) 0.0199(3) 
C8 0.54854(16) 0.93279(15) 0.14755(14) 0.0187(3) 
C9 0.41926(16) 0.86776(15) 0.17510(15) 0.0194(3) 
C10 0.17339(19) 0.8409(2) 0.1322(2) 0.0377(5) 
C11 0.0584(2) 0.8703(3) 0.0467(3) 0.0549(6) 
C12 0.58104(17) 0.73626(16) 0.04117(15) 0.0217(3) 
C13 0.68046(16) 0.66468(15) 0.05237(15) 0.0200(3) 
C14 0.67829(17) 0.58448(16) 0.93426(15) 0.0233(3) 
C15 0.76474(18) 0.51427(17) 0.94152(17) 0.0278(4) 
C16 0.85419(18) 0.52203(17) 0.06644(18) 0.0281(4) 
C17 0.85807(18) 0.60198(18) 0.18503(17) 0.0285(4) 
C18 0.77227(18) 0.67300(17) 0.17758(16) 0.0253(4) 
C19 0.41386(16) 0.28079(15) 0.46918(15) 0.0202(3) 
C20 0.34159(19) 0.29732(18) 0.35164(16) 0.0274(4) 
C21 0.26156(19) 0.37261(18) 0.35309(17) 0.0291(4) 
C22 0.25286(16) 0.43149(16) 0.47117(17) 0.0230(3) 
C23 0.31943(17) 0.41280(16) 0.58699(16) 0.0241(3) 
C24 0.39784(17) 0.33618(16) 0.58555(15) 0.0229(3) 
N1 0.64880(13) 0.86821(13) 0.16146(12) 0.0187(3) 
N2 0.53280(14) 0.17675(13) 0.36587(13) 0.0205(3) 
N3 0.50115(15) 0.21226(14) 0.47349(13) 0.0227(3) 
N4 0.17446(15) 0.51620(14) 0.47441(16) 0.0292(3) 
O1 0.42443(12) 0.82028(11) 0.25803(11) 0.0245(3) 
O2 0.29844(12) 0.87724(12) 0.09908(12) 0.0272(3) 
O3 0.11929(15) 0.53415(15) 0.37100(14) 0.0427(4) 
O4 0.16770(13) 0.56784(12) 0.57998(13) 0.0354(3) 
 
 
Table 20 Bond lengths (Å) for 3-73 
C1-N1 1.4714(19) C1-C2 1.531(2) 
C1-H1A 0.99 C1-H1B 0.99 
C2-C3 1.535(2) C2-C7 1.563(2) 
C2-H2A 1.0 C3-C4 1.522(2) 
C3-H3A 0.99 C3-H3B 0.99 
C4-C5 1.529(2) C4-H4A 0.99 
C4-H4B 0.99 C5-C6 1.503(2) 
C5-H5A 0.99 C5-H5B 0.99 
C6-N2 1.2846(19) C6-C7 1.511(2) 
C7-C8 1.571(2) C7-H7A 1.0 
C8-N1 1.4576(17) C8-C9 1.510(2) 
C8-H8A 1.0 C9-O1 1.2067(18) 
C9-O2 1.3345(17) C10-O2 1.4623(19) 
C10-C11 1.473(3) C10-H10A 0.99 
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C10-H10B 0.99 C11-H11A 0.98 
C11-H11B 0.98 C11-H11C 0.98 
C12-N1 1.4647(19) C12-C13 1.511(2) 
C12-H12A 0.99 C12-H12B 0.99 
C13-C18 1.389(2) C13-C14 1.396(2) 
C14-C15 1.385(2) C14-H14A 0.95 
C15-C16 1.381(2) C15-H15A 0.95 
C16-C17 1.390(2) C16-H16A 0.95 
C17-C18 1.387(2) C17-H17A 0.95 
C18-H18A 0.95 C19-N3 1.3785(19) 
C19-C20 1.400(2) C19-C24 1.402(2) 
C20-C21 1.379(2) C20-H20A 0.95 
C21-C22 1.384(2) C21-H21A 0.95 
C22-C23 1.384(2) C22-N4 1.4536(19) 
C23-C24 1.377(2) C23-H23A 0.95 
C24-H24A 0.95 N2-N3 1.3762(17) 
N3-H3N 0.88(2) N4-O4 1.2290(19) 
N4-O3 1.2340(19)   
 
 
Table 21 Bond angles (°) for 3-73 
N1-C1-C2 104.91(12) N1-C1-H1A 110.8 
C2-C1-H1A 110.8 N1-C1-H1B 110.8 
C2-C1-H1B 110.8 H1A-C1-H1B 108.8 
C1-C2-C3 113.48(13) C1-C2-C7 103.50(12) 
C3-C2-C7 112.96(13) C1-C2-H2A 108.9 
C3-C2-H2A 108.9 C7-C2-H2A 108.9 
C4-C3-C2 112.25(13) C4-C3-H3A 109.2 
C2-C3-H3A 109.2 C4-C3-H3B 109.2 
C2-C3-H3B 109.2 H3A-C3-H3B 107.9 
C3-C4-C5 109.49(13) C3-C4-H4A 109.8 
C5-C4-H4A 109.8 C3-C4-H4B 109.8 
C5-C4-H4B 109.8 H4A-C4-H4B 108.2 
C6-C5-C4 112.59(12) C6-C5-H5A 109.1 
C4-C5-H5A 109.1 C6-C5-H5B 109.1 
C4-C5-H5B 109.1 H5A-C5-H5B 107.8 
N2-C6-C5 124.89(13) N2-C6-C7 113.70(12) 
C5-C6-C7 121.41(12) C6-C7-C2 115.39(12) 
C6-C7-C8 113.44(12) C2-C7-C8 103.60(11) 
C6-C7-H7A 108.0 C2-C7-H7A 108.0 
C8-C7-H7A 108.0 N1-C8-C9 113.53(12) 
N1-C8-C7 105.51(11) C9-C8-C7 111.09(11) 
N1-C8-H8A 108.9 C9-C8-H8A 108.9 
C7-C8-H8A 108.9 O1-C9-O2 124.10(14) 
O1-C9-C8 125.99(13) O2-C9-C8 109.81(12) 
O2-C10-C11 107.56(15) O2-C10-H10A 110.2 
C11-C10-H10A 110.2 O2-C10-H10B 110.2 
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C11-C10-H10B 110.2 H10A-C10-H10B 108.5 
C10-C11-H11A 109.5 C10-C11-H11B 109.5 
H11A-C11-H11B 109.5 C10-C11-H11C 109.5 
H11A-C11-H11C 109.5 H11B-C11-H11C 109.5 
N1-C12-C13 112.96(11) N1-C12-H12A 109.0 
C13-C12-H12A 109.0 N1-C12-H12B 109.0 
C13-C12-H12B 109.0 H12A-C12-H12B 107.8 
C18-C13-C14 118.29(14) C18-C13-C12 121.77(13) 
C14-C13-C12 119.93(13) C15-C14-C13 120.92(14) 
C15-C14-H14A 119.5 C13-C14-H14A 119.5 
C16-C15-C14 120.25(14) C16-C15-H15A 119.9 
C14-C15-H15A 119.9 C15-C16-C17 119.50(14) 
C15-C16-H16A 120.2 C17-C16-H16A 120.2 
C18-C17-C16 120.12(15) C18-C17-H17A 119.9 
C16-C17-H17A 119.9 C17-C18-C13 120.92(14) 
C17-C18-H18A 119.5 C13-C18-H18A 119.5 
N3-C19-C20 121.58(14) N3-C19-C24 119.27(13) 
C20-C19-C24 119.15(14) C21-C20-C19 120.11(14) 
C21-C20-H20A 119.9 C19-C20-H20A 119.9 
C20-C21-C22 119.66(15) C20-C21-H21A 120.2 
C22-C21-H21A 120.2 C23-C22-C21 121.15(14) 
C23-C22-N4 119.35(14) C21-C22-N4 119.49(14) 
C24-C23-C22 119.43(14) C24-C23-H23A 120.3 
C22-C23-H23A 120.3 C23-C24-C19 120.38(14) 
C23-C24-H24A 119.8 C19-C24-H24A 119.8 
C8-N1-C12 111.24(11) C8-N1-C1 103.44(11) 
C12-N1-C1 113.08(12) C6-N2-N3 118.04(12) 
N2-N3-C19 117.89(13) N2-N3-H3N 122.7(13) 
C19-N3-H3N 118.9(13) O4-N4-O3 123.10(14) 
O4-N4-C22 118.76(14) O3-N4-C22 118.13(14) 
C9-O2-C10 115.93(13)   
 
 
Table 22 Anisotropic atomic displacement parameters (Å2) for 3-73 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
 U11 U22 U33 U23 U13 U12 
C1 0.0208(7) 0.0274(8) 0.0294(8) 0.0118(7) 0.0157(6) 0.0130(6) 
C2 0.0213(7) 0.0234(8) 0.0314(8) 0.0133(7) 0.0161(7) 0.0107(6) 
C3 0.0187(7) 0.0309(9) 0.0294(8) 0.0063(7) 0.0093(6) 0.0117(7) 
C4 0.0263(8) 0.0304(9) 0.0229(8) 0.0104(7) 0.0075(6) 0.0180(7) 
C5 0.0247(7) 0.0237(8) 0.0209(7) 0.0102(7) 0.0105(6) 0.0132(6) 
C6 0.0203(7) 0.0175(7) 0.0226(7) 0.0096(6) 0.0105(6) 0.0085(6) 
C7 0.0218(7) 0.0229(8) 0.0230(7) 0.0136(7) 0.0130(6) 0.0134(6) 
C8 0.0203(7) 0.0243(8) 0.0187(7) 0.0126(6) 0.0106(6) 0.0140(6) 
C9 0.0198(7) 0.0213(7) 0.0190(7) 0.0085(6) 0.0090(6) 0.0119(6) 
C10 0.0263(9) 0.0504(11) 0.0557(11) 0.0349(10) 0.0265(8) 0.0213(8) 
C11 0.0323(10) 0.0821(17) 0.0733(15) 0.0493(14) 0.0306(10) 0.0324(11) 
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 U11 U22 U33 U23 U13 U12 
C12 0.0201(7) 0.0254(8) 0.0180(7) 0.0073(6) 0.0076(6) 0.0119(6) 
C13 0.0172(7) 0.0204(7) 0.0223(7) 0.0089(6) 0.0102(6) 0.0077(6) 
C14 0.0234(7) 0.0249(8) 0.0196(7) 0.0081(7) 0.0097(6) 0.0107(6) 
C15 0.0313(8) 0.0256(8) 0.0290(8) 0.0082(7) 0.0182(7) 0.0146(7) 
C16 0.0251(8) 0.0275(8) 0.0367(9) 0.0134(8) 0.0165(7) 0.0159(7) 
C17 0.0277(8) 0.0332(9) 0.0258(8) 0.0133(7) 0.0095(7) 0.0183(7) 
C18 0.0287(8) 0.0301(8) 0.0204(7) 0.0094(7) 0.0125(7) 0.0173(7) 
C19 0.0173(7) 0.0202(7) 0.0242(7) 0.0103(6) 0.0096(6) 0.0093(6) 
C20 0.0315(8) 0.0373(9) 0.0244(8) 0.0169(7) 0.0166(7) 0.0215(7) 
C21 0.0290(8) 0.0415(10) 0.0315(9) 0.0247(8) 0.0166(7) 0.0225(7) 
C22 0.0185(7) 0.0221(7) 0.0338(8) 0.0149(7) 0.0138(6) 0.0114(6) 
C23 0.0225(7) 0.0246(8) 0.0264(8) 0.0092(7) 0.0130(6) 0.0123(6) 
C24 0.0243(7) 0.0269(8) 0.0211(7) 0.0120(7) 0.0103(6) 0.0149(6) 
N1 0.0171(6) 0.0220(6) 0.0200(6) 0.0086(5) 0.0094(5) 0.0118(5) 
N2 0.0224(6) 0.0224(6) 0.0215(6) 0.0109(6) 0.0129(5) 0.0118(5) 
N3 0.0271(7) 0.0308(7) 0.0199(6) 0.0136(6) 0.0133(6) 0.0195(6) 
N4 0.0225(7) 0.0261(7) 0.0451(9) 0.0197(7) 0.0168(6) 0.0134(6) 
O1 0.0277(6) 0.0293(6) 0.0262(6) 0.0164(5) 0.0163(5) 0.0161(5) 
O2 0.0195(5) 0.0384(6) 0.0363(6) 0.0243(6) 0.0152(5) 0.0180(5) 
O3 0.0429(7) 0.0530(8) 0.0566(8) 0.0375(7) 0.0248(7) 0.0360(7) 
O4 0.0324(6) 0.0311(7) 0.0496(8) 0.0146(6) 0.0238(6) 0.0198(5) 
 
 
Table 23 Hydrogen atomic coordinates and isotropic atomic displacemnt parameters (Å2) for 3-73 
 x/a y/b z/c U(eq) 
H1A 0.7740 -0.0229 0.0899 0.029 
H1B 0.8741 -0.0465 0.2147 0.029 
H2A 0.8640 0.1875 0.2591 0.028 
H3A 1.0033 0.1263 0.4374 0.034 
H3B 0.9601 0.2474 0.4884 0.034 
H4A 0.9038 0.0811 0.5815 0.032 
H4B 0.7801 -0.0350 0.4285 0.032 
H5A 0.6422 0.0446 0.5158 0.027 
H5B 0.7675 0.2031 0.5842 0.027 
H7A 0.6284 0.1474 0.2039 0.024 
H8A 0.5059 -0.0739 0.0522 0.022 
H10A 0.2102 -0.1034 0.2309 0.045 
H10B 0.1293 -0.2586 0.1125 0.045 
H11A -0.0284 -0.1556 0.0647 0.082 
H11B 0.0248 -0.1835 -0.0506 0.082 
H11C 0.1024 -0.0304 0.0692 0.082 
H12A 0.5612 -0.2464 -0.0418 0.026 
H12B 0.4825 -0.3262 0.0296 0.026 
H14A 0.6167 -0.4220 -0.1523 0.028 
H15A 0.7625 -0.5394 -0.1397 0.033 
H16A 0.9126 -0.5269 0.0713 0.034 
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 x/a y/b z/c U(eq) 
H17A 0.9196 -0.3920 0.2713 0.034 
H18A 0.7764 -0.2719 0.2593 0.03 
H20A 0.3477 0.2566 0.2708 0.033 
H21A 0.2126 0.3840 0.2735 0.035 
H23A 0.3111 0.4525 0.6668 0.029 
H24A 0.4413 0.3208 0.6638 0.027 
H3N 0.544(2) 0.204(2) 0.549(2) 0.036(5) 
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Figure 12 ORTEP structure of 3-74 
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Table 24 Sample and crystal data for 3-74 
Chemical formula C24H27NO3 
Formula weight 377.46 g/mol 
Temperature 150(2) K 
Wavelength 1.54178 Å 
Crystal size 0.030 x 0.130 x 0.220 mm 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions a = 15.8756(4) Å α = 90° 
 b = 5.98440(10) Å β = 106.6901(12)° 
 c = 21.9116(5) Å γ = 90° 
Volume 1994.03(8) Å3  
Z 4 
Density (calculated) 1.257 g/cm3 
Absorption coefficient 0.654 mm-1 
F(000) 808 
 
 
Table 25 Data collection and structure refinement for 3-74 
Theta range for data collection 4.21 to 68.31° 
Index ranges -18<=h<=19, -7<=k<=7, -23<=l<=26 
Reflections collected 22788 
Independent reflections 3617 [R(int) = 0.0670] 
Max. and min. transmission 0.9800 and 0.8700 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2017/1 (Sheldrick, 2017) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3617 / 0 / 253 
Goodness-of-fit on F2 1.338 
Final R indices 3236 data; I>2σ(I) R1 = 0.0405, wR2 = 0.1145 
 all data R1 = 0.0445, wR2 = 0.1181 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0680P)2] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.312 and -0.239 eÅ-3 
R.M.S. deviation from mean 0.050 eÅ-3 
 
 
Table 26 Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 3-74 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x/a y/b z/c U(eq) 
N1 0.26000(6) 0.55685(16) 0.19506(4) 0.0184(2) 
O1 0.26618(6) 0.77519(17) 0.01334(4) 0.0322(2) 
C1 0.23340(7) 0.63400(19) 0.12813(5) 0.0178(2) 
O2 0.14264(5) 0.41125(15) 0.04707(4) 0.0237(2) 
C2 0.30819(7) 0.79540(19) 0.12639(5) 0.0192(3) 
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 x/a y/b z/c U(eq) 
O3 0.28658(5) 0.32382(15) 0.07769(4) 0.0244(2) 
C3 0.32459(8) 0.8133(2) 0.06162(6) 0.0231(3) 
C4 0.41455(9) 0.8896(3) 0.05915(7) 0.0341(3) 
C5 0.48501(8) 0.8911(2) 0.12363(7) 0.0323(3) 
C6 0.47175(8) 0.6913(2) 0.16315(6) 0.0280(3) 
C7 0.38854(7) 0.7272(2) 0.18326(5) 0.0216(3) 
C8 0.35591(7) 0.5248(2) 0.21239(5) 0.0217(3) 
C9 0.22560(7) 0.44100(19) 0.08096(5) 0.0182(2) 
C10 0.12420(8) 0.2307(2) 0.00074(6) 0.0286(3) 
C11 0.02705(8) 0.2411(2) 0.96772(6) 0.0287(3) 
C12 0.21124(7) 0.36181(19) 0.20820(5) 0.0180(2) 
C13 0.07974(8) 0.6111(2) 0.20511(5) 0.0215(3) 
C14 0.98957(8) 0.6445(2) 0.19164(6) 0.0254(3) 
C15 0.93141(8) 0.4774(2) 0.16212(6) 0.0281(3) 
C16 0.96362(8) 0.2769(2) 0.14647(6) 0.0275(3) 
C17 0.05379(8) 0.2425(2) 0.16075(5) 0.0227(3) 
C18 0.11279(7) 0.4087(2) 0.19032(5) 0.0191(3) 
C19 0.28169(7) 0.0821(2) 0.29476(6) 0.0222(3) 
C20 0.31269(8) 0.0183(2) 0.35848(6) 0.0272(3) 
C21 0.30767(8) 0.1655(2) 0.40644(6) 0.0284(3) 
C22 0.27259(8) 0.3768(2) 0.39035(6) 0.0266(3) 
C23 0.24230(8) 0.4407(2) 0.32682(6) 0.0228(3) 
C24 0.24614(7) 0.2936(2) 0.27822(5) 0.0193(3) 
 
 
Table 27 Bond lengths (Å) for 3-74 
N1-C8 1.4722(14) N1-C12 1.4739(15) 
N1-C1 1.4786(14) O1-C3 1.2114(16) 
C1-C9 1.5310(15) C1-C2 1.5396(16) 
C1-H1A 1.0 O2-C9 1.3252(14) 
O2-C10 1.4538(14) C2-C3 1.5185(16) 
C2-C7 1.5598(15) C2-H2A 1.0 
O3-C9 1.2140(15) C3-C4 1.5152(18) 
C4-C5 1.530(2) C4-H4A 0.99 
C4-H4B 0.99 C5-C6 1.5257(19) 
C5-H5A 0.99 C5-H5B 0.99 
C6-C7 1.5232(16) C6-H6A 0.99 
C6-H6B 0.99 C7-C8 1.5278(16) 
C7-H7A 1.0 C8-H8A 0.99 
C8-H8B 0.99 C10-C11 1.5050(17) 
C10-H10A 0.99 C10-H10B 0.99 
C11-H11A 0.98 C11-H11B 0.98 
C11-H11C 0.98 C12-C18 1.5243(15) 
C12-C24 1.5295(15) C12-H12A 1.0 
C13-C14 1.3906(17) C13-C18 1.3943(17) 
C13-H13A 0.95 C14-C15 1.388(2) 
 263 
C14-H14A 0.95 C15-C16 1.385(2) 
C15-H15A 0.95 C16-C17 1.3901(18) 
C16-H16A 0.95 C17-C18 1.3924(17) 
C17-H17A 0.95 C19-C24 1.3911(17) 
C19-C20 1.3937(18) C19-H19A 0.95 
C20-C21 1.391(2) C20-H20A 0.95 
C21-C22 1.386(2) C21-H21A 0.95 
C22-C23 1.3896(18) C22-H22A 0.95 
C23-C24 1.3963(16) C23-H23A 0.95 
 
 
Table 28 Bond angles (°) for 3-74 
C8-N1-C12 114.11(9) C8-N1-C1 106.03(8) 
C12-N1-C1 115.13(8) N1-C1-C9 112.25(9) 
N1-C1-C2 102.58(8) C9-C1-C2 111.72(9) 
N1-C1-H1A 110.0 C9-C1-H1A 110.0 
C2-C1-H1A 110.0 C9-O2-C10 117.36(9) 
C3-C2-C1 114.06(9) C3-C2-C7 116.40(9) 
C1-C2-C7 106.01(9) C3-C2-H2A 106.6 
C1-C2-H2A 106.6 C7-C2-H2A 106.6 
O1-C3-C4 121.23(11) O1-C3-C2 120.61(11) 
C4-C3-C2 118.10(10) C3-C4-C5 114.54(11) 
C3-C4-H4A 108.6 C5-C4-H4A 108.6 
C3-C4-H4B 108.6 C5-C4-H4B 108.6 
H4A-C4-H4B 107.6 C6-C5-C4 109.66(11) 
C6-C5-H5A 109.7 C4-C5-H5A 109.7 
C6-C5-H5B 109.7 C4-C5-H5B 109.7 
H5A-C5-H5B 108.2 C7-C6-C5 109.03(11) 
C7-C6-H6A 109.9 C5-C6-H6A 109.9 
C7-C6-H6B 109.9 C5-C6-H6B 109.9 
H6A-C6-H6B 108.3 C6-C7-C8 115.80(10) 
C6-C7-C2 112.58(10) C8-C7-C2 104.10(9) 
C6-C7-H7A 108.0 C8-C7-H7A 108.0 
C2-C7-H7A 108.0 N1-C8-C7 103.79(9) 
N1-C8-H8A 111.0 C7-C8-H8A 111.0 
N1-C8-H8B 111.0 C7-C8-H8B 111.0 
H8A-C8-H8B 109.0 O3-C9-O2 124.78(11) 
O3-C9-C1 124.35(10) O2-C9-C1 110.75(9) 
O2-C10-C11 106.13(10) O2-C10-H10A 110.5 
C11-C10-H10A 110.5 O2-C10-H10B 110.5 
C11-C10-H10B 110.5 H10A-C10-H10B 108.7 
C10-C11-H11A 109.5 C10-C11-H11B 109.5 
H11A-C11-H11B 109.5 C10-C11-H11C 109.5 
H11A-C11-H11C 109.5 H11B-C11-H11C 109.5 
N1-C12-C18 111.17(9) N1-C12-C24 110.36(9) 
C18-C12-C24 110.87(9) N1-C12-H12A 108.1 
C18-C12-H12A 108.1 C24-C12-H12A 108.1 
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C14-C13-C18 120.58(11) C14-C13-H13A 119.7 
C18-C13-H13A 119.7 C15-C14-C13 120.10(12) 
C15-C14-H14A 119.9 C13-C14-H14A 119.9 
C16-C15-C14 119.72(11) C16-C15-H15A 120.1 
C14-C15-H15A 120.1 C15-C16-C17 120.15(11) 
C15-C16-H16A 119.9 C17-C16-H16A 119.9 
C16-C17-C18 120.69(12) C16-C17-H17A 119.7 
C18-C17-H17A 119.7 C17-C18-C13 118.75(11) 
C17-C18-C12 119.41(10) C13-C18-C12 121.79(10) 
C24-C19-C20 120.69(11) C24-C19-H19A 119.7 
C20-C19-H19A 119.7 C21-C20-C19 120.20(12) 
C21-C20-H20A 119.9 C19-C20-H20A 119.9 
C22-C21-C20 119.45(11) C22-C21-H21A 120.3 
C20-C21-H21A 120.3 C21-C22-C23 120.28(12) 
C21-C22-H22A 119.9 C23-C22-H22A 119.9 
C22-C23-C24 120.81(12) C22-C23-H23A 119.6 
C24-C23-H23A 119.6 C19-C24-C23 118.56(11) 
C19-C24-C12 120.48(10) C23-C24-C12 120.95(10) 
 
 
Table 29 Anisotropic atomic displacement parameters (Å2) for 3-74 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
  U11 U22 U33 U23 U13 U12 
N1  0.0159(5) 0.0226(5) 0.0165(5) 0.0001(4) 0.0045(3) -0.0008(4) 
O1  0.0371(5) 0.0372(5) 0.0210(5) 0.0038(3) 0.0064(4) -0.0071(4) 
C1  0.0163(5) 0.0207(6) 0.0165(5) 0.0005(4) 0.0050(4) 0.0015(4) 
O2  0.0192(4) 0.0303(5) 0.0209(4) -0.0072(3) 0.0047(3) -0.0021(3) 
C2  0.0181(5) 0.0192(6) 0.0210(6) -0.0003(4) 0.0065(4) 0.0008(4) 
O3  0.0239(4) 0.0244(5) 0.0251(4) -0.0022(3) 0.0072(3) 0.0043(3) 
C3  0.0265(6) 0.0201(6) 0.0241(6) 0.0031(4) 0.0095(5) 0.0009(5) 
C4  0.0312(7) 0.0437(8) 0.0321(7) 0.0067(5) 0.0167(5) -0.0022(6) 
C5  0.0213(6) 0.0384(8) 0.0399(8) 0.0052(6) 0.0130(5) -0.0031(5) 
C6  0.0182(6) 0.0340(7) 0.0326(7) 0.0041(5) 0.0083(5) 0.0003(5) 
C7  0.0174(5) 0.0252(6) 0.0216(6) -0.0010(4) 0.0046(4) -0.0013(4) 
C8  0.0165(5) 0.0287(6) 0.0186(6) 0.0017(4) 0.0032(4) 0.0004(4) 
C9  0.0189(5) 0.0204(6) 0.0157(5) 0.0021(4) 0.0058(4) -0.0001(4) 
C10  0.0288(7) 0.0313(7) 0.0243(6) -0.0111(5) 0.0055(5) -0.0030(5) 
C11  0.0295(7) 0.0319(7) 0.0219(6) -0.0057(5) 0.0029(5) -0.0054(5) 
C12  0.0197(6) 0.0189(6) 0.0169(6) -0.0022(4) 0.0074(4) -0.0003(4) 
C13  0.0228(6) 0.0241(6) 0.0184(6) -0.0003(4) 0.0072(4) 0.0004(4) 
C14  0.0248(6) 0.0309(7) 0.0229(6) 0.0037(5) 0.0106(5) 0.0065(5) 
C15  0.0171(5) 0.0428(8) 0.0253(6) 0.0071(5) 0.0077(4) 0.0022(5) 
C16  0.0217(6) 0.0338(7) 0.0255(6) 0.0017(5) 0.0043(5) -0.0076(5) 
C17  0.0240(6) 0.0250(6) 0.0195(6) -0.0003(4) 0.0070(4) -0.0026(5) 
C18  0.0193(6) 0.0239(6) 0.0150(5) 0.0016(4) 0.0064(4) -0.0004(4) 
C19  0.0194(6) 0.0230(6) 0.0247(6) -0.0009(4) 0.0070(4) 0.0000(4) 
C20  0.0227(6) 0.0261(6) 0.0301(7) 0.0056(5) 0.0033(5) 0.0000(5) 
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  U11 U22 U33 U23 U13 U12 
C21  0.0240(6) 0.0389(7) 0.0202(6) 0.0059(5) 0.0032(4) -0.0060(5) 
C22  0.0242(6) 0.0358(7) 0.0203(6) -0.0037(5) 0.0071(4) -0.0039(5) 
C23  0.0226(6) 0.0244(6) 0.0217(6) -0.0017(4) 0.0069(4) 0.0000(4) 
C24  0.0154(5) 0.0242(6) 0.0190(6) 0.0004(4) 0.0062(4) -0.0015(4) 
 
 
Table 30 Hydrogen atomic coordinates and isotropic atomic displacemnt parameters (Å2) for 3-73 
 x/a y/b z/c U(eq) 
H1A 0.1764 0.7169 0.1188 0.021 
H2A 0.2896 0.9472 0.1366 0.023 
H4A 0.4092 1.0424 0.0411 0.041 
H4B 0.4343 0.7904 0.0298 0.041 
H5A 0.5441 0.8836 0.1171 0.039 
H5B 0.4811 1.0314 0.1466 0.039 
H6A 0.4664 0.5527 0.1377 0.034 
H6B 0.5230 0.6756 0.2013 0.034 
H7A 0.4000 0.8509 0.2153 0.026 
H8A 0.3709 0.3838 0.1943 0.026 
H8B 0.3817 0.5219 0.2592 0.026 
H10A 0.1400 0.0847 0.0223 0.034 
H10B 0.1582 0.2506 -0.0303 0.034 
H11A 0.0110 0.1221 -0.0642 0.043 
H11B -0.0056 0.2216 -0.0009 0.043 
H11C 0.0125 0.3866 -0.0532 0.043 
H12A 0.2211 0.2344 0.1815 0.022 
H13A 0.1192 0.7271 0.2246 0.026 
H14A -0.0323 0.7819 0.2027 0.03 
H15A -0.1302 0.5004 0.1527 0.034 
H16A -0.0760 0.1628 0.1259 0.033 
H17A 0.0754 0.1040 0.1502 0.027 
H19A 0.2849 -0.0200 0.2623 0.027 
H20A 0.3373 -0.1262 0.3692 0.033 
H21A 0.3281 0.1215 0.4499 0.034 
H22A 0.2692 0.4783 0.4229 0.032 
H23A 0.2187 0.5862 0.3163 0.027 
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Figure 13 ORTEP structure of 3-116 
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Table 31 Sample and crystal data for 3-116 
Chemical formula C23H23NO3 
Formula weight 361.42 g/mol 
Temperature 150(2) K 
Wavelength 1.54178 Å 
Crystal size 0.080 x 0.150 x 0.210 mm 
Crystal system monoclinic 
Space group C 1 c 1 
Unit cell dimensions a = 16.9789(3) Å α = 90° 
 b = 7.49480(10) Å β = 102.6470(10)° 
 c = 14.4748(2) Å γ = 90° 
Volume 1797.28(5) Å3  
Z 4 
Density (calculated) 1.336 g/cm3 
Absorption coefficient 0.705 mm-1 
F(000) 768 
 
Table 32 Data collection and structure refinement for 3-116 
Theta range for data collection 5.34 to 70.09° 
Index ranges -20<=h<=20, -8<=k<=8, -17<=l<=17 
Reflections collected 15918 
Independent reflections 3286 [R(int) = 0.0233] 
Max. and min. transmission 0.9800 and 0.9200 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/4 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2017/1 (Sheldrick, 2017) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3286 / 2 / 336 
Goodness-of-fit on F2 1.052 
Final R indices 3270 data; I>2σ(I) R1 = 0.0264, wR2 = 0.0736 
 all data R1 = 0.0265, wR2 = 0.0737 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0680P)2] 
where P=(Fo2+2Fc2)/3 
Absolute structure parameter 0.04(4) 
Largest diff. peak and hole 0.155 and -0.197 eÅ-3 
R.M.S. deviation from mean 0.041 eÅ-3 
 
Table 33 Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 3-116 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
 x/a y/b z/c U(eq) 
C1 0.49574(9) 0.6434(2) 0.60916(12) 0.0180(3) 
N1 0.53575(7) 0.52915(17) 0.55088(9) 0.0160(3) 
O1 0.71761(7) 0.26829(15) 0.64600(9) 0.0232(3) 
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 x/a y/b z/c U(eq) 
C2 0.56008(9) 0.6625(2) 0.69918(11) 0.0179(3) 
O2 0.60627(8) 0.92868(17) 0.63604(10) 0.0321(3) 
C3 0.62186(10) 0.8077(2) 0.69232(12) 0.0205(3) 
O3 0.66139(7) 0.33364(18) 0.49869(9) 0.0277(3) 
C4 0.70152(10) 0.7895(2) 0.76199(14) 0.0266(4) 
C5 0.73799(9) 0.6060(2) 0.75028(13) 0.0228(3) 
C6 0.68296(9) 0.4559(2) 0.76940(12) 0.0189(3) 
C7 0.71317(10) 0.2758(2) 0.74528(13) 0.0234(4) 
C8 0.65567(9) 0.3316(2) 0.58003(12) 0.0196(3) 
C9 0.58024(9) 0.3907(2) 0.61310(11) 0.0159(3) 
C10 0.59540(9) 0.47245(19) 0.71434(11) 0.0163(3) 
C11 0.48540(8) 0.4682(2) 0.46004(11) 0.0173(3) 
C12 0.39897(11) 0.1998(2) 0.47684(12) 0.0231(3) 
C13 0.32754(12) 0.1213(2) 0.49027(12) 0.0267(4) 
C14 0.26233(11) 0.2273(3) 0.49723(12) 0.0263(4) 
C15 0.26747(10) 0.4118(2) 0.49035(13) 0.0249(4) 
C16 0.33850(10) 0.4891(2) 0.47569(11) 0.0206(3) 
C17 0.40560(9) 0.3841(2) 0.46975(11) 0.0186(3) 
C18 0.42014(9) 0.5989(2) 0.30078(12) 0.0213(3) 
C19 0.41244(10) 0.7284(2) 0.23051(13) 0.0257(4) 
C20 0.45889(12) 0.8833(2) 0.24695(14) 0.0267(4) 
C21 0.51328(12) 0.9050(2) 0.33289(14) 0.0270(4) 
C22 0.52163(10) 0.7736(2) 0.40297(12) 0.0221(3) 
C23 0.47435(9) 0.6193(2) 0.38726(12) 0.0191(3) 
 
Table 34 Bond lengths (Å) for 3-116 
C1-N1 1.4686(19) C1-C2 1.513(2) 
C1-H1A 0.93(2) C1-H1B 1.04(2) 
N1-C9 1.4699(19) N1-C11 1.4753(18) 
O1-C8 1.343(2) O1-C7 1.457(2) 
C2-C3 1.530(2) C2-C10 1.542(2) 
C2-H2 0.96(2) O2-C3 1.209(2) 
C3-C4 1.506(2) O3-C8 1.202(2) 
C4-C5 1.533(2) C4-H4A 0.95(2) 
C4-H4B 0.99(3) C5-C6 1.526(2) 
C5-H5A 0.95(2) C5-H5B 0.99(3) 
C6-C7 1.512(2) C6-C10 1.5304(19) 
C6-H6 0.96(3) C7-H7A 0.98(2) 
C7-H7B 0.95(3) C8-C9 1.5276(19) 
C9-C10 1.557(2) C9-H9A 0.97(2) 
C10-H10 0.95(2) C11-C17 1.528(2) 
C11-C23 1.530(2) C11-H11 0.99(2) 
C12-C17 1.392(2) C12-C13 1.399(2) 
C12-H12 0.97(3) C13-C14 1.384(3) 
C13-H13 0.99(3) C14-C15 1.390(3) 
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C14-H14 0.97(2) C15-C16 1.395(2) 
C15-H15 0.97(3) C16-C17 1.402(2) 
C16-H16 1.00(2) C18-C23 1.390(2) 
C18-C19 1.391(2) C18-H18 0.99(2) 
C19-C20 1.394(3) C19-H19 0.95(3) 
C20-C21 1.387(3) C20-H2-0 0.98(3) 
C21-C22 1.398(2) C21-H21 1.01(3) 
C22-C23 1.398(2) C22-H22 0.98(3) 
 
Table 35 Bond angles (°) for 3-116 
N1-C1-C2 102.26(12) N1-C1-H1A 112.0(12) 
C2-C1-H1A 111.2(13) N1-C1-H1B 110.3(13) 
C2-C1-H1B 115.2(13) H1A-C1-H1B 106.1(17) 
C1-N1-C9 107.45(13) C1-N1-C11 116.22(12) 
C9-N1-C11 116.55(12) C8-O1-C7 119.10(12) 
C1-C2-C3 112.80(13) C1-C2-C10 102.71(12) 
C3-C2-C10 114.55(12) C1-C2-H2 113.3(14) 
C3-C2-H2 105.5(14) C10-C2-H2 108.1(13) 
O2-C3-C4 123.48(15) O2-C3-C2 121.68(15) 
C4-C3-C2 114.83(14) C3-C4-C5 109.44(13) 
C3-C4-H4A 110.8(15) C5-C4-H4A 110.6(14) 
C3-C4-H4B 110.4(15) C5-C4-H4B 107.6(15) 
H4A-C4-H4B 108.(2) C6-C5-C4 111.29(14) 
C6-C5-H5A 107.5(13) C4-C5-H5A 112.5(14) 
C6-C5-H5B 110.2(13) C4-C5-H5B 109.1(13) 
H5A-C5-H5B 106.1(19) C7-C6-C5 111.36(14) 
C7-C6-C10 106.98(13) C5-C6-C10 114.18(13) 
C7-C6-H6 105.6(17) C5-C6-H6 110.1(17) 
C10-C6-H6 108.2(16) O1-C7-C6 110.83(13) 
O1-C7-H7A 109.4(14) C6-C7-H7A 109.9(14) 
O1-C7-H7B 105.7(16) C6-C7-H7B 113.2(16) 
H7A-C7-H7B 108.(2) O3-C8-O1 118.82(14) 
O3-C8-C9 123.79(14) O1-C8-C9 117.34(14) 
N1-C9-C8 111.48(13) N1-C9-C10 104.81(12) 
C8-C9-C10 115.58(12) N1-C9-H9A 112.4(14) 
C8-C9-H9A 106.8(13) C10-C9-H9A 105.7(13) 
C6-C10-C2 116.87(12) C6-C10-C9 113.57(12) 
C2-C10-C9 104.51(12) C6-C10-H10 106.8(11) 
C2-C10-H10 107.5(11) C9-C10-H10 107.1(11) 
N1-C11-C17 113.47(12) N1-C11-C23 110.12(12) 
C17-C11-C23 113.00(12) N1-C11-H11 104.8(14) 
C17-C11-H11 108.3(13) C23-C11-H11 106.6(14) 
C17-C12-C13 120.92(16) C17-C12-H12 116.1(14) 
C13-C12-H12 122.9(14) C14-C13-C12 120.03(17) 
C14-C13-H13 121.1(14) C12-C13-H13 118.8(14) 
C13-C14-C15 120.12(16) C13-C14-H14 120.6(14) 
 270 
C15-C14-H14 119.3(14) C14-C15-C16 119.57(17) 
C14-C15-H15 118.9(18) C16-C15-H15 121.6(18) 
C15-C16-C17 121.14(15) C15-C16-H16 118.9(14) 
C17-C16-H16 119.9(14) C12-C17-C16 118.19(15) 
C12-C17-C11 120.23(14) C16-C17-C11 121.53(14) 
C23-C18-C19 121.30(16) C23-C18-H18 120.6(13) 
C19-C18-H18 117.9(13) C18-C19-C20 119.79(17) 
C18-C19-H19 120.3(16) C20-C19-H19 119.8(16) 
C21-C20-C19 119.43(16) C21-C20-H2-0 120.7(14) 
C19-C20-H2-0 119.9(14) C20-C21-C22 120.66(17) 
C20-C21-H21 121.0(15) C22-C21-H21 118.3(15) 
C23-C22-C21 120.08(17) C23-C22-H22 121.1(13) 
C21-C22-H22 118.8(13) C18-C23-C22 118.74(16) 
C18-C23-C11 119.72(15) C22-C23-C11 121.40(15) 
 
Table 36 Anisotropic atomic displacement parameters (Å2) for 3-116 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... 
+ 2 h k a* b* U12 ]  
 U11 U22 U33 U23 U13 U12 
C1 0.0170(7) 0.0182(7) 0.0194(8) -0.0023(5) 0.0052(6) -0.0003(5) 
N1 0.0163(6) 0.0157(6) 0.0158(6) -0.0009(4) 0.0031(5) 0.0010(4) 
O1 0.0190(5) 0.0223(6) 0.0271(7) -0.0020(4) 0.0027(4) 0.0045(4) 
C2 0.0169(7) 0.0195(8) 0.0181(8) -0.0033(6) 0.0058(6) -0.0010(5) 
O2 0.0361(7) 0.0201(6) 0.0372(8) 0.0023(5) 0.0020(5) -0.0050(5) 
C3 0.0224(7) 0.0148(7) 0.0248(8) -0.0053(6) 0.0062(6) -0.0022(6) 
O3 0.0263(6) 0.0334(7) 0.0259(7) -0.0016(5) 0.0112(5) 0.0052(5) 
C4 0.0216(8) 0.0207(9) 0.0351(11) -0.0056(6) 0.0011(7) -0.0059(6) 
C5 0.0164(7) 0.0225(8) 0.0280(9) -0.0008(6) 0.0019(6) -0.0035(6) 
C6 0.0169(7) 0.0208(8) 0.0177(7) 0.0016(5) 0.0009(6) -0.0010(5) 
C7 0.0219(8) 0.0230(9) 0.0231(9) 0.0027(6) 0.0000(7) 0.0013(6) 
C8 0.0184(7) 0.0162(8) 0.0247(9) -0.0018(5) 0.0061(6) -0.0003(5) 
C9 0.0155(7) 0.0154(7) 0.0172(8) 0.0010(5) 0.0041(5) -0.0012(5) 
C10 0.0159(7) 0.0180(8) 0.0156(7) -0.0007(5) 0.0049(6) -0.0036(5) 
C11 0.0173(7) 0.0195(8) 0.0148(7) -0.0012(6) 0.0028(6) 0.0006(5) 
C12 0.0269(8) 0.0229(8) 0.0183(8) -0.0015(6) 0.0027(6) -0.0014(6) 
C13 0.0352(9) 0.0236(9) 0.0191(8) -0.0012(6) 0.0009(7) -0.0114(6) 
C14 0.0248(8) 0.0355(10) 0.0177(8) -0.0010(6) 0.0028(6) -0.0116(6) 
C15 0.0203(8) 0.0321(9) 0.0215(8) -0.0009(6) 0.0031(6) -0.0023(6) 
C16 0.0207(7) 0.0228(9) 0.0172(7) -0.0006(6) 0.0020(5) -0.0028(6) 
C17 0.0215(8) 0.0205(8) 0.0129(7) -0.0015(5) 0.0018(6) -0.0027(5) 
C18 0.0154(7) 0.0301(9) 0.0192(9) 0.0020(6) 0.0059(6) 0.0039(6) 
C19 0.0201(8) 0.0383(9) 0.0197(9) 0.0050(7) 0.0065(6) 0.0107(7) 
C20 0.0301(8) 0.0283(9) 0.0249(9) 0.0103(7) 0.0132(7) 0.0120(6) 
C21 0.0322(9) 0.0242(9) 0.0282(9) 0.0035(7) 0.0143(7) 0.0025(6) 
C22 0.0234(8) 0.0238(8) 0.0202(8) 0.0018(6) 0.0075(6) 0.0012(6) 
C23 0.0186(7) 0.0226(7) 0.0178(8) 0.0010(5) 0.0078(6) 0.0037(5) 
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Table 37 Hydrogen atomic coordinates and isotropic atomic displacemnt parameters (Å2) for 3-116 
 x/a y/b z/c U(eq) 
H2 0.5389(14) 0.693(3) 0.7531(17) 0.019(5) 
H4A 0.7375(14) 0.882(3) 0.7533(18) 0.025(5) 
H4B 0.6937(15) 0.797(3) 0.828(2) 0.029(6) 
H5A 0.7894(14) 0.589(3) 0.7919(16) 0.019(5) 
H5B 0.7472(14) 0.596(3) 0.6855(18) 0.022(5) 
H6 0.6830(16) 0.451(4) 0.836(2) 0.036(7) 
H9A 0.5480(14) 0.285(3) 0.6153(16) 0.019(5) 
H10 0.5634(11) 0.407(2) 0.7486(14) 0.006(4) 
H11 0.5182(14) 0.375(3) 0.4373(17) 0.021(5) 
H12 0.4460(15) 0.131(3) 0.4711(18) 0.027(6) 
H13 0.3245(14) -0.011(4) 0.4939(18) 0.032(6) 
H15 0.2213(19) 0.484(4) 0.496(2) 0.039(6) 
H16 0.3416(15) 0.621(3) 0.4711(17) 0.022(5) 
H18 0.3889(14) 0.488(3) 0.2857(17) 0.023(5) 
H19 0.3785(16) 0.708(3) 0.170(2) 0.031(6) 
H2-0 0.4543(15) 0.973(4) 0.1971(19) 0.031(6) 
H21 0.5492(15) 1.014(4) 0.3456(18) 0.032(6) 
H22 0.5609(15) 0.793(3) 0.4630(17) 0.018(5) 
H1A 0.4495(12) 0.590(3) 0.6210(14) 0.012(4) 
H1B 0.4771(13) 0.762(3) 0.5738(17) 0.019(5) 
H7A 0.6771(14) 0.181(3) 0.7584(17) 0.026(6) 
H7B 0.7660(17) 0.249(4) 0.780(2) 0.029(6) 
H14 0.2121(15) 0.174(3) 0.5056(17) 0.028(6) 
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